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2. Preface 
2.1 Biocatalysis in Organic Synthesis  
The term ‘biocatalysis’ delineates the family of catalytic processes operating in a living 
biological system to perform chemical transformations on organic compounds. The main 
‘actors’ of these processes are the biological systems enzymes, globular proteins possessing 
the ability of promoting chemical transformation with peculiar characteristics and 
outstanding performances. For instance, a narrow group of biocatalysts (i.e. 
acetylcholinesterase, β-lactamase, catalase …), defined as ‘diffusion-limited enzymes’, can 
accelerate a chemical reaction so efficiently that the rate determining step becomes the 
diffusional limits of the reactants and/or products in the reacting media itself; reaching the 
so-called ‘catalytic perfection’ with values of kinetic constants estimated to be between 108 
M−1 s−1 and 109 M−1 s−1.  
Even if most of the known enzymes operate by accelerating a reaction speed to a rate that is 
1000 – 10000 times slower than a diffusion-controlled reaction, biocatalysts possess a broad 
range of features that makes them an appealing resource for an organic chemist. Proteins are 
in fact macromolecules constituted by a network of chiral (L)-a-amino acids linked by amide 
bonds that, thanks to their extensive chirality and 3D-folding, can catalyze highly selective 
transformations. Thus, enzymes can discriminate between two enantiomers (ndr kinetic 
resolution), interact with a pro-chiral group leading to the stereoselective formation of a new 
stereocenter (ndr asymmetric synthesis) or can guide the chemical bonds formation or 
breaking in a specific direction as well as toward a specific functional group (ndr regio- and 
chemo-selective processes).  
 
 In this thesis work different enzymatic activities have been exploited to promote 
selective transformations to assess synthetic problems in organic chemistry. The results that 
will be presented have been collected in six different papers published ISI journals and one 
submitted manuscript.  
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Paper I: ‘Dicarboxylic esters: Useful tools for the biocatalyzed synthesis of hybrid 
compounds and polymers’  
Bassanini, Ivan; Hult, Karl; Riva, Sergio* 
Beilstein J. Org. Chem., 2015, 11, 1583–1595. doi:10.3762/bjoc.11.174 
 
Paper II: ‘Self-assembled 4-(1,2-diphenylbut-1-en-1-yl) aniline based nanoparticles: 
podophyllotoxin and aloin as building blocks’ 
Fumagalli, Gaia; Christodoulou, Michael S.; Riva, Benedetta; Revuelta, Inigo; Marucci, 
Cristina; Collico, Veronica; Prosperi, Davide; Riva, Sergio; Perdicchia, Dario; Bassanini, 
Ivan; García-Argáez, Aida; Via, Lisa Dalla; Passarella, Daniele* 
Org. Biomol. Chem., 2017, 15, 1106  
Contribution: enzymatic modification of aloin  
 
Paper III: ‘A sustainable one-pot two-enzymes synthesis of naturally occurring 
arylalkyl glucosides’ 
Bassanini, Ivan; Krejzová, Jana; Panzeri, Walter; Monti, Daniela; Křen, Vladimír; Riva, 
Sergio*  
ChemSusChem., 2017, 10, 2040 –2045   
Major Contribution  
 
Paper IV: ‘Novel thermostable amine transferases from hot spring metagenomes’ 
Ferrandi, Erica Elisa; Previdi, Alessandra; Bassanini, Ivan; Riva, Sergio; Peng, Xu; Monti, 
Daniela* 
Appl. Microbiol. Biotechnol., 2017, 101, 4963–4979 
Contribution: screening of the amino/donor acceptor scope of these new enzymes 
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Paper V: ‘Peroxygenase-catalyzed enantioselective sulfoxidations’ 
Bassanini, Ivan; Ferrandi, Erica Elisa; Vanoni, Marta; Riva, Sergio; Crotti, Michele; Brenna, 
Elisabetta; Monti, Daniela* 
Eur. J. Org. Chem. 2017, 10.1002/ejoc.201701390 
Major contribution 
 
Paper VI: ‘Laccase-catalyzed dimerization of glycosylated lignols’ 
Bassanini, Ivan; Gavezzotti, Paolo; Monti, Daniela; Krejzová, Jana; Křen, Vladimír; Riva, 
Sergio* 
J. Mol. Catal. B: Enzym., 2016, 134, 295– 301  
Major contribution 
 
Submitted Manuscript I: ‘Facile chemo-enzymatic synthesis of substituted (E)-2,3-
diaryl-5-styryl-trans-2,3-dihydrobenzofurans, a novel family of potential allosteric 
modulators of the 90 kDa heat shock protein (Hsp90)’ 
Bassanini, Ivan; Costa, Massimo; D’Annessa, Ilda; Colombo, Giorgio; Monti, Daniela; 
Riva, Sergio*  
Major contribution 
 
In chapter three, the regioselectivity of lipase-mediated trans-acylations (Paper I) will be 
discussed to introduce the enzymatic strategy exploited to produce aloin conjugates to be 
tested for their ability to self-assembly into nanoparticles (Paper II).  
A novel highly stereo- and regio-selective enzymatic synthesis of naturally occurring 
bioactive arylalkyl glucosides will be presented in chapter four (Paper III).  
Introduction 
 4 
The discovery of novel thermostable aminotransferases from hot-spring metagenomes and, 
more importantly for this thesis, their potential synthetic exploitation to produce 
enantiomerically enriched amines will be discussed in chapter five (Paper IV).  
The AaeUPO-catalyzed enantioselective sulfoxidation of arylalkyl sulfides to the 
correspondent (R)-sulfoxides will be the focus of chapter six (Paper V).  
Finally, chapter seven will be dedicated to the description of laccases as selective activators 
of Csp2-H bond. The oxidation of glycosylated lignols (Paper VI) and the chemo- and regio-
selective oxidative coupling of (4)-E-styrylphenols to produce a family of potential allosteric 
modulators of the 90 kDa heat-shock protein (Hsp90) will be extensively discussed 
(Submitted Manuscript I) 
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2.2 General information  
a) Materials, chemicals, and equipment 
NMR spectra were recorded with a Bruker AC spectrometer (400 or 500 MHz) in 
[D4]MeOH, [D6]DMSO, [D1]CHCl3 or D2O. Mass spectra were recorded with Bruker 
Esquire 3000 Plus spectrometer.  
Biotransformations were performed with a G24 Environmental Incubator New Brunswick 
Scientific Shaker (Edison, USA) or a Thermomixer Comfort (Eppendorf, DE).  
Reactions were monitored by thin-layer chromatography (TLC) [precoated silica gel 60 F254 
plates (Merck, DE)]; development with UV lamp, Komarovsky reagent (1 mL 50% ethanolic 
H2SO4 with 10 mL 2% methanolic 4-hydroxybenzaldehyde), a 20% solution of H2SO4 in 
ethanol or a molybdate reagent ((NH4)6Mo7O24·4 H2O, 42 g; Ce(SO4)2, 2 g; H2SO4 conc., 62 
mL; made up to 1 L of deionized water). Flash chromatography: silica gel 60 (70–230 mesh, 
Merck, DE).   
All reagents were of the highest purity grade from commercial suppliers: Sigma-Aldrich (St 
Louis, MO, USA) or VWR (Radnor, PA, USA). 
GC-MS analyses were performed using a HP-5MS column (30 m × 0.25 mm × 0.25 µm, 
Agilent) on a Finnigan TRACE DSQ GC/MS instrument (ThermoQuest, San Jose, CA). 
HPLC analyses were conducted using a Jasco 880-PU pump equipped with a Jasco 875-
UV/Vis detector and. 
Uv-spectra were recorded on a nitrogen flushed Jasco J-1100 spectrophotometer (Easton, 
MD, USA) interfaced with a thermostatically controlled cell holder. 
 
b) List of abbreviations 
MeOH = methanol; 
DMSO = dimethyl sulfoxide; 
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AcOEt = ethyl acetate; 
ETP = petroleum ether;  
THF = tetrahydrofuran; 
DMAP = N,N-dimethylamino pyridine; 
DBU = 1,5-diazabiciclo(5.4.0)undec-5-ene;  
TMSOTf = trimethylsilyl trifluoromethanesulfonate; 
DCM = dichloromethane;  
TBAF = Tetra-n-butylammonium fluoride;  
TBDMS = tert-butyldimethylsilyl 
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3. Lipases: regioselective biocatalyzed trans-
acylations 
Since the discovery that enzymes can operate in organic solvents, the scope of 
preparative scale biocatalyzed transformations has dramatically increased over the past four 
decades.1, 2, 3, 4  
Moreover, enzymatic reactions in organic solvents are nowadays emerging as a fruitful and 
promising research investment for the industrial preparation of bulk and fine chemicals, to 
reduce the cost of the biocatalytic process and improve its economics. In fact, due to water’s 
high boiling point and low vapor pressure, the isolation of products from an aqueous-media 
is very often expansive and difficult.5 
The outstanding impact that this new synthetic tool had and has on biocatalyzed organic 
synthesis is attested by the uncountable number of scientific reports published on the topic 
since the eighties of the last century, most of them dealing with the exploitation of hydrolases 
in organic solvents.6, 7 
When used in an organic media, lipases and proteases, two of the best characterized 
hydrolases, were found to be able to efficiently catalyze reactions that are thermodynamically 
unfavorable in water. In fact, stereo and regio-selective esterification, amidation and trans-
acylation (trans-esterification) reactions are successfully catalyzed by a lipase or an esterase 
suspended in an anhydrous organic solvent: the biocatalytic formation of a novel carbon-
hetero atom bond instead of its hydrolytic breaking, is the favored catalyzed process in an 
organic media. The proposed mechanisms for lipase-catalyzed hydrolysis and trans-acylation 
are reported in Figure 3.1.8 As it can be seen, the need of an anhydrous media appears 
fundamental to guarantee the nucleophilic attack to the acyl-enzyme intermediate by a 
nucleophile different from water, whose action would promote a ‘classical’ hydrolytic 
reaction.  
Lipases 
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The use of organic media had also significantly expanded both the substrates and the 
acylating agents’ scope. Lipases, whose natural substrates are fatty acid triglycerides, were 
found to be able to catalyze the esterifications of a plethora of natural and un-natural 
compounds, including sugars and steroids, using both simple aliphatic acylating agents and 
more complex and sterically demanding acyl-donors.9, 10, 11  
 
Figure 3.1: Lipase catalyzed trans-acylation (left) and lipase-mediated hydrolysis (right). 
In this context, among the number of acyl donors, ‘activated esters’ of dicarboxylic acids 
proved to be promising and versatile tools to produce bifunctionalized compounds. 
 
In Paper I, a review on the use of dicarboxylic esters as acyl donors in lipase-
mediated acylations, we have shown that the synthetic employment of vinyl and/or trifluoro 
esters to make biocatalytic trans-acylations irreversible processes is a well-described strategy, 
thanks to their ability of releasing poor-nucleophilic alcohols. Along with the remarkable 
number of examples dealing with the biocatalytic synthesis of polymers, the development of 
these biotransformations resulted in a versatile and, more important, regioselective entry to 
Lipases 
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‘hybrid compounds’. In fact, the combination of an activated di-ester and a proper lipase 
allowed the regioselective formation of symmetrical and un-symmetrical conjugates starting 
from polyhydroxylated substrates, without the need of protective group chemistry or 
activating coupling agents. The efficiency and potency of these biocatalytic trans-acylations 
led Dordick and coworkers to propose the so-called ‘combinatorial biocatalysis’ as an 
approach to easily produce small libraries of derivatives of bioactive natural compounds, 
using a panel of different acylating-agents and hydrolases.12, 13, 14  
Bifunctional hybrid conjugates, very interesting molecular scaffold in the field of medicinal 
and pharmaceutical chemistry, were easily prepared by exploiting the two extremities of the 
activated dicarboxylates to connect two different molecules, generally via a two-step 
approach (Scheme  3.1).  
 
Scheme  3.1: Two-step entry to hybrid compounds. 
A quick overview over the regioselective production of symmetrical and, most important, 
un-symmetrical conjugates of polyhydroxylated natural compounds, will be proposed therein 
through the selection of notable examples from Paper I. 
 
Figure 3.2: C6-dicarboxylic acid diesters derivatives of NAG-thiazoline. 
Dicarboxylic acid diesters derivatives of the thiazoline of N-acetylglucosamine (NAG-
thiazoline, Figure 3.2) were prepared by Křen and co-workers, starting from the ‘nude’ 
NAG-thiazoline using an immobilized Candida antarctica preparation from Novozyme® 
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(Novozym435) in dry acetone. Their inhibitor activities towards fungal β-N-
acetylhexosaminidase was evaluated as well.15  
According to the simple synthetic entry proposed in Scheme  3.1, a sugar-conjugate of 
paclitaxel (3.2) was obtained in a pretty straightforward synthetic pathway (Scheme  3.2) 
involving the regioselective acylation of its side chain to give the key-intermediate 2’-vinyl 
adipate (3.3) in 60% isolated yields. The following Novozym435-catalyzed elaboration of 3.3 
allowed the linkage to glucose, producing the water-soluble hybrid compound 3.5.16  
As a second example, Scheme  3.3 shows the biocatalytic entry to the hybrid conjugates 3.9 
and 3.10, obtained by our group linking together a bioactive alkaloid (colchicoside, 3.7; 
thiocolchicoside, 3.8) and the steroid cortisone (3.6), to merge their analgesic and anti-
inflammatory and effects. Worth of notice is the use of activated esters of dithio-dicarboxylic 
acids, in 3.10.17 
  
 
Symmetrical dimers of lignols (phytochemicals acting as source materials for biosynthesis of 
both lignans and lignin) and phenolic stilbenes, were also synthetized using Novozym435 in 
combination with different activated diesters (Figure 7.11, chapter 7.3, results unpublished) 
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Scheme  3.2: Biocatalyzed synthesis of a paclitaxel sugar-conjugate (3.5) 
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to be used as substrate to study the possibility of conducing laccase-mediated oxidative 
macrocylizations, as described in chapter 7 on ‘Laccases’.18 
 
Scheme  3.3: Biocatalyzed synthesis of hybrid diesters 3.9 and 3.10. 
In general, these classes of compounds can be synthesized by (sometimes 
troublesome) chemical protocols that require an accurate control over the reaction 
conditions and, in most of the cases, several protection/deprotection steps.   
As it has been shown, these drawbacks are totally avoided using a biocatalyzed approach, 
exploiting, once again, the well-known efficiency, selectivity and versatility of lipase-mediated 
trans-acylations in organic solvents. 
Thrilled by this elegant biocatalytic approach, able to solve issues of regioselectivity, 
we developed a chemo-enzymatic entry to aloin-based drug conjugates suitable for 
applications in the field of cancer nanotherapy, as it will be discussed in paragraph 3.1.  
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3.1 Lipase-mediated synthesis of aloin conjugates  
The self-assembling of drug conjugates and the consequent spontaneous formation of 
nanoparticles (NPs) in aqueous media is emerging as a promising research niche in the field 
of cancer nanotechnology.19, 20, 21  
Specifically, the use of drugs conjugates obtained by a covalent bonding with biocompatible 
lipid moieties, has gained considerable attention.22, 23  
The spontaneous self-assembly into NPs is mediated by an ordered structural organization 
of building blocks, as a consequence of specific local interactions. In this scenario, to 
promote self-assembly under controlled experimental conditions, the role of the 
amphiphilicity has been largely established.  
In Paper II, the use of 4-(1,2-diphenylbut-1-en-1-yl)aniline (3.11, Figure 3.3), a 
tamoxifen analog possessing antiproliferative properties, as new self-assembly inducer was 
investigated. In fact, the establishment of π-stacking interactions among the aromatic rings 
of the adjacent molecules of 3.11 could promote the formation of a hydrophobic core, 
forcing the exposure of the polar moieties toward the aqueous environment.24, 25 
 
Figure 3.3: Building blocks and schematic composition of the designed drug conjugates. 
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Aloin (3.12) and podophyllotoxin (3.13) were also selected as building blocks for the drug 
conjugates (Figure 3.3). The former, a natural polyhydroxylated bioactive compound, was 
chosen because of its hydrophilic structure to test the self-assembly properties of amphiphilic 
conjugates; the latter, a lipophilic antiproliferative compound, was used to prove the ability 
of 3.11 to induce self-assembly also in a totally lipophilic conjugate. To this purpose, four 
different conjugates were prepared (Figure 3.4). 
 
Figure 3.4: Structure of the drug conjugates 3.14 – 3.17. 
The synthesis of the molecular conjugate 3.14 and 3.17 was easily achieved following classical 
chemical coupling protocols starting from aloin, sebacid acid and aniline 3.11 (Scheme  3.4).  
To synthetize conjugates 3.15 and 3.16, a selective single acylation of one of the two 
primary hydroxyl groups of aloin was strictly needed.  
O
HO
OH
HO
OOH OH
O
O
(3.14)
O
HO
OH
HO
OOH OH
O
O
N
H
O
(3.16)
O
HO
OH
HO
OOH OH
O
OH
O (3.15)
N
H
O
N
H
O
HN
O
H
N
O
(3.17)
O
O
O
O
MeO
OMe
OMe
O
O
O
O
O
O
H
H
H
Lipases 
 
 14 
 
Scheme  3.4: Chemical synthesis of compounds 3.14 and 3.17 
Reagents and conditions: sebacic acid, DIPEA, HATU, 42 %; (b) aloin, EDC, DMAP, 8 %; (c) podophyllotoxin, EDC, 
DMAP, 80 %. 
This task resulted very tricky by classical chemicals means, but, given the nature of the 
compounds involved, it appeared to us as a promising field for the exploitation of the 
previously described lipase-controlled regioselective trans-acylations. In fact, aloin is a 
polyhydroxylated natural compound possessing two primary hydroxyl groups in two 
different regions of the its molecular skeleton (one on the aglycone and the other on the 
sugar moiety) on which a lipase may operate selectively. Indeed, the target hybrid compounds 
(3.15 and 3.16) could be easily obtained using an activated diester as acyl donor, via a sequence 
of biocatalyzed and chemical acylations, as it will be described in the following. 
A small library of lipases, different in nature, formulation and origin was tested on aloin, 
using both vinyl acetate (a) and divinyl dodecanoate (b) as acyl donors, to study the 
regiochemical outcome of the biocatalyzed trans-acylation. The results obtained are reported 
in Table 3.1. From this screening, as shown by 1H NMR analysis, it appeared clear that 
almost all the tested lipases showed a marked preference for the benzylic C15-OH. Lipase 
AK, CE and PS on Celite® (1 % w/w lipase/celite) allowed the regioselective production of 
compound 3.20 (Scheme  3.5) while 3.22 was obtained easily by the action of Novozyme435 
and, again, lipase AK and CE (Scheme  3.6). Specifically, when Novozym435 was used as 
catalyst, product 3.20 was obtained in a 1:1 mixture with the corresponding acid 3.21 
(Scheme  3.5).  
Thus, acid 3.21 was easily synthesized from aloin in the presence of Novozyme435 via a one-
pot process in which the cleavage of the second vinyl moiety of 3.20 was triggered in situ by 
HN
R
(3.11) R = H
(3.19) R = CO(CH2)8COOH
from 3.19
a
b
c
3.14
3.17
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adding a controlled amount of water. 3.21 was then transformed into the target conjugate 
3.15, as an inseparable mixture of diastereoimers at position 10, by condensation with the 
aniline derivative 3.11 in the presence of HBTU (Scheme  3.5).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the preparation of conjugate 3.16, aloin was at first acetylated on the aglycone primary 
OH exploiting, again, a lipase-based strategy. In fact, a combination of lipase PS on celite® 
(1 % w/w lipase/celite) and vinyl acetate gave intermediate 3.22 with complete control over 
the regioselection of the C-O bond formation. Isolated was yield up to the 80 %. 
 
 
Lipase 
Vinyl  
Acetate 
Divinyl 
Dodecanoate 
C15-OH C21-OH C15-OH C21-OH 
Porcine 
Pancreatic 
Lipase 
n.r. n.r. n.r. n.r. 
Lipase 
AK 
X n.r. X n.r. 
Lipase 
CE X n.r. X n.r. 
Candida 
rugosa 
Lipase 
n.r. n.r. n.r. n.r. 
Lipozyme 
IM20 X X n.r. n.r. 
Lipase PS 
on Celite® X n.r. n.r. n.r. 
Novozym435 X X X[a] n.r. 
Lipase 
N n.r. n.r. n.r. n.r. 
Table 3.1: Lipase regioselectivity in the acylation of aloin. 
Reagents and conditions: aloin (0.05 M, 1.0 eq), acyl donor (2.0 eq), dry acetone, 45 °C, 250 rpm, 48 h. 
n.r. = no reaction; [a]1:1 mixture of 3.20 and 3.21 
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The synthesis of 3.16, as an inseparable mixture of diastereoimers at position 10, was then 
accomplished by condensation of 3.22 and acid 3.19 in the presence of EDC (Scheme  3.6). 
 
Scheme  3.5: Chemo-enzymatic synthesis of 3.15.  
Reagents and conditions: a, b) Aloin, Novozym435 then water, 40 %; c) DIPEA, HATU, 65 %. 
 
 
Scheme  3.6: Chemo-enzymatic synthesis of 3.16.  
Reagents and conditions: a) Aloin, lipase PS on Celite® (1 % w/w lipase/celite). then water, 80 %;  
b) DMAP, EDC, 65%. 
The ability of the obtained compounds (3.14 - 3.17) to form NPs was finally 
investigated: all the conjugates, except 3.15, seemed to self-assemble, and the resulting 
homogeneous suspensions were characterized by dynamic light scattering (DLS), 
transmission electron microscopy (TEM, Figure 3.5) and nanoparticle tracking analysis 
(NanoSight). 
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Figure 3.5: TEM micrographs of nanoparticles formed by self-assembly of (1) compound 3.14, (2) compound 3.16 and 
(4) compound 3.17. All samples were stained with uranyl acetate solution. In all the panels scale bar represents 100 nm. 
All rights reserved to ©The Royal Society of Chemistry.  
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3.2 Experimental 
3.2.1 Lipase-catalyzed synthesis of compound 3.21 
To a solution of aloin (100 mg, 0.24 mmol) in dry acetone (15 
mL) divinyl dodecanedioate (101 mg, 0.36 mmol) and 
Novozym435 (30 mg) were added. The resulting 
heterogeneous mixture was incubated at 45 °C and 210 rpm 
for 48h. After that, 5 µL water were added to the mixture 
which was incubated again for additional 2 h, checking the formation of the target acid by 
TLC (CHCl3/MeOH/HCOOH = 8:2:0.1, UV). The crude mixture was then filtered, 
concentrated in vacuo and purified by flash column chromatography on silica gel 
(AcOEt/MeOH/H2O = 9.5:0.5:0.1) affording the purified product as a yellow oil (60 mg, 
40%). 1H-NMR (CD3OD, 400 MHz; mixture of diastereoisomers, 25 °C): δ 7.50 (1H, 
ddd, J = 8.3, 7.5, 6.3 Hz), 7.06 (2H, q, J = 6.0 Hz), 6.89-6.84 (2H, m), 5.16 (2H, d, J = 3.7 
Hz), 4.59 (1H, d, J = 1.5 Hz), 3.58 (1H, dd, J = 11.7, 1.9 Hz), 3.43-3.39 (2H, m), 3.33 (2H, 
dt, J = 3.3, 1.6 Hz), 3.28 (1H, t, J = 8.6 Hz), 3.03-2.97 (1H, m), 2.94-2.89 (2H, m), 2.47-2.37 
(4H, m), 1.70-1.58 (4H, m), 1.29 (12H, bs). 13C-NMR (CD3OD, 100 MHz; mixture of 
diastereoisomers, 25 °C): δ 194.1, 173.68, 173.60, 170.9, 161.84, 161.75, 161.62, 161.59, 
145.5, 145.08, 145.04, 144.4, 142.1, 135.8, 135.0, 119.9, 118.60, 118.59, 117.5, 117.24, 117.22, 
116.88, 116.70, 115.8, 115.5, 114.1, 113.9, 85.0, 80.30, 80.20, 78.55, 78.53, 70.62, 70.53, 70.46, 
64.74, 64.71, 61.89, 61.85, 44.5, 33.6, 33.2, 29.08, 29.03, 28.91, 28.88, 28.74, 28.65, 24.7, 24.3. 
MS (ESI) = 653.3 [(M+Na)+].  
 
3.2.1 Lipase-catalyzed synthesis of compound 3.22 
Aloin (100 mg, 0.24 mmol) and vinyl acetate (33 µL, 0.36 mmol) 
were dissolved in 15 mL of dry acetone under nitrogen atmosphere. 
Molecular sieves 4Å (30 mg) and lipase PS supported on Celite® (80 
mg, 1 % w/w lipase/celite) were then added to the resulting solution 
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which was incubated at 45 °C and 210 rpm for 48 h. After that, the formation of the desired 
product was observed by TLC (CHCl3/MeOH/HCOOH = 8:2:0.1, UV) and the crude 
mixture filtered, concentrated in vacuo and purified by flash column chromatography on silica 
gel (AcOEt/MeOH/H2O = 9.5:0.5:0.1), affording the purified product as a yellow solid (85 
mg, 80%). 1H-NMR (CD3OD, 400 MHz; mixture of diastereoisomers, 25 °C): δ 7.47 
(1H, ddd, J = 8.3, 7.6, 5.8 Hz), 7.04-7.00 (2H, m), 6.86-6.81 (2H, m), 5.16 (2H, d, J = 3.6 
Hz), 4.50 (1H, d, J = 1.9 Hz), 3.59-3.55 (1H, m), 3.42-3.37 (2H, m), 3.29-3.25 (1H, m), 3.00-
2.88 (3H, m), 2.17 (1H, s), 2.15 (2H, s). 13C-NMR (CD3OD, 100 MHz; mixture of 
diastereoisomers, 25 °C): δ 194.0, 171.6, 171.13, 171.03, 161.77, 161.69, 161.55, 161.51, 
145.4, 145.01, 144.88, 144.2, 142.0, 141.6, 135.7, 135.0, 119.9, 118.58, 118.51, 117.4, 117.2, 
116.82, 116.63, 115.7, 115.5, 114.1, 113.8, 85.18, 85.01, 80.26, 80.17, 78.53, 78.50, 70.60, 
70.58, 70.50, 70.46, 64.96, 64.91, 61.88, 61.83, 60.2, 44.45, 44.38, 19.50, 19.44, 13.1. MS 
(ESI) = 483.1 [(M+Na)+]. 
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4. Glycosidases: a stereo- and regio-selective 
synthesis of naturally occurring arylalkyl 
glucosides 
Substituted benzyl, phenethyl and phenylpropenyl glucosides (Figure 4.1) are bioactive 
natural compounds largely occurring in plants.26, 27, 28, 29, 30, 31 As an example, salidroside (4.2a) 
is associated with a wide number of pharmacological effects, including antioxidant, anti-
inflammatory and anticancer activities. Furthermore, isoconiferin (4.7a) and triandrin (4.5a) 
are respectively studied for their potential antidepressant and hypotensive effects. Those 
biological effects are primary related to the structures of the aglycone. However, the 
physicochemical, the pharmacological and the toxicity profiles of these chemicals are 
strongly influenced by the conjugation with the sugar.  
 
Figure 4.1: Compounds 4.1-4.8 and natural bioactive products 4.1a-4.8a. 
O
HOHO
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(4.1a) R = β-Glc
= β-Glc
(4.2)   R1 = OH, R2 = H 
(4.2a) R1 = β-Glc, R2 = H
(4.4)   R1 = OH, R2 = OH
(4.4a) R1 = β-Glc, R2 = OH
R3
(4.3)   R1 = OH, R2 = R3 = R4 = H 
(4.3a) R1 = β-Glc, R2 = R3 = R4 = H
(4.5)   R1 = OH, R3 = OH, R2 = R4 = H
(4.5a) R1 = β-Glc, R3 = OH, R2 = R4 = H
(4.6)   R1 = OH, R3 = OMe, R2 = R4 = H
(4.6a) R1 = β-Glc, R3 = OMe, R2 = R4 = H
(4.7)   R1 = OH, R2 =H, R3 = OH, R4 = OMe
(4.7a) R1 = β-Glc, R2 =H, R3 = OH, R4 = OMe
(4.8)   R1 = OH, R3 = OH, R2 = R4 = OMe
(4.8a) R1 = β-Glc, R3 = OH, R2 = R4 = OMe
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These bioactive glucosides have been either isolated in low amounts from natural sources or 
synthesized using classical glycosylation protocols. As an example, we have recently 
synthetized the (D)-glucoside 4.7a. The selected synthetic pathway (Scheme 4.1, for details 
see Paper VI) was based on well-defined and reliable protocols; nevertheless, the sequence 
of protective and deprotective reactions consisted of seven steps. Moreover, two 
chromatographic purifications were required when glucose and the respective primary 
alcohol were used as starting materials. Such procedures were time-consuming and resulted 
in mediocre overall yields, also requiring the use large amounts of solvents, silica gel, and 
various toxic chemicals.  
 
Scheme 4.1: Multi-step chemical synthesis of compound (4.7a).  
Reagents and conditions: a. N2, TBDMSiCl, imidazole, THF dry, 0 °C, 2h; b. N2, NaBH4, MeOH, 0 °C to r.t., 5h; c. 
Py, Ac2O, DMAP, r.t., 24 h; d. AcOH glacial, NH2(CH2)2NH2, THF, r.t., 3 h; e. N2, DBU, CCl3CN, DCM dry, r.t.; f. 
TMSOTf, powdered sieves 4 Å, DCM dry, −15◦C, 30 min, 30 % g. TBAF, THF dry, 0 °C, 2 h;  
h. MeONa/MeOH, r.t., 3 h. 
Therefore, an alternative and greener approach to synthetize arylalkyl glucosides was 
investigated, aiming at improving the overall efficiency and ensuring regio- and stereo-
selectivity by exploiting the inherent selectivity properties of enzymes. 
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4.1 Biocatalytic entries to glycosides  
As a general concept, the formation of stereoselective glycosidic bonds in Nature is mainly 
operated by glycosyltransferases (EC 2.4, GTFs). These enzymes catalyze the transfer of 
saccharide moieties from an activated glycosyl donor to a nucleophilic glycosyl acceptor 
building a new bond between the sugar moiety and a nucleophilic oxygen, carbon, nitrogen 
or sulfur atom.32 
 
Figure 4.2: Proposed glycosyltransferase mechanisms. HOAcc = glycosyl acceptor.   
(A) Double displacement mechanism: two inversions, via (B) an SN2 process, with net retention of stereochemistry 
involving a covalent glycosyl-enzyme intermediate. (C) Orthogonal mechanism: nucleophilic attack on C1 concurrent with 
leaving group loss from a position approximately at right angles to the C1-leaving group axis; (D) SNi mechanism: 
oxocarbenium-like intermediate character followed by rapid internal nucleophilic attach. (E) SN1 mechanism: discreet 
oxocarbenium intermediate. All rights reserved to PlosOne®. 
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GTFs can be classified in two main groups, depending on the stereochemical outcome of 
the glycosyl bond formation: ‘retaining GTFs’ preserve the stereochemistry of the donor's 
anomeric bond (i.e. α→α) while ‘inverting GTFs’ invert the absolute configuration at the 
anomeric position (i.e. α→β). In Figure 4.2, an overview about the possible mechanisms 
occurring for the two groups of GTFs’ is reported.33  
While, the inverting mechanism (A) appears as straightforward, requiring just a single 
nucleophilic attack from the accepting atom to invert stereochemistry, the nature of the 
retentive mechanism has been widely debated. Eventually, the ‘orthogonal associative 
mechanism’ (E), in which a single nucleophilic attack from a non-linear angle (as observed 
in many crystal structures) is postulated, was proposed and accepted. 
 
Figure 4.3: Schematic representation of a N-glycosylated asparagine residue of a protein backbone.34 
The glycosyl transfer operated by GTFs occurs in biological systems on a plethora of 
compounds, from small molecules, with the production of glycosylated metabolites, to 
macromolecular structures. As an example, GTFs can glycosylate proteins by transferring a 
glycosyl moiety to nucleophilic protein residues, leading to the formation of O-linked or N-
linked glycoproteins (Figure 4.3), depending on the nature of the residues involved in the 
reaction (serine, tyrosine and threonine or asparagine). GTFs can also use lipids as acceptors, 
thus promoting the formation of glycolipids.32 
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Regardless the synthetic potential of this class of biocatalysts to produce glycosides, the 
application of GTFs in organic synthesis is mainly affected by their need of activated glycosyl 
donors. They are expansive sugar nucleotides whose stereoselective synthesis can often be 
tricky (i.e. UDP-glucose or other nucleosides, glycosyl phosphate, Figure 4.4).35, 36, 37 
 
Figure 4.4: Examples of activated sugar donor. (i) uracil-diphosphate glucose, UDP-glucose; (ii) uridine diphosphate 
galactose, UDP-galactose; (iii) uridine diphosphate glucuronic acid; uridine diphosphate N-acetylglucosamine (iv) . 
The biocatalytic formation of stereoselective glycosidic bonds can also be 
accomplished by means of the promiscuous transglycosylation activity of the hydrolytic 
enzymes glycosidases, or by the action of the so-called glycosynthases, artificial mutants of 
natural glycosidases.38, 39  
 
Scheme 4.2: Transglycosylation reaction 
Promiscuous glycosidases are a group of enzymes widely used in organic chemistry as 
catalysts to synthetize glycosides. The synthesis of a new glycosidic bond can occur through 
either reverse hydrolysis (thermodynamic approach), where the equilibrium position is 
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reversed, or by transglycosylation (kinetic approach) whereby a glycosyl moiety is transferred 
from a glycoside to an acceptor alcohol to afford a new glycoside, as shown in Scheme 4.2.40 
As described for glycosyltransferases, also glycosidases can be either ‘retentive’ or ‘inverting’, 
depending on the stereochemical configuration of the new installed bond with the respect 
to the starting glycosyl donor.  
Glycosynthases, enzymes generated by site-directed mutagenesis to eliminate the hydrolytic 
attitude of natural glycosidases, can catalyze the formation of a glycosidic bond, but they are 
no longer able to hydrolyze it, owing to their mutated active sites. Traditionally, 
glycosynthases (Figure 4.5) were formed from glycosidase by mutating the nucleophilic 
amino acids in the active site (usually an aspartate or a glutamate) to a small, non-nucleophilic 
amino acid such as alanine or glycine).  
 
Figure 4.5: A glycosynthase: mutant endomannase with bounded mannodiose.41 
The development of modern approaches to directed evolution for the screening of amino 
acid substitutions, allowed to obtain glycosynthases with more and more enhanced synthase 
activity, able to successfully catalyze elegant glycoside syntheses.42 However, to properly 
promote the formation of glycosidic bonds, glycosynthases usually need activated sugar 
donors, such as fluorides or azides, and, generally speaking, require considerable workload, 
affecting, as in the case of glycosyltransferases, their synthetic exploitation. In fact, 
biotransformations carried out in the presence of ‘nude’ sugars and nucleophilic alcohols 
typically occur with low conversions.43  
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In the quest of a novel and convenient biocatalytic strategy to produce naturally 
occurring glucosides (Figure 4.1), in Paper III we have exploited the action of a 
promiscuous, stereo- and regio-selective glycoside hydrolase to build a one-pot, two-
enzymes strategy to synthetize glycosidic bonds between glucose and primary arylalkyl 
alcohols. 
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4.2 Two-enzymes approach 
Rutin (4.8), a glycosyl derivative of the flavonoid quercetin (4.9) (glycon: rutinose, α-L-
rhamnopyranosyl-β-D-glucopyranoside, 4.10), is an important phytochemical contained in 
various plants and fruits (i.e. buckwheat, apples, tobacco, tomatoes, citrus, and grapes), that 
was named after one of its primary natural sources, the common rue Ruta graveolens.44, 45  
In Nature, among all the metabolic pathways related to this compound, rutin conversion into 
quercetin occurs via the action of a specific diglycosidase, the enzyme called rutinosidase. 
Rutinosidase, whose systematic name is α-L-rhamnopyranosyl-β-D-glucosidase, is a fugal 
biocatalyst that selectively hydrolyses the glycosidic bond between the disaccharide moiety 
(rutinose) and the aglycone (quercetin), as shown in Scheme 4.3. 
 
Scheme 4.3: Rutinosidase-mediated hydrolysis of ruin. 
It has been recently shown by the group headed by professor Vladimir Křen that the 
diglycosidase rutinosidase from Aspergillus niger, cloned and expressed in Pichia pastoris, 
possesses such a strong promiscuous transglycosylation activity both for aliphatic alcohols 
and phenols, that can be regarded as much more efficient in these kind of biotransformations 
than other commonly used (mono)glycosidases. Moreover, thanks to its ‘retentive’ nature, 
the products obtained from the transfer of a rutinose moiety to a primary alcohol or phenol 
are formed stereospecifically as β-glycosides (Figure 4.6).46 Nevertheless, this specific 
reaction has another advantage: both the reactant and the by-product(s) are nontoxic 
(natural) flavonoids and, thus, they do not compromise the potential pharmaceutical and/or 
nutraceutical applications of the obtained glycosyl products.  
Regardless its complex structure, rutin (4.8) appears as a cheap and convenient glycosyl 
donor. It is in fact produced as a multiton commodity chemical from the brazilian tree Fava 
d’anta (Dimorphandra mollis) along with being accumulated as a waste by-product in different 
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manufacturing processes (e.g. the production of fruit juices). Also, it possesses a GRAS status 
(www.hcsc.gc.ca) and it’s used in a plethora of nutraceuticals and pharmaceutical 
preparations as a capillary/blood vessel protectant and as an antiviral agent.  
 
 C 
Figure 4.6: SDS-PAGE, 10% gel: A. 1 – crude secreted recombinant rutinosidase (after dialysis), 2 – purified 
recombinant rutinosidase; B. 3 – Endo Hf-deglycosylated purified recombinant rutinosidase; 4 – untreated purified 
recombinant rutinosidase. C. Synthetized β-rutinosides. © Wiley-VCH Verlag. 
Given all the listed advantages, the combination of rutinosidase and rutin, as an 
inexpensive (presently it costs less than 50 € kg-1) and nontoxic activated sugar donor, for 
the regio- and stereo-selective synthesis of rutinosylated conjugates appeared to us as highly 
versatile and promising. Therefore, a one-pot, two-enzymes entry to arylalkyl glucosides was 
built by exploiting the activity of the mentioned diglycosidase in combination with a proper 
glycoside hydrolase to selectively remove the unwanted rhamnose moiety, converting the 
rutinosylated substances into the desired β-glucosides. 
The hydrolase that was selected for this purpose was a robust α-L-rhamnosidase from 
Aspergillus terreus (cloned and expressed in Pichia Pastoris) characterized by a significant 
selectivity and high activity in the trimming of the α(6→1)rhamnosyl unit of rutin to yield 
isoquercetrin (4.11, Scheme 4.6).47, 48 The one-pot, two-enzymes approach is showed in 
(Scheme 4.4).  
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Scheme 4.4: One-pot, two-enzymes entry to arylalkyl glucosides.  
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4.3 Reaction optimization: toward a one-pot synthesis 
Transglycosylations are kinetically controlled reactions in which both the products and the 
reactants may become substrates for a subsequent hydrolysis catalyzed by the same enzyme, 
virtually lowering the overall yield (Scheme 4.5).  
 
Scheme 4.5: Transglycosylation and hydrolysis. 
Therefore, the first critical point of our investigation was the thorough optimization of the 
rutinosidase-catalyzed reaction, to promote a neat transgycosylation between rutin and the 
desired alcohol. As shown in Scheme 4.6, coniferyl alcohol (4.7), the aglycone of the natural 
hypotensive agent coniferin (4.7a), was chosen as a model glycosyl acceptor. 
 
Scheme 4.6: Two-enzymes entry to 4.7a. 
According to the published transglycosylation protocol (50 mM 1:1 mixture of rutin 
and glycosyl acceptor dissolved in a 50 vol% DMSO solution in citrate/phosphate buffer at 
pH 5, incubated at 35 °C for 7 h with 0.026 U mmolalcohol-1), a set of biotransformations was 
carried out to investigate the influence of four selected key parameters: a) enzyme loading, 
b) relative stoichiometry of the reactants, c) concentration of glycosyl donor (rutin) and d) 
amount of cosolvent (DMSO). 
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a) Enzyme loading. Different loads of biocatalyst were used: 0.0065, 0.013, 0.026 or 0.052 
U mmolalcohol-1 of rutinosidase. The obtained results showed that the highest was the amount 
of the enzyme, the fastest the hydrolysis of rutin to quercetin was. Moreover, when 0.0065 
U mmolalcohol-1 of rutinosidase were used, almost no transglycosylation was observed and only 
a slow hydrolysis occurred under these conditions. For all this reason, loading of rutinosidase 
was set to 0.013 U mmolalcohol-1: the hydrolysis reaction was in this case slow enough to permit 
a modest accumulation of the target disaccharide 4.7b in a reaction time of 7 hours. 
b-c) Stoichiometry/rutin concentration. The stoichiometric ratio between rutin and 
coniferyl alcohol was deeply investigated. Four different biotransformations were run using 
a 0.5:1, a 1:1, a 2:1 and a 4:1 stoichiometric ratio of glycosyl donor/acceptor, respectively. 
When a 1:1 or a 2:1 mixture of rutin and alcohol was used, the conversion of coniferyl alcohol 
into the rutinoside was rather low (15 %, evaluated by HPLC) as quercetin was obtained as 
major product. Furthermore, when a 4:1 ratio was used, no reactions were catalyzed by the 
enzyme - neither the hydrolysis nor the transglycosylation. However, when a 0.5:1 mixture 
of rutin and alcohol was used, the conversion of the arylalkyl alcohol to the target 
disaccharide was higher (up to the 50 %, evaluated by HPLC). Thanks to these results, it was 
concluded that an excess of glycosyl acceptor was needed to promote the transglycosylation 
reaction over hydrolysis. Moreover, a strong inhibitory effect was observed for the enzyme 
at high concentrations of rutin.  
c-d) Stoichiometry/cosolvent. The amount of DMSO (in terms of % v/v) was 
investigated, as the reaction mixture appearance was strongly dependent to it: both rutin and 
quercetin are in fact almost completely insoluble in water at acid pHs, unless more than the 
40 % v/v of DMSO is used as cosolvent. Therefore, different concentrations of DMSO 
were used to run control biotransformations (40, 30, 20, 15 and 10 vol%), with a 1:1 
stoichiometric ratio between rutin and coniferyl alcohol. The reaction run in the presence of 
40 % v/v DMSO was a clear solution that gave just a 10 % (HPLC) conversion into the 
desired product. When 15 % v/v of DMSO was used, the system appeared as a solid-liquid 
biphasic system with rutin (and quercetin) just partially dissolved while the glycosyl acceptor 
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was in solution. Interesting enough, in this case conversion, evaluated by HPLC, was more 
than the 40 %. 
On the base of these results, 4.7 was subjected to the action of rutinosidase (ca. 0.013 
U mmolalcohol-1) using an initial excess of alcohol acceptor relative to the glycosyl donor 
(rutin/alcohol = 0.5:1 equiv.). To limit the significant substrate inhibition caused by rutin, a 
15 % v/v of DMSO was used to decrease the active concentration of rutin in the reaction 
media as, in this system, the donor was just suspended and only partially dissolved. Moreover, 
to make this procedure fully scalable and green, a purification strategy avoiding the use of 
silica gel chromatography was developed. By fully exploiting the physicochemical differences 
between the starting alcohol 4.7, the rutinoside product 4.7b, the residual rutin 4.8 (if any), 
the produced quercetin 4.9 and the free disaccharide rutinose always formed as a byproduct 
4.10, it was possible to purify 4.7b by means of i) centrifugation; ii) extraction with organic 
solvents and iii) solid-phase extraction on Amberlite® XAD4 non-ionic resin.49 Accordingly, 
the produced 4.9 was removed by centrifugation, the unconsumed coniferyl alcohol 4.7 was 
extracted with AcOEt, and the hydrolyzed rutinose 4.10, the buffer salts, and the residual 
DMSO cosolvent were easily removed in the eluate. Product 4.7b was instead adsorbed on 
the XAD4 resin and then eluted using MeOH. The cosolvent DMSO did not compromise 
the green concept of this protocol: its toxicity is very low (DMSO is currently used in 
cosmetics and medications to increase skin permeability) and its residual presence could not 
be detected in the isolated products by NMR spectroscopy. 
The preparative-scale transrutinosylation of 4.7 was conducted starting from a 1 g 
alcohol. Rutin (a total of 1.5 equiv.) was added portion-wise (0.5 equiv. each time) over 8 h 
(its disappearance was monitored by TLC). Following the described protocol, product 4.7b 
was finally isolated in 70% yield and fully characterized by MS (m/z 511.3 [M+Na+]) and 
NMR spectroscopy. In addition to the expected signals owing to the coniferyl moiety, the 
presence of a disaccharide unit was clearly demonstrated by the respective signals in the 1H 
NMR spectrum. Specifically, the anomeric protons of the rhamnopyranose and 
glucopyranose units gave rise to doublets (J 1.6 and 7.8 Hz, respectively) centered at 4.80 and 
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4.37 ppm. The presence of the rhamnopyranose unit was further confirmed by the signal of 
its methyl group (dH =1.30, d, J 6.3 Hz). Moreover, the initial transglycosylation reaction was 
not only stereospecific (production of a β-glycoside from a β-glycosyl donor), but it was also 
highly regioselective, as no formation of phenolic glycoside was observed. 
Once the first transglycosylation step had been optimized, the synthesis of the target 
natural glucoside 4.7 was straightforward. The enzymatic trimming of the rhamnose unit was 
easily obtained by incubating 4.7b in a citrate phosphate solution (50 mM, pH 5) at 45 °C 
for 3 h with ca. 2 U mmolalcohol-1 of a rhamnosidase from A. terreus. After a solid phase 
extraction on XAD4 resin, the purified glucoside 4.7 was obtained in 90 % yield. Compound 
7a was characterized by MS (m/z 365.2 [M+Na+]) and 1H and 13C NMR spectroscopy, which 
showed the presence of both the coniferyl aglycone and the glucopyranosyl moiety, in perfect 
agreement with literature data.50 
Once 4.7 was successfully obtained via this novel two-enzymes catalyzed entry, the 
target one-pot approach was investigated by merging the two enzymatic reactions. A so-
called telescoping synthesis was studied: the reactants were added sequentially to the reactor 
without any intermediate purification or work-up and the reactions were run in one pot. In 
this way, the rutinose grafting by glucosylation of coniferyl alcohol was achieved by 
sequentially combining the transglycosylation grafting and the rhamnose trimming by 
hydrolysis. The two enzymes, in fact, demonstrated to conveniently share the same optimal 
operational conditions, being both stable and active at the same pH and temperature. 
However, rutinosidase had to be thermally inactivated prior to adding the rhamnosidase (0.5 
U mmolalcohol-1) and stirring the final reaction mixture overnight. The target glucoside 4.7a 
was isolated in 75% yield after purification following the previously described procedure 
based on XAD4 resin.  
The above described and optimized one-pot synthesis was then applied to the 
alcohols 4.1–4.8. As shown in (Table 4.1), all compounds were accepted by the rutinosidase, 
except for sinapyl alcohol 4.8. Compounds 4.4-4.6 behaved analogously to 4.7, and with 
coumaryl alcohol 4.5 the transglycosylation reaction was also fully regioselective. 
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Compounds 4.1-4.3 were also glycosylated, but, apparently, they were less reactive as the 
yields of isolated products were lower. Kinetic studies of the enzymatic glycosylation of 4.1 
and 4.2, evaluating the formation of the rhamnosidase derivatives 4.1b and 4.2b (Figure 
4.7), showed how the lower yield could be a consequence of an inevitable enzymatic 
hydrolysis of the target monosaccharide. Therefore, the reactions needed to be carefully 
monitored to maximize the yields.  
 
 
 
 
 
 
 
The structural rigidity of the fully conjugated system characterizing compounds 4.4-
4.7 apparently made them suitable substrates for the transglycosylation reactions, as they 
proved to be good acceptors and bad donors. Therefore, the enzymatic hydrolysis of their 
corresponding rutinoside derivatives was almost completely avoided. Tyrosol (4.3) on the 
contrary, behaved similarly to compounds 4.1 and 4.2, possessing neither a rigid p-system 
nor a 3-long carbon chain connecting the nucleophilic primary alcohol to the phenyl ring. 
The differences between the streoelectronic features of compounds 4.1-4.3 and 4.4-4.7 could 
have led to the different performances that the two family of nucleophiles showed in the 
one-pot synthesis. This was especially the case with compound 4.3. 
 Product Yield[a] % 
1[b] 1a 12 
2[b] 2b 24 
3[b] 3a 3c 
44.5[c] 
  4.5[c] 
4 4 70 
5 5a 68 
6 6a 58 
7 7a 75 
8 -- -- 
Table 4.1: One-pot, two-enzymes synthesis.  
Reagents and conditions: i) rutinosidase (0.013 U mmolalcohol-1), arylalkyl alcohol (130 mM, 1 equiv), rutin (1.25 equiv.), 
citrate-phosphate buffer 50 mM pH 5/dimethyl sulphoxide = 85 % : 15 %, 35 °C and 750 rpm; ii) rhamnosidase (0.5 U 
mmolalcohol-1), 35 °C and 750 rpm , overnight. Centrifugation, extraction, XAD4 solid phase extraction. [a] Yields of 
isolated products. [b] Reactions with substrates 1, 2, and 3 were performed for 24 h instead of 8 h.  
[c] Relative ratio estimated by 1H NMR spectroscopy. 
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Figure 4.7: Kinetic profiles of the production of 4.1b and 4.2b. 
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4.4 The case of tyrosol 
Tyrosol (4.3) behaved differently also in terms of regioselectivity. In fact, along with the 
lower isolated yield, the desired glucoside 4.3a was obtained in a 10 : 1 mixture with the 
regioisomer 4.3c (Figure 4.8).  
 
Figure 4.8: Glycosides of tyrosol (4.3). A) Two-enzyme synthesis of tyrosol glu- cosides 4.3a and 4.3c. B) Rutinosidase-
catalyzed synthesis of tyrosol rutinosides 4.3b and 4.3d. © 2017 VILEY Wiley-VCH 
The mass spectrum of the isolated product (m/z 232.2 [M+Na+]) confirmed the introduction 
of a glucose moiety. However, the 1H NMR spectrum clearly showed the presence of two 
products in 10 : 1 ratio. The signal resulting from the α-anomeric proton of the major 
product, a doublet with J 7.8 Hz resonating at 4.29 ppm, could be overlapped with the 
corresponding signal of the glucoside of phenylethanol (4.2a). As a consequence, it could be 
possible to assign the structure 4.3a to this compound. The significant downfield shift of the 
aromatic protons of the minor product [the two coupled doublets (J 8.4 Hz) resulting from 
the AA’BB’ aromatic system resonate at 7.18 and 7.03 ppm in the case 4.3b, whereas they 
were recorded at 7.08 and 6.71 ppm in 4.3a], indicated, instead, the glucosylation of the 
phenolic OH group (4.3c).  
To further investigate the glycosylation of this compound, the intermediate tyrosol 
rutinosides 4.3b and 4.3d were isolated and a set of kinetic experiments conducted. 
HO
O-β-D-Glc
Glc-D-β-O
OH
HO
OH
HO
O-β-D-Glc-α-L-Rha
Rha-L-α-Glc-D-β-O
OH
(4.3)
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B)
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Following the previously described protocol, a mixture of the expected regioisomers 4.3b 
and 4.3d (MS and 1H NMR spectrum in accordance with the proposed structures) was again 
obtained, this time in 3 : 1 ratio. 
The different regioisomeric ratio observed between 4.3a/4.3c (10:1) and 4.3b/4.3d (3:1) 
could be kinetically rationalized by considering the different reaction time allowed for the 
transrutinosylation step in the two protocols, which was longer in the telescopic synthesis. 
In fact, kinetics studies performed by monitoring the reactions by reversed-phase HPLC 
clearly showed that the phenolic rutinoside 4.3d could be hydrolyzed faster than alkyl 
rutinoside 4.3b (Figure 4.9).  
 
Figure 4.9: Kinetic profiles of the production of 4.3d and 4.3c.  
The separation of the two regioisomeric glycosides (4.3a from 4.3c, 4.3b from 4.3d) 
proved to be quite troublesome, and several techniques failed, including silica-gel flash 
chromatography and reverse phase preparative HPLC. On the contrary, the separation of 
the regioisomeric rutinosides 4.3b and 4.3d could be achieved by gel filtration with Biogel 
P2 (BioRad), and the major product 4.3b could be obtained in a 94% purity, as determined 
by 1H NMR spectroscopy. 
  
0
20
40
60
80
100
0 3 6 9 12 15 18 21 24 27 30
C
on
ve
rs
io
n 
%
Time (hours)
4.3d 4.3c Tyrosol
Glycosidases 
 
 38 
4.5 Conclusions 
A small library of naturally occurring bioactive glucosides was successfully synthetized by 
combining the action of a promiscuous diglycosidase rutinosidase from Aspergillus niger and 
of a rhamnosidase from A. terreus (both cloned and expressed in Pichia pastoris) in a 
biocatalytic process characterized by complete control over the stereochemical outcome. The 
target natural b-glucosides were obtained in isolated yield up to the 80% via a convenient 
telescoping synthesis that avoided the need of intermediate isolation and product purification 
by flash column chromatography.  
In comparison, the chemical synthesis of, i.e., 4.7a required seven reactions 
(protection of carbohydrate hydroxyl groups, deprotection of the anomeric OH group, 
activation of the anomeric OH group, protection of the phenolic OH group, condensation 
between activated sugar and aglycone, deprotection of the phenolic moiety, deprotection of 
the sugar OH groups) and two silica-gel chromatography steps.  
Therefore, the proposed enzymatic approach is superior to the chemical one in terms of 
better atom economy.51 Both enzymes used in this work, that is, rutinosidase and 
rhamnosidase, do not need to be recycled. They are both produced heterologously by P. 
pastoris and their production costs are very low. In fact, the typical activity obtained is 
approximately 0.15 U mL-1 cultivation broths. This means that less than 1 mL of the medium 
is required for 1 g coniferyl alcohol. The previously described experiments were run in the 
presence of purified rutinosidase, but it was also verified that even the crude enzyme (that is 
just using the fermentation medium) could be equivalently used. By rough estimation, the 
substrate used for the optimization study (coniferyl alcohol) is significantly (ca. 100–1000 
times) more expensive than the enzymes, thus making not economical the additional work 
required to regenerate the biocatalysts. Moreover, the use of immobilized enzymes was not 
compatible with the proposed protocol: ss the reactions were run with a suspension of 
substrates, soluble enzymes were needed.  
On the contrary, polystyrene microporous resin Amberlite XAD4 could be well 
reused in tens of cycles and refreshed by simple washing with MeOH or acetone. Moreover, 
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well-assessed regeneration protocols are available in the case resin starts to lose capacity. 
Therefore, the resin can be technically used for tens to hundreds of cycles. 
 
Some of the synthetized glycosides, specifically compounds 4.5a and 4.7a, were also 
tested as substrates for a laccase-mediated oxidative-dimerization to synthesize, in a one-pot 
process, 2,3-dihydrobenzofuran-based analogues of these bioactive compounds. This topic 
will be discussed later in the paragraph ‘Oxidative dimerization of glycosylated lignols’ of the chapter 
‘Laccases’.  
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4.6 Experimental 
4.5.1 Two-step two-enzymatic synthesis of coniferin (4.7a) 
a) A suspension of rutin (1.70 g, 2.78 mmol) in a 15 % solution of DMSO in citrate-
phosphate buffer (50 mM pH 5) containing 
coniferyl alcohol (1.00 g, 5.56 mmol) and 
rutinosidase from A. niger (0.073 U) were prepared 
and incubated at 35 °C and 750 rpm. The 
consumption of the glycosyl donor was checked by 
TLC analysis and 1.70 g of rutin was added again to the reacting mixture after 3 and 5 h. 
After 8 h the obtained yellow suspension was heated to 100 °C for 10 minutes and then 
cooled again to room temperature, diluted with ten 400 mL of citrate-phosphate buffer and 
centrifuged, recovering only the supernatant. The pH was changed from 5 to 7.5 – 7.7 and 
the water layer was extracted with AcOEt (2 × 200 mL) and then, after removing the residual 
AcOEt via concentration in vacuo, it was loaded to a column (5 × 30 cm) with Amberlite 
XAD4 resin (300 g) in water (elution with slow gradient H2O to MeOH), affording the pure 
rutinoside 4.7b (yellow solid, 755 mg, 70 %). The resin can be simply reused after washing 
with pure MeOH followed by extensive washing with water. 1H-NMR (400 MHz; MeOD, 
25 °C): d 7.04 (d, J = 1.9 Hz, 1H: H-5), 6.89 (dd, J = 8.2, 1.9 Hz, 1H: H-3), 6.76 (d, J = 8.1 
Hz, 1H: H-3), 6.60 (d, J = 15.9 Hz, 1H: H-7), 6.21 (ddd, J = 15.8, 6.8, 5.9 Hz, 1H: H-8), 4.80 
(d, J = 1.6 Hz, 1H: H-16), 4.48 (ddd, J = 12.3, 5.8, 1.3 Hz, 1H: H-9A), 4.37 (d, J = 7.8 Hz, 
1H: H-10), 4.28 (ddd, J = 12.3, 7.0, 1.1 Hz, 1H: H-9B), 4.01 (dd, J = 11.3, 1.7 Hz, 1H: H-
15A), 3.88 (s, 3H: OCH3), 3.73-3.64 (m, 3H: H-15B, H-18, H-20), 3.44-3.21 (m, 6H: H-11, H-
12, H-13, H-14, H-17, H-19), 1.30 (d, J = 6.3 Hz, 3H: H-21). 13C-NMR (101 MHz; MeOD, 
25 °C): d 147.7, 146.3, 133.1, 128.9, 122.1, 119.7, 114.8, 109.2, 101.6, 100.9, 76.7, 75.5, 73.7, 
72.6, 70.97, 70.83, 70.3, 69.5, 68.4, 66.8, 54.9, 29.3, 16.7. EI-MS, m/z 511.3 [M+Na]+. 
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b) Rhamnosidase from A. terreus (0.82 U) was dissolved in citrate-phosphate buffer (50 mM, 
pH 5) solution of 4.7a (200 mg, 0.41 mmol, 2.5 mL). The 
resulting mixture was incubated at 35 °C and 750 rpm for 
3 h. After checking the complete conversion of the 
starting rutinoside into the target glucoside by TLC analysis, heated to 100 °C for 10 minutes 
and then cooled again to room temperature to be subjected to an Amberlite XAD4 solid 
phase extraction (loaded and washed with H2O; eluted with MeOH), affording pure 
coniferin, 4.7a (yellow solid, 126 mg, 90%). 1H-NMR (400 MHz; MeOD, 25 °C): d 7.03 
(d, J = 1.9 Hz, 1H: H-5), 6.87 (dd, J = 8.2, 1.9 Hz, 1H: H-3), 6.76 (d, J = 8.1 Hz, 1H: H-2), 
6.59 (d, J = 15.9 Hz, 1H: H-7), 6.21 (ddd, J = 15.9, 6.7, 6.0 Hz, 1H: H-8), 4.51 (ddd, J = 12.4, 
5.9, 1.4 Hz, 1H: H-9A), 4.39 (d, J = 7.8 Hz, 1H: H-10), 4.32 (ddd, J = 12.4, 6.8, 1.2 Hz, 1H: 
H-9B), 3.90 (dd, J = 11.9, 2.0 Hz, 1H: H-15A), 3.88 (s, 3H: OCH3), 3.70 (dd, J = 11.9, 5.4 Hz, 
1H: H-15B), 3.41-3.23 (m, 4H: H-11, H-12, H-13, H-14). 13C-NMR (101 MHz; MeOD, 
25 °C): d 147.7, 146.3, 132.9, 129.0, 122.4, 119.8, 114.8, 109.3, 101.8, 76.74, 76.57, 73.7, 70.3, 
69.6, 61.4, 55.0. EI-MS, m/z 365.2 [M+Na]+. 
 
4.5.2 Telescoping two-enzymatic glucosylation: general procedure. arylalkyl alcohol (1 
eq, 128 mM) and rutinosidase from A. niger (0.013 U mmol-1substrate) were dissolved in a 15 % 
solution of DMSO in citrate-phosphate buffer (50 mM pH 5) and incubated at 35 °C and 
750 rpm. The glycosylation reaction was started by adding 0.5 eq of rutin. Monitoring the 
consumption of the glycosyl donor by TLC analysis, two portions of rutin, 0.5 eq each, were 
added. The transglycosylations were conducted for 8 or 16 h, depending on the substrate 
used. When all the rutin was consumed, the suspension was heated to 100 °C for 10 minutes 
and then cooled again to 35 °C and rhamnosidase from A. terreus (0.5 U mmol-1substrate) was 
added to the mixture, which was incubated overnight at 35 °C and 750 rpm. The complete 
conversion of the intermediate disaccharide to the target b-glucopyranoside was checked by 
TLC analysis and then the resulting yellow suspension was cooled to room temperature, 
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diluted with ten volumes of citrate-phosphate buffer and centrifuged. The solid proved to 
be the expected quercetin (10) containing ca 20-25 % of unreacted rutin. The supernatant 
water layer, after shifting the pH from 5 to 7.5 – 7.7, was extracted twice with half the volume 
of AcOEt and then, after removing the residual AcOEt in vacuo, subjected to an Amberlite 
XAD4 solid phase extraction (mobile phase H2O : MeOH, from 100 : 0 to 0 : 100), affording 
the pure arylalkylglucoside.  
Compound 4.1a: According to the General Procedure, compound 4.1a (30 mg, 0.11 mmol, 
isolated yield: 12 %, yellow oil, 24 h) was obtained from 100 mg 
of benzyl alcohol and 846 mg of rutin. 1H-NMR (500 MHz; 
MeOD, 25 °C): d 7.44 (d, J = 7.3 Hz, 2H: H-2, H-6), 7.35 (t, J 
= 7.4 Hz, 2H: H-3, H-5), 7.29 (t, J = 7.3 Hz, 1H: H-1), 4.95 (d, J = 11.8 Hz, 1H: H-7A), 4.69 
(d, J = 11.8 Hz, 1H: H-7B), 4.38 (d, J = 7.7 Hz, 1H: H-10), 3.92 (d, J = 10.2 Hz, 1H: H-15A), 
3.72 (dd, J = 11.8, 5.5 Hz, 1H: H-15B), 3.39-3.26 (m, 6H: H-11, H-12, H-13, H-14). 13C-
NMR (101 MHz; MeOD, 25 °C): d 132.4, 122.55, 122.48, 122.0, 96.6, 71.41, 71.36, 71.33, 
71.32, 68.49, 68.44, 65.04, 65.03, 56.1, 33.7. EI-MS, m/z 293.1 [M+Na]+. 
Compound 4.2a: According to the General Procedure, compound 4.2a (36 mg, 0.20 mmol, 
isolated yield: 24 %, yellow solid, 24 h) was obtained from 100 
mg of 1-phenyl ethanol  and 750mg of rutin. 1H-NMR (500 
MHz; MeOD, 25 °C): d 7.27 (d, J = 4.5 Hz, 4H: H-2, H-3 H-
5, H-6), 7.19 (q, J = 4.4 Hz, 1H: H-1), 4.32 (d, J = 7.8 Hz, 1H: H-10), 4.11 (dt, J = 9.5, 7.5 
Hz, 1H: H-8A), 3.88 (dd, J = 11.7, 1.5 Hz, 1H: H-15A), 3.81-3.76 (m, 1H: H-8B), 3.69 (dd, J 
= 11.8, 5.2 Hz, 1H: H-15B), 3.39-3.19(m, 4H: H-11, H-12, H-13, H-14), 2.96 (td, J = 7.3, 1.6 
Hz, 2H: H-7). 13C-NMR (101 MHz; MeOD, 25 °C): d 133.4, 123.3, 122.67, 122.64, 120.53, 
120.50, 97.7, 71.43, 71.29, 68.4, 65.0, 56.1, 33.7, 30.6. EI-MS, m/z 307.0 [M+Na]+. 
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Compound 4.3a, salidroside: According to the General Procedure, compound 4.3a (106 
mg, 0.35 mmol, isolated yield: 49 %, yellow solid, 24 h) was 
obtained from 100 mg of tyrosol and 663 mg of rutin. 1H-
NMR (500 MHz; D2O, 25 °C): d 7.05 (d, J = 8.3 Hz, 2H: 
H-3, H-5), 6.69 (d, J = 8.3 Hz, 2H: H-2, H-6), 4.29 (d, J = 7.8 Hz, 1H: H-10), 4.04-3.99 (m, 
1H: H-8A), 3.85 (d, J = 10.7 Hz, 1H: H-15A), 3.68 (td, J = 13.2, 5.8 Hz, 3H: H-7A, H-8B, H-
15B), 3.36 (t, J = 8.7 Hz, 1H: H-11), 3.31-3.24 (m, 3H: H-7A, H-12, H-14), 3.18 (t, J = 8.4 Hz, 
1H: H-13). 13C-NMR (101 MHz; D2O, 25 °C): d154.3, 128.45, 128.26, 113.7, 101.8, 75.59, 
75.41, 72.6, 69.6, 69.1, 60.3, 38.0, 33.9. EI-MS, m/z 323.2 [M+Na]+.  
Compound 4.4a, rosin: According to the General Procedure, compound 4.4a (140 mg, 
0.47 mmol, isolated yield: 70 %, yellow solid, 8 h) was 
obtained from 100 mg of cinnamyl alcohol and 684 mg of 
rutin. 1H-NMR (400 MHz; MeOD, 25 °C): d 7.44-7.42 (m, 2H: H-2, H-6), 7.31 (dd, J = 
8.2, 6.7 Hz, 2H: H-3, H-5), 7.23 (t, J = 7.3 Hz, 1H: 1), 6.70 (d, J = 16.0 Hz, 1H: H-7), 6.39 
(ddd, J = 16.0, 6.4, 5.8 Hz, 1H: H-8), 4.55 (ddd, J = 12.8, 5.7, 1.5 Hz, 1H: H-9A), 4.39 (d, J = 
7.8 Hz, 1H: H-10), 4.35 (ddd, J = 12.8, 6.5, 1.4 Hz, 1H: H-9B), 3.91 (dd, J = 11.9, 2.0 Hz, 
1H: H-15A), 3.71 (dd, J = 11.9, 5.3 Hz, 1H: H-15B), 3.42-3.24 (m, 4H:H-11, H-12, H-13, H-
14). 13C-NMR (101 MHz; MeOD, 25 °C): d 136.8, 132.4, 128.2, 127.3, 126.1, 125.3, 102.0, 
76.72, 76.59, 73.7, 70.3, 69.4, 61.4. EI-MS, m/z 319.2 [M+Na]+. 
Compound 4.5a, triandrin: According to the General Procedure, compound 4.5a (141 mg, 
0.45 mmol, isolated yield: 68 %, yellow solid, 8 h) was 
obtained from 100 mg of 4-hydroxycinnamyl alcohol (5) 
and 603 mg of rutin (9).1H-NMR (400 MHz; D2O, 
25 °C): d 7.32 (d, J = 8.0 Hz, 2H: H-3, H-5), 6.83 (d, J = 7.8 Hz, 2H: H-2, H-6), 6.58 (d, J = 
15.9 Hz, 1H: H-7), 6.16 (dt, J = 15.0, 7.1 Hz, 1H: H-7), 4.47-4.40 (m, 2H: H-9A, H-10), 4.31-
4.27 (m, 1H: H-9B), 3.86 (d, J = 12.6 Hz, 1H: H-15A), 3.69-3.66 (m, 1H: H-15B), 3.44-3.24 
(m, 4H: H-11, H-12, H-13, H-14). 13C-NMR (101 MHz; D2O, 25 °C): d 215.4, 155.6, 133.6, 
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128.9, 128.2, 122.3, 115.7, 101.1, 75.92, 75.90, 73.2, 70.5, 69.7, 60.8, 38.8, 30.3. EI-MS, m/z 
335.1 [M+Na]+. 
Compound 4.6a, vimalin: According to the General Procedure, compound 4.6a (115 mg, 
0.35 mmol, isolated yield: 58 %, yellow solid, 8 h) was 
obtained from 100 mg of 4-methoxycinnamyl alcohol 
and 558 mg of rutin. 1H-NMR (500 MHz; MeOD, 
25 °C): d 7.35 (d, J = 8.7 Hz, 2H: H-3, H-5), 6.87 (d, J = 8.8 Hz, 2H: H-2, H-6), 6.61 (d, J = 
16.0 Hz, 1H: H-7), 6.22 (dt, J = 15.9, 6.3 Hz, 1H: : H-8), 4.51 (ddd, J = 12.5, 5.8, 1.3 Hz, 1H: 
H-9A), 4.38 (d, J = 7.8 Hz, 1H: H-10), 4.30 (ddd, J = 12.4, 6.8, 1.1 Hz, 1H: H-9B), 3.90 (dd, J 
= 11.9, 2.2 Hz, 1H: H-15A), 3.78 (s, 3H: OCH3), 3.71 (dd, J = 11.9, 5.5 Hz, 1H: H-15B), 3.41-
3.24 (m, 4H: H-11, H-12, H-13, H-14). 13C-NMR (101 MHz; MeOD, 25 °C): d 154.1, 
127.0, 124.1, 122.0, 117.5, 108.3, 96.5, 71.36, 71.20, 68.4, 64.9, 64.3, 56.1, 49.0, 33.7. EI-MS, 
m/z 349.2 [M+Na]+. 
Compound 4.7a, coniferin: According to the General Procedure, compound 4.7a (508 mg, 
isolated yield: 75 %, yellow solid, 8 h) was obtained from 250 mg of coniferyl alcohol and 
1.30 g of rutin. The NMR and mass spectra were in accordance with those described above.  
 
4.5.3 HPLC analysis: methods  
Biotransformations were run following protocol 4.5.1a. Substrates were incubated for 30 
hours at 35 °C and 750 rpm. Rutin was added at 3h, 7h until a total amount of 1.5 equiv. 
were reached. When all the rutin added was consumed, the mixtures were left reacting to 
investigate the hydrolysis of the obtained disaccharide in the absence of the glycosyl donor.  
Sample preparation. 50 µL of the reaction mixtures were diluted with three volumes of 
distilled water, incubated at 100 °C and then centrifuged, recovering only the supernatant. 
The obtained clear solutions were used for the HPLC analysis.  
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Analysis conditions.  
- Column = Kinetex C18 HPLC 5µm EVO C18 100Å, 150x4.6 mm 
- Flow = 0.8 mL/min; - Loop = 20 µL; - Detection Lambda =: 270 nm; - Injection = 10 µL of the 
sample prepared flowing the listed procedure. 
- Gradient A = CH3CN = A; H2O (0.1 ppm TFA, pH 3) = B  
  0 min: 20 % of A; 1-10 min: 30 % of A; 11-14 min: 90 % of A; 15-17 min: 20 % of A; 
- Gradient B = CH3CN = A; H2O (0.1 ppm TFA, pH 3) = B  
   0 min: 10 % of A; 1-10 min: 20 % of A; 11-14 min: 90 % of A; 15-17 min: 10 % of A 
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5. Amine transferases: from hot spring 
metagenomes to chiral amines  
The discovery of novel, convenient and efficient methods for the selective preparation of 
stereogenic carbon-nitrogen bonds is a prosperous research topic in the field of synthetic 
organic chemistry. Specifically, organocatalytic, organometallic and biocatalytic entries to 
enantiomerically enriched chiral amines, valuable building blocks for the preparation of 
pharmaceutical agents that span a range of therapeutic areas (including antihypertensive, 
antibiotics, antidepressants, antihistamines, and antidiabetics), have been and are being 
proposed nowadays. 
In the last two decades, biocatalysis has emerged as an interesting alternative to conventional 
chemical methods in generating also chiral amine compounds. Specifically, amine 
transferases (ATAs) represent an attractive option for chiral amine synthesis and have been 
demonstrated to be suitable tools for application on industrial scale.  
However, the number of useful enzymes that are commercially and industrially available is 
still pretty limited. This is especially true for thermostable ATAs which are needed for 
industrial processes run under harsh (i.e. conditions such as high temperature and/or in the 
presence of organic solvents). 
 
In the work described in Paper VI, in the quest of a selective and robust biocatalyst 
to perform the asymmetric synthesis of chiral amines, a metagenomics-based approach was 
exploited to find novel thermostable ATAs. The identified new ATAs were then fully 
characterized in terms of stability (i.e. high temperatures and organic co-solvents) and 
screened for their ability to selectively produce chiral amines.  
  
Aminotransferases 
 47 
5.1 Biocatalysis and chiral amines: amine transferases  
Transaminases (TAs, EC 2.6.1.x) are ubiquitous enzymes in Nature where they play a key 
role in nitrogen metabolism.52,53 These pyridoxal-5′-phosphate (PLP)-dependent biocatalysts 
are capable of transferring an amino group between an amino donor and a carbonyl acceptor, 
creating a novel stereogenic center in the transamination reaction, when the carbonyl is 
prochiral group (Figure 5.1). 
 
Figure 5.1: Example of a aminotransferase PLP-dependent mechanism. 
In this case, an aspartate transaminase converting aspartate to oxaloacetate. 
Generally, TAs are classified into α-TAs, which represent the majority of TAs and are able 
to interconvert only α-amino and α-keto acids, and ω-TAs, which can have amino acids with 
a distal carboxylic acid group as substrates/products.53, 54 
Among ω-TAs, the class of amine transaminases (ATAs) is of particular interest for synthetic 
applications, as they also convert amines lacking a carboxylic acid group in addition to α-
amino acids and ω-amino acids. The action of a proper ATA can in fact promote the selective 
(both regio- and enantio-) preparation of chiral amines as synthons or late-structural 
modification of drugs and chemical intermediates. Moreover, these promising selectivity 
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features do not depend on the use of metal catalysts (i.e. Ru, Pd and/or Ni) at high pressure, 
as often reported in chiral amine chemical syntheses.55  
Both (S)- and (R)-selective ATAs could be found in Nature and exploited both for the kinetic 
resolution of racemic amines and the synthesis of chiral amines starting from the 
corresponding ketones, 52, 56, 57 thus allowing a fully-biocatalytic entry to both the enantiomers 
of a selected chiral amine (Figure 5.2) and confirming the synthetic potential of amine 
transferases. 
 
Figure 5.2: Complementary approaches for the preparation of enantio-enriched primary amines.  
(a) Kinetic resolution starting with racemic (rac) amines is (limited by 50% maximum yield);  
(b) Asymmetric synthesis of prochiral ketones.  
For example, both enantiomers of mexiletine (Figure 5.3a) [1-(2,6-dimethylphenoxy)-2-
propanamine], a chiral antiarrhythmic agent, were prepared by deracemization of 
commercially available racemic amine using two different enantioselective ATAs. 58 
In another interesting application of ATA-chemistry the stereoselective synthesis of (R)-4-
phenylbutan-2-amine, a precursor of the antihypertensive dilevalol (Figure 5.3c), and of (R)-
1-(4-methoxyphenyl)ethylamine, an important building block for the biologically active 
compound formoterol (Figure 5.3d), was successfully achieved.59, 60  
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However, many challenges inherent to transaminase stability under industrial process 
conditions still remain to be tackled before developing large-scale processes, the most 
important regarding the stability of ATAs in the presence of organic solvents.  
 
Figure 5.3: Amine containing bioactive compounds.  
(a) mexiletine; (b) dilevalol; (c) formoterol; (d) sitagliptin. 
In fact, even if the promising ATAs’ performances in the stereoselective formation of C-N 
bonds is attested by the wide number of examples found in literature52,61 (among them it 
surely deserves to be cited the outstanding case of sitagliptin reported by companies Merck® 
and Codexis® Figure 5.3d), transamination processes on preparative scale are often impaired 
by the need of organic co-solvents, that might be ‘toxic’ to the biocatalysts.62 Moreover, 
increased reactions temperatures are often required (for example for the stripping of volatile 
co-products, i.e., acetone, to shift the equilibrium of the transamination reaction toward 
product formation).63 
 In an attempt to tackle this drawback, hot spring metagenomics was exploited to 
develop novel thermostable ATAs able to catalyze the stereoselective production of chiral 
amines and possessing an enhanced structural tolerance and stability toward the presence of 
organic co-solvents and working at higher temperature.  
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5.2 From hot spring metagenomics to novel biocatalysts 
In general, biocatalysts produced by thermophiles, organisms that thrives at relatively high 
temperatures between 41 and 122 °C, show attractive inherent properties such as high 
stability in the presence of organic solvent, under operational conditions and during long-
term storage.64, 65 So that, the use of thermophiles genomes as source for the search and 
development of novel thermostable transaminases has lately revealed to be a promising 
tool.66, 67 Recently, a (S)-selective ATA with a broad substrate scope showing a remarkable 
thermostability has been identified from Thermomicrobium roseum and was successfully 
exploited in asymmetric syntheses and kinetic resolutions at high temperatures to produce 
enantiomerically enriched amines.68  
 As an alternative to selected genomes mining, metagenomics, i.e., the study of the 
genetic material (metagenome) recovered directly from environmental samples69, 70 was selected 
to find new thermostable ATAs. The potential of this innovative approach for the 
identification of novel active and stable biocatalysts has been recently demonstrated with 
enzymes of different classes.71, 72, 73 
To this purpose, samples were collected from three different hot springs in Iceland, China 
and Italy at very high temperature (76-90 °C), ideal environments for (hyper)thermophilic 
microorganisms. Their metagenome was extracted and sequenced to generate a database of 
DNA sequences potentially coding for different biocatalysts, as described by Menzel et al.74 
This database was then subjected to bioinformatic search to find in silico sequences coding 
for the target biocatalysts ATAs: the query sequences were aligned with database sequences 
using the program LAST (http://last.cbrc.jp/) with default settings.75 
Three sequences (B3-TA, Is3-TA, and It6-TA) showing similarity with known (S)-selective 
ATAs were found in metagenomes collected in Iceland (B3-TA, hot spring at 85 °C, pH 7.0; 
Is3, TA-hot spring at 90 °C, pH 3.5) and in Italy (It6-TA, hot spring at 76 °C, pH 3.5), 
respectively, while only partial sequences were found in a sample collected in China (hot 
spring at 55 °C, pH 7.0). These proteins can be classified as class III aminotransferases 
(IPR005814), which is the class that comprises most of the known (S)-selective ATAs; no 
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sequences similar to (R)-selective ATAs were found in the investigated metagenomes. The 
three identified ATAs sequences were then cloned for recombinant expression in E. coli, (up 
to 180 mg of pure protein from 1 L of culture).76 The three novel thermostable potential 
biocatalysts were then to be tested for their ability of producing chiral amines from prochiral 
ketones and hypothesized enhanced stability. The whole discovery and expression process is 
summarized in (Figure 5.4). 
 
Figure 5.4 From hot-spring metagenome to chiral amines. 
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5.3 Functional properties of the novel ATAs 
 
Scheme 5.1: Model reaction. 
At first, the functional characterization of the ATA homologs was started by evaluating the 
effect of different reaction conditions in the transamination reaction between the benchmark 
and common substrates (S)-MBA (methylbenzyl amine) and pyruvate (Scheme 5.1).  
 
Figure 5.5: Influence of pH (a) and temperature (b) on ATA activity, influence of temperature (c) on ATA stability, and 
long-term stability of B3-TA at 80 °C (d).  
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Specifically, their stability toward temperature and co-solvents was determined, as all the 
three enzymes displayed high levels of activity under alkalophilic conditions, this result being 
in agreement with the average pH optimum of 9.0 the typical of ATAs (Figure 5.5a).77 
 The hypothesized thermophilic character of three new biocatalysts was confirmed as 
the three ATAs showed optimal activity at high temperatures: in particular, both It6-TA and 
Is3-TA presented optimal activity at temperatures around 50 °C and retained >10% relative 
activity at 60 and 70 °C, respectively (Figure 5.5b). Even more interesting, the activity of 
B3-TA increased constantly with temperature up to 90 °C, showing a typical 
hyperthermophilic behavior. Moreover, thermal stability studies performed by incubating the 
three enzymes at different temperatures between 20 and 90 °C for 3 h and estimating their 
residual activity by spectrophotometric analysis, demonstrated that Is3-TA and It6-TA 
maintained about 40% of the starting activity at 40 °C, while B3-TA remarkably retained 
100% activity after 3 h thermal treatments between 20 and 80 °C (Figure 5.5c). 
Furthermore, the long-term thermal stability of B3-TA resulted outstanding, as after five 
days of incubation at 80 °C the biocatalyst retained the 85 % of its initial activity. After two 
weeks at 80 °C, the enzyme was still alive showing 40 % residual (Figure 5.5d).  
 
Figure 5.6: Influence of organic co-solvents on ATA stability.  
Residual activity was estimated after 5 h of incubation at room temperature.  
 The stability of the three enzymes was tested in the presence of 5–20% (v/v) organic 
co-solvents, i.e., MeOH, EtOH, DMSO, and CH3CN, by measuring their residual activities 
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at 25 °C after a 5 h incubation (Figure 5.6). The residual activity of B3-TA under any 
condition tested (with the exception of 20% (v/v) EtOH) was always above 40%, thus 
indicating this enzyme, the most thermophilic, as the most tolerant to organic co-solvents 
among the three new ATAs.  
Considering the superior performances shown by B3-TA, its stability in buffer/organic 
solvent biphasic systems was investigated as well. The enzymatic aqueous solution was 
incubated in the presence of either tert-butyl methyl ether, ethyl acetate, toluene, or 
petroleum ether (1:1 v/v) under vigorous shaking, and the residual activity was evaluated 
after 5 and 24 h. As shown in Figure 5.7, B3-TA was quite tolerant to toluene and petroleum 
ether, retaining more than 50% of its activity in the presence of these two organic solvents 
after 24 h of incubation. It proved to be sensitive to tert-butyl methyl ether and ethyl acetate, 
retaining only 25% activity in the presence of these two organic solvents after 5 h of 
incubation. 
 
Figure 5.7: Influence of organic co-solvents on B3-TA stability. Residual activity was estimated after 5 h of incubation at 
room temperature. Ctrl = control; Etp = petroleum ether; Tol = toluene; MTBE = methyl tert-butyl ether; AcOEt = 
ethyl acetate.  
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5.4 Asymmetric synthesis of chiral amines: ATAs’ substrate 
scope  
Once the stability of the three novel biocatalysts had been investigated, the B3-TA being the 
most promising one, their synthetic exploitation to produce enantiomerically enriched (S)-
chiral amines was explored by studying their substrate scope. As the transamination reaction 
catalyzed by ATAs requires a ‘sacrificial’ amine donor and a suitable acceptor, the 
investigation was focused on both the partner. Moreover, obtained results were compared 
to those achieved using the well-known ATA from Vibrio fluvialis (Vf-TA)78, 52 obtained by 
recombinant expression in E. coli from its synthetic gene, to better evaluate the practical 
synthetic utility of the novel ATAs. 
To this purpose, several keto acids, ketones, and aldehydes were considered as potential 
acceptors (amino donor: (S)-methyl benzyl amine, MBA), as well as a series of aliphatic and 
aromatic amines and amino acids were investigated as potential donors (amino acceptor: 
pyruvate). Reaction conversions were estimated after 24 h and analyzed by HPLC or GC/MS 
and performed in triplicate. Standard deviation was below 5%, and no significant degradation 
of substrates/products or formation of by-products was observed. 
 
Figure 5.8: Enantioselectivity of the novel ATAs. Specific activities (U/mg) of ATAs and Vf-TA toward different (S) and 
(R) aromatic amines were determined spectrophotometrically as described by Nobili et al.79 
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As shown in Figure 5.8 , the (S)-selectivity of the novel ATAs inferred by sequence analysis 
was confirmed by determining spectrophotometrically their specific activity using as 
substrates either (R) or (S) aromatic amines, bearing a methyl, ethyl, or propyl side chain 
adjacent to the amine function. As previously stated, Vf-TA was included in this study for 
comparison. The obtained data indicate a very strict (S)-selectivity for all the novel ATAs 
that showed very low or negligible activity toward the tested (R)-amines. 
 As reported in Table 5.1, the novel ATAs and Vf-TA displayed a quite similar 
behavior in the transamination reactions using different keto acids and aliphatic ketones as 
amino acceptors. Specifically, concerning the use of keto acids as acceptors, it was possible 
to appreciate that an increase in the acceptor side chain length from pyruvate to 2-
oxobutyrate resulted in higher conversions, while the presence of a second carboxylic group 
in the acceptor, such as α-ketoglutarate, significantly decreased the substrate conversions. 
Furthermore, conversions were significantly lower also in case of methyl acetoacetate (the 
carboxylic group of the keto acid is protected as methyl ester) or aliphatic ketones as amine 
acceptors. On the other hand, in some cases, the use of aldehydes in place of ketones resulted 
in a significant increase of conversions. In particular, quantitative conversions were obtained 
with Is3-TA, B3-TA, and Vf-TA using glyoxylate, while acetaldehyde demonstrated to be a 
very good amino acceptor for B3-TA, as well as propionaldehyde for Is3-TA.  
 As far as the amino donor specificity is concerned (Table 5.2), the three novel ATAs 
showed a good activity toward phenyl-substituted secondary amines bearing either a methyl 
or an ethyl group, while significant decreases in conversions were observed when (S)-α-
phenylbutylamine was the substrate. When testing the primary amine 2-phenylethylamine, 
the best performances were observed with B3-TA, while 1-aminoindan was well accepted by 
all the tested enzymes. Among nonaromatic amines, isopropylamine was the best donor for 
all the novel enzymes, lower conversions being observed when using aliphatic primary 
mono- and diamines as donors. Interestingly, all the novel ATAs converted β-alanine, which, 
in agreement with literature data,57 was instead not accepted by Vf-TA. However, no 
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detectable activities were measured in the presence of more sterically hindered β-amino acids, 
such as (DL)-β-phenylalanine and (DL)-β-homoleucine. 
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Table 5.1: Amino acceptors screening. 
 
Conversion (%)  
 Is3-TA It6-TA B3-TA Vf-TA 
Amino Acceptor     
Pyruvate 
 
48 45 51 50 
2-Oxobutyrate 
 
>99 >99 >99 >99 
α-Ketoglutarate 
 
8 1 4 8 
Methyl acetoacetate 
 
16 6 5 15 
Acetone 
 
7 2 8 5 
2-Butanone 
 
3 2 5 11 
Methyl isobutyl ketone 
 
 
1 1 5 10 
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2-Oxoacetic acid 
 
>99 62 >99 >99 
Acetaldehyde 
 
6 6 68 18 
Propionaldehyde 
 
74 
 
10 
 
33 
 
34 
Benzaldehyde 
 
3 
 
10 
 
10 
 
15 
2-Phenylpropionaldehyde 
 
16 3 16 19 
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Table 5.2: Amino donors screening. 
a) n.d. below detection limit 
 
Conversion (%)  
 Is3-TA It6-TA B3-TA Vf-TA 
Amino Donor     
(S)-α-Methylphenylamine 
 
50 41 43 >99 
(S)-α-Ethylphenylamine 
 
63 46 23 >99 
(S)-α-Phenylbutylamine 
 
2 3 1 >99 
2-Phenylethylamine 
 
8 18 30 15 
(±)-1-Aminoindan 
 
97 89 43 99 
Isopropylamine 
 
12 27 13 28 
NH2
NH2
NH2
NH2
NH2
NH2
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Propylamine 
 
6.5 3.7 n.d.a) 28 
Butylamine 
 
1.4 3.5 1 1.2 
1,3-Diaminopropane 
 
0.7 3 2 n.d. 
β-Alanine 
 
67 57 29 n.d. 
(±)-β-Phenylalanine 
 
n.d. n.d. n.d. n.d. 
(±)-β-Homoleucine 
 
n.d. n.d. n.d. n.d. 
 
  
NH2
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H2N OH
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5.5 Conclusions 
This work further demonstrated the potential of metagenomics in the search of relatively 
rare enzymatic activities, such as thermostable ATAs from extreme environments. The three 
novel ATAs, identified as a subfamily of mostly uncharacterized B3-TA-like transaminases 
and all from thermophilic microorganisms, showed the desired thermophilic character and, 
in the case of B3-TA, an outstanding stability toward organic co-solvents, both in mono and 
biphasic systems. Moreover, structural stability data obtained by CD analysis (comparison of 
the data collected at 20 and 80 °C to get some information about any conformational 
changes) reveled an apparent melting temperatures of 57.32 ± 0.55 and 79.23 ± 0.31 °C for 
It6-TA and Is3-TA, respectively and remarkably, of 88.15 ± 1.17 °C for B3-TA.  
The catalytic performances of these new ATAs were investigated in the asymmetric synthesis 
of commonly reported chiral amines, exploring the scope of amino donors/acceptors and 
demonstrating their strictly (S)-selectivity. At the same time, given their origin and stability 
features, it can be foreseen that members of this subfamily could possess useful applicative 
features, such as high stability under harsh reaction conditions and different substrate 
specificities.  
Moreover, this biochemical study on the discovery of new thermostable enzymes to 
assess stability issues in the biocatalytic preparation of enantiomerically enriched amines, can 
be regarded as a way for the rational modification of an existing (bio)catalyst aimed at 
achieving enhanced catalytic performances. As for organo- and/or metallorganics a lead 
catalyst can be structurally modified to fulfill desired new features, the genetic information 
collected from the hot-spring metagenomes were filtered and refined on the base of well-
known families of ATAs sequences found literature. In fact, at variance to what can be and 
is usually done with chemical catalysis, biocatalysis gathers strength from the exploitation of 
what Nature offers in the struggle for life: forms of stereoselective organic synthesis against 
unselective processes.  
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5.6 Experimental 
Acceptor spectrum of ATA homologs was determined at 30 °C in 0.5 mL reaction mixture 
containing 20 mM KP buffer, pH 9.0, 10 mM acceptor, 10 mM (S)-MBA, 1 mM PLP, and 
0.5 mg of purified enzyme. Conversion of (S)-MBA (after acetylation) into acetophenone 
was determined after 24 h by GC-MS analysis. 
Donor spectrum of ATA homologs was determined at 30 ° C in 0.5 mL reaction mixture 
containing 20 mM KP buffer, pH 9.0, 10 mM donor, 10 mM pyruvate, 1 mM PLP, and 0.5 
mg of purified enzyme. Conversions were determined after 24 h by GC-MS analysis or, 
alternatively, by estimating the formation of L-alanine (after OPA derivatization) through 
HPLC analysis. 
GC/MS analysis Samples of amine derivatives were acetylated before injection as follows: 
transamination reactions (0.5 mL) catalyzed by TAs were recovered after 24 h, then reaction 
pH was adjusted to 11.0 by adding 6 M NaOH (50 µL) and products were extracted with 
ethyl acetate (350 µL). To 100 µL of organic phase dried over anhydrous Na2SO4, pyridine 
and acetic anhydride (15 µL each) were subsequently added and the mixture was kept 
overnight at room temperature before analysis. The following temperature program was 
employed: 60 °C (1 min)/6 °C min−1/150 °C (1 min)/12 °C min−1/210 °C (5 min).  
HPLC analyses were conducted using a Kinetex 5-µm EVO C18 100-Å 150 Å~ 4.6-mm 
column (Phenomenex, Torrance, CA). L-Alanine derivatization was achieved by diluting the 
reaction samples (50 µL) in 1 mM HCl and then adding 50 µL of phthaldialdehyde (OPA) 
reagent (Sigma-Aldrich). The mobile phase consisted of MeOH/THF/50 mM phosphoric 
acid (20:20:960), pH adjusted to 7.5 with NaOH (eluent A) and MeOH/H2O (65:35) (eluent 
B). L-alanine-OPA derivative was eluted at a flow rate of 0.5 mL min−1 with the following 
gradient: t = 0 min, 80% A; t = 17min, 70%A; t = 32min, 20%A; t = 37min, 20%A; t = 47 
min, 80% A. Peaks were detected at 340 nm and calibration curves were prepared using 
standard solutions of L-alanine-OPA derivative.  
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6. Unspecific peroxigenases: the asymmetric 
sulfoxidation of arylalkyl sulfides 
Unspecific peroxygenases (UPOs, EC 1.11.2.1) represent an emerging class of 
biocatalysts with a wide range of potential applications in different oxyfunctionalization 
reactions.80, 81, 82, 83 They are extracellular heme-thiolate enzymes (Figure 6.1), a class of 
hemoproteins in which a thiolate group, typically from a cysteine residue, is the axial ligand 
of heme iron.  
 
Figure 6.1: Heme-thiolate structure with its typical cysteine axial ligand. © Elsevier. 
UPOs are usually produced by several fungi (Figure 6.2), and they show no significant 
sequence homology to cytochrome P450s and are only distantly related to CPO (Chloride 
peroxidase,~ 30% sequence similarity).  
 
Figure 6.2: UPOs have been isolated form: A. Agrocybe aegerita (edible, pioppino), AaeUPO; B. Coprinellus radians, 
CraUPO and C. from Marasmius rotula, MroUPO. 
 
A.
B.
C.
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UPOs systematic classification appears to be tricky: they use hydrogen peroxide as 
electron-acceptor during their redox processes, like peroxidase do, but they work via a catalytic 
cycle resembling the ‘peroxide shunt’ (yellow section, Figure 6.3) pathway of P450s-
mediated reactions. Thanks to their ‘peroxide shunt’ mechanism, UPOs show a peroxide-
dependent monooxygenase activity resulting e.g., in the hydroxylation of different alkanes 
and aromatic compounds, in alkene epoxidation and O- and N-dealkylation reactions.  
 
Figure 6.3: P450-peroxyde shunt mechanism. © Elsevier 
 
The best characterized UPO (AaeUPO, Figure 6.4) has been identified in 2004 from 
the edible mushroom Agrocybe aegerita.84 Its structural and functional features have been 
largely investigated in the last years.85, 86, 87, 88, 89 Moreover, the practical application of AaeUPO 
in useful synthetic biotransformations has been recently implemented by developing 
improved systems for enzyme production/optimization90, 91 and for the efficient set-up of 
preparative-scale reactions.92, 93, 94  
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Figure 6.4: AaeUPO structure and proposed catalytic cycle. © Elsevier  
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6.1 Chiral sulfoxides  
Chiral sulfoxides are valuable compounds that find several applications as synthons in the 
preparation of biologically active molecules as well as chiral auxiliaries in asymmetric 
synthesis (Figure 6.5).95, 96  
 
Figure 6.5: Sulfur-containing chiral ligands/catalyst for asymmetric synthesis A. Tetradental bis-sulfoxides ligands;  
B. chiral imino- and aminosulfoxides and C. biphenyl sulfinimines containing diphenylphospphine moieties.  
Among the different methods aimed at the efficiently prepare optically enriched sulfoxides, 
enzyme-catalyzed enantioselective oxidation of prochiral sulfides has been widely 
investigated in the last decades.97 In particular, the best results, in terms of both 
enantioselectivity and conversions, have been obtained with the chloroperoxidase (CPO) 
from Caldariomyces fumago,98, 99, 100 and different Baeyer-Villiger monooxygenases (BVMOs), in 
the presence of either H2O2 or O2 as oxidant, respectively. 101,102, 103, 104, 105 
In recent reviews about the current state-of-the-art on the applications of peroxygenases, 
sulfoxidations are commonly listed among the wide number of possible reactions catalyzed 
by UPOs.80, 81, 82, 83  However, to the best of our knowledge, only a few preliminary data were 
available so far about the exploitation of UPOs, including AaeUPO, in the (enantioselective) 
oxyfunctionalization of sulfides to sulfoxides. 
A.
B.
C.
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Figure 6.6: Synthetic potential of AaeUPO. © Elsevier 
Specifically, the enantioselective oxidation of thioanisole 6.1 to the corresponding (R)-
sulfoxide 6.1a was previously reported in a poster presentation presented by  A. Horn, R. 
Ullrich, M. Hofrichter, K. Scheibner, U. Kragl at the 8th International Conference on 
Biocatalysis & Biotranformations (BIOTRANS), Oviedo (Spain); while the S-oxidation of 
the heterocyclic compound dibenzothiophene has been investigated to a deeper extent by 
using both whole cells of basidiomycetes and purified UPOs.106 In particular, the authors 
obtained a mixture of oxidized products, involving both the oxidation of the S-atom to the 
correspondent sulfone and the un-selective hydroxylation of the two aromatic rings.   
The aim of the presented work (Paper V) was to assess the performances of AaeUPO 
in the asymmetric synthesis of different chiral sulfoxides (compounds 6.1a-6.10a, Scheme 
6.1) starting from differently substituted arylalkyl sulfides (compounds 6.1-6.10, Scheme 
6.1), thus filling this gap in the knowledge of the biocatalytic potential of this unspecific 
peroxygenases.   
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6.2 Biocatalyzed asymmetric sulfoxidation 
 
Scheme  6.1: Biocatalyzed sulfoxidation. 
To investigate the ability of AaeUPO to catalyze the sulfoxidation of the model substrate 
thioanisole (6.1), a peroxygenase preparation was easily obtained from the wild-type Agrocybe 
aegerita TM-A1 (DSM 22459) strain as described in the literature (Figure 6.7).80 
 
Figure 6.7: Agrocybe aegerita strain TM-A1 (DSM 22459) was grown in 2 L-shaken flasks containing 0.5 L of 30 g L-1 
soybean peptone. The culture was maintained at 25°C and monitored daily for laccase and UPO activity. After 14-15 
days, the mycelium was filtrated and the crude AaeUPO was recovered from the culture medium by ammonium sulphate 
precipitation. 
In a first set of experiments, the starting concentration of both the substrate 6.1 and 
the oxidant H2O2 were kept at 1 mM to avoid the well-described peroxide-dependent 
inactivation of the enzyme.82, 92, 107 Reactions with AaeUPO were carried out at 20 °C in citrate 
phosphate buffer (10 mM, pH 7.0) in the presence of 20 % CH3CN as cosolvent and stopped 
S R'
R
AaeUPO
S R'
R
O
S
(R) R'
R
O
S
(S) R'
R
O
(6.1)   R' = CH3; R = H
(6.2)   R' = CH3; R = o-Cl
(6.3)   R' = CH3; R = m-Cl
(6.4)   R' = CH3; R = p-Cl
(6.5)   R' = CH3; R = p-CH3
(6.6)   R' = CH3; R = p-CN
(6.7)   R' = CH3; R = m-OCH3
(6.8)   R' = CH2=CH2; R = H
(6.9)   R' = c-propyl; R = H
(6.10) R' = CH2OCH3; R = H
(6.1a)   R' = CH3; R = H
(6.2a)   R' = CH3; R = o-Cl
(6.3a)   R' = CH3; R = m-Cl
(6.4a)   R' = CH3; R = p-Cl
(6.5a)   R' = CH3; R = p-CH3
(6.6a)   R' = CH3; R = p-CN
(6.7a)   R' = CH3; R = m-OCH3
(6.8a)   R' = CH2=CH2; R = H
(6.9a)   R' = c-propyl; R = H
(6.10a) R' = CH2OCH3; R = H
0,00
150,00
300,00
450,00
600,00
750,00
6 8 10 12 14
U
/m
L
Days	
Activity
U/mL	UPO U/mL	Laccases
 Unspecific Peroxigenases 
 70 
at scheduled times by extraction with ethyl acetate to analyze the obtained crude mixtures by 
means of direct-phase HPLC on a chiral column. Control reactions were performed in the 
absence of the enzyme or the oxidant. Under these reaction conditions, the (R)-sulfoxide 
6.1a could be obtained after 20 min in quantitative conversions and 80% enantiomeric excess 
(ee) (Table 6.1).  
 
AaeUPO showed a good operative stability, retaining >90% of the starting activity for at 
least 2 h, as assayed by spectrophotometric measurement of the activity with 2,2'-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) (ABTS) as substrate. Moreover, no formation of by-
products, and of the corresponding over-oxidation sulfone products was observed (Figure 
6.8) even when in a control reaction the racemic mixture of sulfoxides 6.1a was used as 
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Figure 6.8: HPLC chromatograms of A. standard sulfone 6.1b; B. thioanisole 6.1; C. standard racemic 6.1a and D. 
reaction of 6.1 with AaeUPO: quantitative conversion, 80 % ee (R)-enantiomer. 
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substrate. The same result was previously reported also for a number of CPO-catalyzed 
sulfoxidations on different aryl and alkyl substrates.99, 100, 80 
To study the possibility of overcoming the well-known peroxide-dependent inactivation of 
the AaeUPO, the same reaction conditions were used in the presence tert-butyl 
hydroperoxide (t-BuOOH) as oxidant. Differently from the performances of CPO in the 
same conditions, AaeUPO showed negligible activity (<1% conversion). However, this 
finding was not surprising since the use of t-BuOOH as an alternative to H2O2 showed to 
be more challenging also in other oxyfunctionalization reactions catalyzed by AaeUPO.93  
To assess the practical utility of this biotransformation, the concentration of 6.1 was 
increased to 10 mM (35 µmol in 3.5 mL final volume) and 20% (v/v) CH3CN was used to 
keep it in solution. The presence of cosolvent in the reaction medium had no significant 
effect on enzyme stability and was strictly needed to ensure the substrate solubility. Instead, 
as mentioned before, the in situ H2O2 concentration was the critical point in the 
stability/efficiency of this peroxygenase.  
Among the several options described in the literature to face this issue,80,92 it was decided to 
use a simple step-wise addition of a 100 mM H2O2 solution (35 µmol added in 10 aliquots at 
30 min intervals in the first 4.5 h, then the reaction was maintained for additional 2.5 h 
without further oxidant addition). The residual AaeUPO activity in the reaction solution, 
conversion of substrate 6.1 and ee value of the formed product were monitored at scheduled 
times.  
As shown in Figure 6.9, the controlled supplementation of H2O2 allowed to obtain a 
quantitative conversion of 6.1 without observing dramatic drops of enzyme activity during 
oxidant addition (~60% residual activity after the first 5 h).  
In agreement with previous studies, the application of an optimized substrate/H2O2/enzyme 
ratio allowed a minimization of the catalase side-activity, which has been suggested as the 
main responsible of UPOs inactivation. In fact, only one equivalent of oxidant was required 
to obtain almost a complete conversion of the target substrate, thus suggesting the lack of 
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significant H2O2 consumption by dismutation to O2 and H2O. A possible protective effect 
of the substrate toward peroxide-induced inactivation, previously investigated by Alexander 
and coauthors for UPO-catalyzed hydroxylation reactions,107 was suggested also in this case 
by the superior operative stability shown by AaeUPO at low (<50%) conversion degrees. 
The ee value of the formed (R)-sulfoxide 6.1a was unaltered (80%) during the whole reaction 
time.  
 
Figure 6.9: step-wise addiction of H2O2 to a 10 mM thioanisole reacting solution:  
profiles of conversion into sulfoxide 6.1b and enzyme stability in terms of residual activity. 
In addition to thioanisole 6.1, the versatility of AaeUPO in promoting 
enantioselective sulfoxidations was further studied by testing a panel of differently 
substituted aryl alkyl sulfides (compounds 6.2-6.10, Table 6.1).  
The obtained conversions and ee values of the sulfoxide products were compared with those 
available in the literature for CPO and three different BVMOs (CHMO, PAMO and 
HAPMO) for the biooxidation of the same compounds. 
In general, AaeUPO converted the tested arylalkyl sulfides into the corresponding sulfoxides 
with good conversions, except for the o-substituted substrate 6.2 (35%) and the p-
cyanophenyl methyl sulfide 6.6 (<5%). The formation of the R enantiomer of the sulfoxide 
products was always observed (the S product was obtained only in the case of 6.10a due to 
a change in the CIP priority rules) with good to excellent enantioselectivity (70-99% ee). The 
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stereochemical outcomes of the biotransformations was assessed by confrontation with the 
literature data reported for compounds 6.1a-6.10a by means of chiral HPLC. Respective 
references are reported in paragraph 6.3, ‘Experimental’.  
Both electron donating and ‘neutral’ groups in the para position of the aromatic ring seemed 
to be well tolerated (entry 4, 5 and 7), as well as substitution on the meta carbon atom (entry 
3), while the presence of an electron withdrawing substituent in para dramatically affected 
the biocatalytic oxidation (entry 6). The best results in terms of enantiomeric excess were 
obtained when a substituent was introduced on the R’-group: the vinyl thioanisole 6.8, as 
well as the cyclopropyl derivative 9, were converted into the corresponding (R)-sulfoxides 
with >99% ee. However, a decrease of both conversion and ee value was observed with 
compound 6.10 whose flexible CH2-OMe R’ substituent and higher of conformational 
freedom could have allowed more than one energetically equivalent conformations during 
the binding with the active site. Moreover, the presence a coordinating oxygen atom on the 
R’ substituent could have impaired the enantioselectivy of the S-oxidation as well.  
Interestingly, during the biocatalytic sulfoxidation of 6.8 only the R enantiomer of sulfoxide 
6.8a was recovered, suggesting a faster kinetic for the sulfoxidation in comparison with olefin 
epoxidation, another example of UPO-catalyzed reactions largely reported in the 
literature.80,81,82,83   
Regarding the comparison with other biocatalyzed sulfoxidations, it is not surprising to 
observe pretty similar results in terms of conversions and enantioselectivity with CPO, as it 
is, as mentioned before, an enzyme structurally related to UPOs. Except for 6.5, AaeUPO 
usually achieved better conversions, but slight lower ee values than CPO, the stereoselectivity 
being in both cases toward the formation of the (R)-enantiomer.  
As far as BMVOs concern, only few data are available with the panel of substrates used with 
the enzymes from Acinetobacter calcoaceticus (CHMO)102 and Thermobifida fusca (PAMO)104, in 
most cases showing less impressive performances than UPO (and CPO) both in terms of 
conversion and enantiomeric excesses. Instead, a full set of data was reported on the 
asymmetric sulfoxidation of 6.1-6.10 catalyzed by the HAPMO enzyme from Pseudomonas 
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fluorescens.105 Interestingly, satisfactory results were obtained with HAPMO. In most cases, 
the formation of the (S)-enantiomers of sulfoxides 6.1a-6.10a was achieved with good 
conversion (except for substrates 6.3 and 6.4) and very good enantiomeric excesses, with the 
only exception of compound 6.4.  
The strict (S)-selectivity previously shown by HAPMO is herein well complemented by the 
preference toward the formation of the (R)-sulfoxides demonstrated by AaeUPO, thus 
enabling a fully biocatalytic entry to both the enantiomers of sulfoxides 6.1a-6.10a 
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Substrate R R' UPO[a] CPO[b] CHMO[c] PAMO[d] HAPMO[e] 
c [%][f] ee [%][f] c [%] ee [%] c [%] ee [%] c [%] ee [%] c [%] ee [%] 
6.1 CH3 H >99 80 (R) >99 98 (R) 88 99 (R) 94 44 (R) 96 99 (S) 
6.2 CH3 o-Cl 35 74 (R) 33 85 (R) 35 32 (R) n.a.[g] n.a. 76 96 (S) 
6.3 CH3 m-Cl >99 90 (R) n.a. n.a. n.a. n.a. n.a. n.a. 42 93 (S) 
6.4 CH3 p-Cl >99 93 (R) 77 90 (R) 78 51 (S) n.a. n.a. 37 44 (S) 
6.5 CH3 p-CH3 83 90 (R) 98 91 (R) 94 37 (S) 68 10 (R) 77 99 (S) 
6.6 CH3 p-CN <5 n.d.[h] n.a. n.a. n.a. n.a. n.a. n.a. 64 96 (S) 
6.7 CH3 p-OCH3 87 70 (R) 72 90 (R) 81 51 (S) 47 25 (R) 78 99 (S) 
6.8 CH=CH2 H 85 >99 (R) n.a. n.a. n.a. n.a. n.a. n.a. 78 98 (S) 
6.9 c-propyl H 95 >99 (R) n.a. n.a. n.a. n.a. 67 48 (R) 74 97 (S) 
6.10 CH2OCH3 H 50 81 (S)[i] n.a. n.a. n.a. n.a. n.a. n.a. 63 98 (R)[i] 
Table 6.1: Comparison of UPO-catalyzed sulfoxidations with literature data for CPO and the Baeyer-Villiger monooxygenases CHMO, PAMO, and HAPMO. 
[a] substrate, 1 mM; H2O2, 1 mM, UPO, 40 U mL-1; 10 mM citrate phosphate buffer, pH 7.0, 2% (v/v) CH3CN; 20°C; 20 min. [b] substrate, 9 mM; H2O2, 2 eq. (added 
portionwise in 13 aliquots), CPO, 0.144 µM; 50 mM citrate buffer, pH 5.0; 25°C; 1 h.100 [c] substrate, 40 mM; NADP+, 0.15 mM; glucose-6-phosphate (G6P), 0.1 M; 
CHMO, 0.3 U mL-1; glucose-6-phosphate dehydrogenase (G6PDH), 2.5 U mL-1; 50 mM Tris/HCl buffer, pH 8.6; 25°C; 24 h.102 [d] substrate, 20 mM; NADP+, 0.02 
mM; G6P, 2 eq.; PAMO, 1 U mL-1; G6PDH, 10 U mL-1; 50 mM Tris/HCl buffer, pH 9.0; 25°C; 24 h.104 [e] substrate, 20 mM; NADP+, 0.02 mM; G6P, 1.5 eq.; HAPMO, 
1 U mL-1; G6PDH, 10 U mL-1; 50 mM Tris/HCl buffer, pH 9.0; 25°C; 24 h.105 [f] Conversions and enantiomeric excesses calculated on the basis of chiral HPLC analysis 
(see Supporting Information for details). [g] n.a.: not available from literature data. [h] n.d.: not determined. [i] Absolute configuration is reversed due to a change in the 
substituent priority according to the sequence rules. 
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6.3 Conclusions  
The performances of the AaeUPO in the asymmetric synthesis of chiral sulfoxides were 
investigated. To the best our knowledge, this is the first example of a systematic investigation 
of the AaeUPO synthetic potential in the asymmetric oxidation of hetero atoms, i.e. the pro-
stereogenic sulfur of sulfides.  
A small library of differently substituted arylalkyl sulfoxides 6.1a-6.5a, 6.7a-6.10a was 
successfully synthetized by incubating the arylalkyl sulfides in the presence of the AaeUPO 
and H2O2. All the sulfoxides were obtained as (R)-enantiomers, regardless the substitution 
pattern both on the aromatic ring and the alkyl chain.  
To furnish a complete overview on the biocatalytic entries to chiral sulfoxides, the 
performances of the AaeUPO were confronted with the literature data available for the sulfur 
oxidation mediated by CPO and different species of BVMOs. While, with no surprise, the 
AaeUPO performances were in very good agreement with the ones obtained using the 
structurally-related CPO, the stereo-complementary showed by the HAPMO from P. 
fluorescens allowed a general biocatalytic entry to both the enantiomers of compounds 6.1a-
6.5a, 6.7a-6.10a. Moreover, as it was shown by Gonzalo de Gonzalo et al., monooxygenase 
PAMO form Thermobifida fusca could also be used to produce chiral sulfoxides by kinetic 
resolutions of racemic mixtures of (R) and (S). This was not the case with AaeUPO, as this 
peroxygenase successfully catalyzed asymmetric S-oxidation of sulfides but did not accept 
sulfoxides as substrates.104 
Furthermore, the performances of the AaeUPO in the presence of arylalkyl sulfides as 
substrates were remarkably better in terms of chemo- and regio-selectivity when compared 
with the results obtained by Aranda et al. in the biooxidation of dibenzothiophene.106 
Specifically, as previously mentioned, the AaeUPO-mediated oxidation of dibenzothiophene 
led to a complex mixture of products in which an un-tunable S-oxidation gave the 
correspondent sulfone and a plethora of hydroxylated products on both the aromatic rings. 
On the contrary, enantiomerically enriched chiral sulfoxides were obtained regio-, chemo- 
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and stereo-selectively. No aromatic hydroxylation products were in fact obtained, as clearly 
demonstrated by the HPLC chromatograms shown in Figure 6.8. 
Despite the tricky scaling up of AaeUPO-catalyzed reactions, a preliminary investigation on 
the possibility of conducing preparative scale biotransformations to access chiral synthons 
containing a stereogenic sulfur atom was undertaken. As follow-up, the immobilization of 
the AaeUPO on a suitable solid phase in under investigation to evaluate the possibility of 
conducing preparative-scale S-oxidations in flow. The use of a flow system could in fact avoid 
the mentioned peroxide-dependent inactivation of the enzyme, increasing the stability of the 
biocatalyst in the reaction media thanks to the possibility of working in continuous with low 
substrates and H2O2 concentrations, thus allowing the accumulation of considerable amounts 
of products.  
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6.4 Experimental 
6.3.1 Enzyme production   
Unspecific peroxygenase (UPO) from Agrocybe aegerita strain TM-A1 (DSM 22459) was 
produced with slight modifications of the method reported in the literature.84 Specifically, 
fungal stock cultures were maintained on malt extract agar slants at 4°C and precultured on 
MEA ([g L-1]: glucose, 20; malt extract, 20; peptone, 2; agar, 20) plates at 25°C for two weeks. 
Mycelial suspensions prepared by homogenization were used to inoculate 0.5 L of 30 g L-1 
soybean peptone (Sigma-Aldrich) in 2-L baffled flasks. The cultures were maintained at 25°C 
and monitored daily for the release of laccase and UPO activity in the culture medium using 
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) as substrate, either in the 
absence and in the presence of H2O2, respectively. Enzyme assays were performed in 0.1 M 
citrate phosphate buffer, pH 4.5, 0.33 mM ABTS, and 3 mM H2O2, and monitored 
spectrophotometrically at 436 nm (ε436 = 29300 M-1cm-1).  Laccase activity was negligible 
throughout the all cultivation period, while production of UPO started typically after 7-9 
days from the inoculum and reached a plateau after 14-16 days. The mycelium was thus 
removed by filtration and proteins secreted into the culture medium were recovered by 
ammonium sulfate precipitation (85% saturation). After centrifugation (5000 rpm, 20 min, 
4°C), the protein precipitate was resuspended in saturated ammonium sulfate solution (10 
mL) and stored at 4°C. Purified UPO samples were prepared by hydrophobic interaction 
chromatography as previously described, and used for control reactions.91 
 
6.3.2 Asymmetric biocatalyzed sulfoxidation of substrates 1-10 
H2O2 (1 eq, 1 mM) and UPO (40 U mL-1, 25 µL mL-1 of reacting solution) are added to a 
solution of arylalkyl sulfide (1 eq, 1 mM) in citrate phosphate buffer (10 mM, pH 7.0, 1 mL 
final volume). The resulting mixture is incubated at 20 °C and 500 rpm for 20 min. Extraction 
with AcOEt allowed the recovery of the desired oxidized product to be analyzed by HPLC 
on chiral column. The absolute configurations of the obtained products were determined by 
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comparing the tR reported in literature for the R and S enantiomers of compounds 1a-5a and 
7a-10a in the same analytic conditions (see below).  
 
6.3.3 Preparative-scale chemical synthesis of racemic 1a-10a  
To obtain suitable racemic mixtures of sulfoxides to be used as NMR and HPLC standards, 
preparative scale chemical sulfoxidation reactions were carried out at 0 °C by adding 
dropwise mCPBA (1.2 eq, 0.5 M in CHCl3) to a CHCl3 solution of the desired arylalkyl sulfide 
(substrates 1-10, 1 eq, 50 mM, 2 mL final volume). After stirring the mixture for 30 – 60 min 
(TLC analysis: MeOH:CHCl3 = 0.25:9.75, UV) racemic sulfoxides 1a-10a were obtained by 
extraction with AcOEt, drying over sodium sulfate and in vacuum concentration. Product 
were obtained in good isolated yields (70-90%) and characterized by 1H NMR and HPLC 
analysis on chiral column. 
 
Phenyl Methyl Sulfoxide, 6.1a 
1H NMR (400 MHz, CDCl3, rt), d: 7.62-7.64 (m, 2 H), 7.46-7.54 (m, 3 H), 
2.72 (s, 3 H) ppm. HPLC: tR (R) = 19.0 min, tR (S) = 22.1 min (Chiralcel OD 
column, petroleum ether/iPrOH = :1, flow rate = 0.5 mL min-1, wavelength = 254 nm). 108 
 
o-Chlorophenyl Methyl Sulfoxide, 6.2a  
1H NMR (400 MHz, CDCl3, rt), d: 7.90 (d, J 7.8 Hz, 1H), 7.52 (m, 1H), 7.43 
(m, 1H), 7.34 (d, J 7.8 Hz, 1H), 2.81 (s, 3H) ppm. HPLC: tR (R) = 25.1 min, 
tR (S) = 29.2 min (Chiralcel IA column, petroleum ether/iPrOH = 9:1, flow 
rate = 0.4 mL min-1, wavelength = 254 nm).109  
 
m-Chlorophenyl Methyl Sulfoxide, 6.3a 
1H NMR (400 MHz, CDCl3, rt), d: 7.95 (t, J 1.8 Hz, 1H), 7.85 (ddd, J 7.8, 
1.7, 1.1 Hz, 1H), 7.56-7.48 (m, 2H), 3.08 (s, 3H) ppm. HPLC: tR (R) = 
S
(R) CH3
O
S
(R) CH3
OCl
S
(R) CH3
O
Cl
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34.3 min, tR (S) = 35.3 min (Chiralcel IA column, petroleum ether/iPrOH = 9:1, flow rate = 
0.4 L min-1, wavelength = 254 nm).109  
 
p-Chlorophenyl Methyl Sulfoxide, 6.4a 
1H NMR (400 MHz, CDCl3, rt), d: 7.56-7.59 (m, 2 H), 7.48-7.52 (m, 2 
H), 2.71 (s, 3 H) ppm. HPLC: tR (R) = 58.8 min, tR (S) = 68.8 min 
(Chiralcel OD column, petroleum ether/iPrOH = 9:1, flow rate = 0.25 
mL min-1, wavelength = 254.110  
 
p-Tolyl Methyl Sulfoxide, 6.5a  
1H NMR (400 MHz, CDCl3, rt), d: 7.84 (d, J 8.3 Hz, 2H), 7.38 (d, J 8.3 
Hz, 2H), 3.04 (s, 3H), 2.46 (s, 3H). ppm. HPLC: tR (R) = 55.0 min, tR 
(S) = 62.0 min (Chiralcel OD column, petroleum ether/iPrOH = 95:5, 
flow rate = 0.25 L min-1, wavelength = 254 nm).104 
 
p-Methoxyphenyl Methyl Sulfoxide, 6.7a 
1H NMR (400 MHz, CDCl3, rt), d: 7.91 (d, J 8.7 Hz, 2H), 7.57 (d, J 
8.7 Hz, 2H), 3.07 (s, 3H), 2.44 (s, 3 H) ppm. HPLC: tR (R) = 37.4 min, 
tR (S) = 40.6 min (Chiralcel OD column, petroleum ether/iPrOH = 
95:5, flow rate = 0.5 mL min-1, wavelength = 254 nm).111  
 
Phenyl Vinyl Sulfoxide, 6.8a  
1H NMR (400 MHz, CDCl3, rt), d: 7.64-7.59 (m, 2 H), 7.55-7.47 (m, 3 H), 6.59 
(dd, J 16.5, 9.6 Hz, 1 H), 6.20 (dd, J = 16.5, 0.5 Hz, 1 H), 5.89 (dd, J = 9.6, 0.5 
Hz, 1 H) ppm. HPLC: tR (R) = 37.5 min, tR (S) = 46.3 min (Chiralcel OD column, petroleum 
ether/iPrOH = 9:1, flow rate = 0.25 mL min-1, wavelength = 254 nm).111 
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Phenyl Cyclopropyl Sulfoxide, 6.9a 
1H NMR (400 MHz, CDCl3, rt), d: 7.71-7.68 (m, 2H), 7.57-7.52 (m, 3H), 2.22 
(ddd, J 7.4, 4.4, 3.0 Hz, 1H), 1.11-1.07 (m, 2H), 0.74-0.70 (m, 2H) ppm. 
HPLC: tR (R) = 28.6 min, tR (S) = 39.6 min (Chiralcel OD column, petroleum ether/iPrOH 
= 8:2, flow rate = 0.3 mL min-1, wavelength = 254 nm).105 
 
Phenyl Methoxymethyl Sulfoxide, 6.10a 
1H NMR (400 MHz, CDCl3, rt), d: 7.65-7.56 (m, 2 H), 7.58-7.43 (m, 3 H), 
4.39 (d, J 10.1 Hz, 1 H), 4.35 (d, J 10.1 Hz, 1 H), 3.69 (s, 3 H) ppm. HPLC: 
tR (S) = 52.3 min, tR (R) = 68.1 min (Chiralcel OD column, petroleum 
ether/iPrOH = 95:5, flow rate = 0.25 mL min-1, wavelength = 254 nm).110 
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7. Laccases: selective Csp2-H bonds activators 
7.1 2,3-dihydro benzofurans-based scaffolds 
Laccases (benzenediol:oxygen oxidoreductases, EC 1.10.3.2) are redox metalloproteins 
widely known as ‘blue oxidases’ thanks to the presence of a tetraatomic copper cluster in 
their active site (Figure 7.1).  
In Nature, they are generally produced by the fungi basidiomycetes and ascomycetes as biocatalysts 
involved in the degradation of lignin, a cross-linked phenolic polymer, via complex oxidative 
mechanisms that involve the production of free radicals.112  
 
Figure 7.1: Ribbon representation of the X-Ray determined crystal structure of a laccase  
from Trametes versicolor (left); detail of the copper-cluster (right). 
The tetraatomic copper cluster represents the pivotal-core of laccases catalytic activity as the 
key redox processes occurs on its copper centers. Specifically, four organic compounds are 
oxidized in the presence of molecular oxygen producing four highly reactive radicals and 
water as the only (theoretical) by-product.  
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Figure 7.2: A. Trametes versicolor; B. A microscope detail of a plant tissue. The blue coloration indicates lignified cell-walls; 
C. Detail of lignin structure.  
Among the four copper atoms (Figure 7.3), the so-called ‘T1’ copper site acts as the primary 
electron acceptor site. It is the place where the single-electron oxidations of four molecules 
of a reducing substrate, the rate determining step of laccase-mediated processes, occurs. The 
other tree metal centers, arranged in a triangular-shaped semi-cluster, ‘T2/T3’ copper site, 
catalyze the reduction of molecular oxygen to water.113, 114, 115  
 
Figure 7.3: Detailed description of the tetratomic cupper cluster of laccases.  
The charge transfer transition ScysàCu(II) provides the enzyme its deep blue coloration. 
A. B.
C.
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Interestingly, the laccase-catalyzed formation of radicals, with the concomitant 
reduction of oxygen and water production, can be exploited in biocatalyzed organic synthesis 
as a green entry to activated organic compounds. In fact, the laccase oxidation of differently 
substituted aromatic amines and phenols offers the possibility of a convenient biocatalytic 
activation of normally inert Csp2-H bonds. Thanks to mesomeric resonance(s), the radical 
species formed by the biooxidation, which at first occurs on the more electronegative 
heteroatom (N or O), can be delocalized along all the carbonaceous skeleton of the p-system, 
allowing the formation of new C-C or C-Het bonds (radicals ii, v, vi and quinon or quininon-
like specie iv, Scheme  7.1).   
 
Scheme  7.1: Laccase-catalyzed activation of Csp2-H bonds via mesomeric resonance. 
These highly reactive radical species usually undergo different reaction pathways, ndr 
quenching processes, to be transformed into more stable species, as shown in Figure 7.4. 
 
Figure 7.4: Quenching processes allowed for laccase-produced radicals. 
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By conducing these transformations in the proper reacting media, the quenching processes 
can be controlled, or at least guided, to promote the formation of fine chemical as products, 
with modest to very good chemoselectivity in the formation of the target new C-C and C-
Het bonds.  
A wide number of example have been reported on the synthetic application of laccases as 
Csp2-H bonds activators and two main classes of processes can be identified:  
a) aromatic nucleophilic substitution (1,4-conjugate addictions to quinones, 
mechanism shown in Scheme  7.2) to form novel C-Het bonds116, 117, 118, 119, 120, 
121, 122   
b) radical C-C couplings to form biaryl compounds123, 124, 125, 126 
 
Scheme  7.2:  Laccase-promoted 1,4-conjugate addictions to quinones. 
Moreover, one of the most interesting synthetic application of laccase Csp2-H bonds 
activation, are the biocatalyzed ring closure reactions. In fact, by the rational design of a 
proper substrate and an accurate optimization of the reaction conditions, the listed 
mechanisms can be merged to obtain domino and cascade processes for the one-pot 
synthesis of substituted (hetero)cyclic compounds. An outstanding example of this strategy 
is the work done by professor Beifuss et al. regarding the use of aromatic 1,3-dicarbonyls as 
carbon nucleophiles. When reacted with and 1,2-dihydroquinones in the presence of 
laccases, 1,3-dicarbonyls are successfully and selectively transformed into oxygenated 
heterocycles via a domino process that involves two nucleophilic 1,4-conjugate addictions to 
in situ generated quinon intermediates, as shown in Scheme  7.3.127, 128, 129, 130, 131 Moreover, 
their investigation was expanded to S- and N-containing equivalents of 1,3-dicarbonyls, as 
in their elegant biocatalytic entry to pirimidobenzothiazoles bases on the use of 2-thioxo 
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pirimidine as nucleophiles (Scheme  7.4).132 It’s noteworthy that no expensive, toxic and/or 
hazardous metal-based chemical catalysts, that usually require inert atmosphere and specific 
experimental conditions, are needed to perform this biocatalytic Csp2-H bond activation.  
 
Scheme  7.3: 1,3-dicarbonyls-based laccase chemistry investigated by Beifuss. 
 
Scheme  7.4: Biocatalytic entry to pirimidobenzothiazoles. 
A domino process to afford oxygen-containing heterocyclic compounds can also be 
built by exploiting the oxidative (homo)coupling of phenolic substrates. In the past years, 
our research group has extensively investigated the laccase-mediated coupling of substituted 
vinyl phenols and stilbenes.133, 134, 135, 136 In Scheme  7.5, the different class of chemical 
structures that were obtained by the oxidative coupling of substituted phenolic substrates is 
presented.  
When the R’ group is second phenolic group and R is both an alkyl or an aryl substituent, a 
dioxane hetocyclic (ii) ring is usually obtained as major product, while in the presence of a 
‘spectator group’ in the R’ position and an allylic alcohol as the R substituent, the formation 
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of racemic pinoresinol (iii) is preferred. The obtainment of the 2,3-dihydrobenfofuran 
structures (b-5 type dimers, i) is instead preferred when the R’ group is, again, a ‘spectator 
group’ (i.e. hydrogen, alkyl chains, protected phenols) and the R substituent is both an alkyl 
or an aryl group.  
 
Scheme  7.5: Overview about the possible heterocyclic products  
obtained via laccase-mediated couplings. 
Thanks to these results, it was discovered that, working under optimum conditions and with 
the proper substrate, the selective formation of 2,3-dihydrobenzofurans could be achieved 
by laccase-mediated oxidations. From a mechanistic point of view, the target 
dihydrobenzofuran skeletons are obtained by a formal oxidative homocoupling reaction via 
a process involving the C-C coupling of two activated radicals formed by the biooxidation 
of two substrate molecules followed by an intramolecular 1,4-conjugate addiction, as shown 
in Scheme  7.6. During these oxidative couplings, two new stereocenters are formed. In 
general, due to steric hindrance and thermodynamics, dimeric products are formed as trans-
stereoisomers, whose absolute configuration is unfortunately randomized. The lack of 
enantioselectivity is a serious synthetic drawback of these biocatalyzed oxidative couplings. 
Nature has solved this problem developing the so-called ‘dirigent proteins’, a group of 
proteins that act as chiral templates and direct the stereochemical outcome of these 
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processes. A significant example of these ‘dirigent proteins’ was isolated from the plant 
Forsythia intermedia and used by Davin et al. for the in vitro stereoselective biocatalyzed 
synthesis of (+)-pinoresinol (iii, R’ = H) by the laccase-catalyzed oxidation of coniferyl 
alcohol.137 Later on, in 2010, Pickel et al. isolated and cloned an enantiocomplementary 
dirigent protein, able to guide the bio-oxidative coupling toward the formation of (-)-
pinoresinol.138 However, this elegant biomimetic approach is of scarce synthetic appeal as, 
for any substrate and desired enantiomer of a dimeric product, a specific dirigent protein 
should be isolated, providing that it does exist in Nature.  
To overcome this limitation, in previous works our research group has exploited the 
‘classical’ lipase-catalyzed kinetic resolution protocols. The racemic mixtures of β-5-type 
dimers derived from the laccase-mediated oxidation of different vinyl phenols were separated 
obtaining both the possible enantiomers as enriched species. The target products could be 
isolated with e.e. up to 98 %.139, 140 
 
Scheme  7.6: Domino process to dihydrobenzofurans via oxidative homocoupling. 
More recently, both the enantiomers of the β-5-type dimers of resveratrol could be isolated 
on a preparative scale starting from the laccase-mediated oxidation of piceid, a natural D-
glucoside of resveratrol (Figure 7.5).141 A mixture of trans-2R,3R and trans-2S,3S glucosylated 
dihydrobenzofurans–based dimers was easily isolated in good yield, and the two 
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diastereomers were separated by preparative HPLC on a chiral column. The target 
enantiomers of resveratrol dimers were eventually obtained with e.e. values up to 97 % by 
glycosidases-catalyzed hydrolysis of the glucose units. 
 
Figure 7.5: Piceid.  
 Paper VI described the possibility of extending this approach to other compounds, 
specifically to phenylpropanoid glucosides (PPGs, also known as glucosylated lignols) a 
family of bioactive arylalkyl glucosides whose biocatalytic synthesis has been extensively 
discussed in chapter 4. Looking for a possible sugar-induced stereochemical enrichment, the 
laccase-catalyzed oxidative coupling of a small family of glycosylated phenylpropanoids 
(using different carbohydrate moieties), has been investigated. Novel structurally modified 
analogues of these bioactive natural compounds have been isolated and characterized. These 
results will be discussed in 7.2. 
 
 To further investigate the laccase-mediated coupling of vinyl phenols and stilbenes 
to produce benzofuran-containing moieties, the possibility of conducting an intramolecular 
oxidative dimerization was investigated, using a substrate a small library of linked compounds 
(Figure 7.11), obtained by exploiting the lipase-mediated transacylation reaction discussed 
in chapter 3. Paragraph 7.3 will be focused on the presentation of these laccase-catalyzed 
biotransformations.  
 
 Moreover, this convenient, chemo- and regio-selective biocatalytic entry to 2,3-
dihydrobenzofurans has been exploited to perform a chemo-enzymatic synthesis of potential  
allosteric modulators of the 90 kDa heatschok protein (Hsp90) (Submitted Manuscript I), 
as it will be discussed in paragraph 7.4.  
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7.2 Oxidative dimerization of glycosylated lignols 
In Paper VI, the laccase-catalyzed oxidative coupling of a small family of water-soluble 
phenylpropenoid glucosides (PPGs), synthesized from coniferyl and p-coumaryl alcohol, has 
been investigated to produce 2,3-dihydrobenzofurans-based analogues of bioactive natural 
compounds. Moreover, to investigate the possibility of promoting a sugar-induced 
stereochemical enrichment of the obtained diasteromeric mixtures of dimers, different 
carbohydrate moieties (D-glucose, L-glucose and the disaccharide rutinose) were considered 
(Figure 7.6). In fact, in these compounds, the glycon moieties are linked very closely to the 
carbons (C-a and C-b, Figure 7.6) that were going to become novel stereocenters. The 
working hypothesis was that a bulky multi stereogenic chiral moiety near the reaction sites 
would have induced a discrimination among the possible diasteromeric products. 
 
Figure 7.6: Glycosylated substrates. 
At first, it was decided to study the laccase-mediated coupling of phenylpropanoid 
glucosides, synthetized as describes in chapter 4, compounds that had never been submitted 
before to the oxidative action of laccases. Furthermore, the presence of the sugar moiety 
linked to the primary alcohol of the propenol side chain, preventing the formation of 
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pinoresinol-like structures (iv, Scheme  7.5), would have allowed to limit the number of 
dimeric products obtained by the radical coupling.  
At first, the naturally occurring PPGs (D)-4.5a and (D)-4.7a were submitted to the action of 
the laccase from Trametes versicolor and the corresponding main products, 7.1 and 7.2, were 
isolated in 35 and 34 % yield, respectively (Scheme  7.7). Their mass spectra showed the 
expected values for dimeric products, the quasi molecular peaks ([M + Na+]) being registered 
at 645.3 at 705.3 Da respectively.  
The trans b-5-type dimeric structure of 7.1 was confirmed by the corresponding 1H-NMR 
spectrum. In addition to the signals due to the expected seven aromatic and two olefinic 
protons, the 1H-NMR spectrum showed the diagnostic signal due to H-a’.  
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Scheme  7.7: Synthesis of compounds 7.1–7.4. 
Reagents and conditions: Phenylpropanoid glycoside (0.05 M), acetate buffer (20 mM pH 5), laccase (0.005 U 
mmolsubstrate-1), at 30 °C and 300 rpm, 6 - 8 hours. Isolated yields: 7.1= 35 %; 7.2= 34 %; 7.3 = 37 %; 7.4= 33 %. All 
products were obtained as mixtures of trans-diasteroisomers.. 
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Provided that 7.1 is a mixture of diasteroisomers, the signals were split in two base line 
separated doublets (relative ratio almost 1:1, Figure 7.7) centered at 5.574 and 5.234 ppm (J 
6.4 Hz). Similarly, the signals due to the two anomeric protons (doublets) were split in two 
doublets each (resonating between 4.403 and 4.347 ppm). All the other signals appeared as 
multiplets, due to the duplication of the expected peaks.  
Similarly, the 1H-NMR spectrum of 7.2 showed the presence of the five aromatic and two 
olefinic protons. The signal due to H-a’ was again split in two base line separated doublets 
centered at 5.547 and 5.503 ppm (J 6.4 Hz), Figure 7.7. However, the relative ratio of these 
two doublets, evaluated by signals integration, was approximately 1.5:1. Among the two 
anomeric protons, the first one resonated as a doublet at 4.217 ppm (J 8.0 Hz). The second 
one was split in two doublets, again in a 1.5:1 ratio, the most abundant being centered at 
4.263 and the second one at 4.256 ppm (J 7.6 Hz). Both the two singlets due the two methoxy 
substituents were also split, resonating respectively at 3.807 and 3.800 ppm and at 3.751 and 
3.742 ppm. 
Intrigued by the observed difference in the relative ratio of the two diasteroisomers 
of 7.2, it was decided to subject to the action of laccases the phenylpropanoid glucoside (L)-
4.7a, carrying the enantiomeric sugar moiety, (L)-glucose. The synthesis of compounds (L)-
4.7a was conducted following standard chemical glycosylation protocols, as it was shown in 
Scheme 4.1 of chapter 4. The key step, again, was the coupling of the trichloroacetimidate 
of L-tetraacetylglucopyranoside to a TBDMS-protected (at the phenolic moiety) alcohol, that 
gave the target glucoside in isolated yield of 20 %. After subjecting (L)-4.7a to the laccase-
catalyzed oxidation, the main product 7.3 was isolated in a yield similar to the previously 
described products (37 %) and the structure was confirmed by mass spectrometry and 1H-
NMR. As expected, its spectrum was mostly equivalent to the one previously obtained with 
7.2. Specifically, the presence of two diastereomeric substituted benzodihydrofuran moieties 
was confirmed by the two doublets resonating at 5.554 and 5.504 ppm (J 6.8 Hz). However, 
at variance to 7.2, the relative ratio of the area of the two doublets of 7.3 was lower (1.1: 1) 
and, moreover, the most abundant dimer was the one whose doublet resonated at higher 
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fields (5.504  ppm, Figure 7.7), whereas with 7.2 it was the one resonating at lower fields 
(5.547 ppm); a result, that was coherent with the presence of two enantiomeric sugars in the 
starting substrates (D)-4.7a and (L)-4.7a. As a comparison, Figure 7.7, shows the relative 
abundance of the signals due to H-a’ in compounds 7.1-7.4. 
 
Figure 7.7: Diasteromeric excesses evaluation: 1H-NMR. 
The difference reaction outcomes, in terms of diastereomeric ratio of the dimeric products 
7.1 and 7.2, was also confirmed by HPLC analysis. Several chiral and achiral columns were 
tested and the best results were obtained with a Kinetex 5µm Biphenyl 100Å Column. 
Figure 7.8 shows the baseline separated HPLC peaks of the diasteromeric mixtures 9 and 
10. The low d.e. (18 % and 6.0 %, respectively) and the stereo complementarity of the two 
reactions outcomes were confirmed. 
 
Figure 7.8: Diasteromeric excesses evaluation: HPLC.  
Derivative 4.7b, that was obtained by exploiting the biocatalytic entry described in 
chapter 4, containing a bulkier sugar moiety linked to coniferyl alcohol, was used as the last 
substrate for, again, a laccase-mediated oxidation. Its dimerization was performed following 
the usual protocol, and the main product 7.4 was isolated in 33 % yield. The mass spectrum 
was in accordance with the structure of a dimeric product ([M + Na+] m/z = 997.3 Da) and 
the 1H-NMR corroborated the structure. The spectrum was quite complex, due to the 
7.1, d.e. = 5.6 %
7.2, d.e. = 21.0 % 7.3, d.e. = 5.0 %
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presence of two disaccharide moieties and two diastereoisomers. The anomeric protons of 
the two glucopyranose units were doublets centered at 4.489 and 4.373 ppm. The presence 
of the rhamnopyranose units was confirmed, i.a., by the signals due to the C-18 methyl 
groups resonating at 1.174 and 1.238 ppm. The diagnostic signals due to H-a’ were two 
baseline separated doublets at 5.602 and 5.552 ppm (J 6.4 Hz, Figure 7.7) with a relative 
ratio of 1.16 : 1. 
 
Thanks to this work, it has been shown that coumaryl and coniferyl glucosides are 
suitable substrates for a laccase-mediated Csp2-H bond activation allowing an easy and 
convenient biocatalytic entry to 2,3-dihydrobenzfuran-based analogies of bioactive natural 
products. The presence of a carbohydrate moiety increased the water solubility of these 
compounds and reduced the number of dimeric products, as pinoresinol-like structures 
could not be formed. However, the sugar substituents had a minor effect on the 
stereochemical outcome of the radical coupling reactions, the best results being the 21 % d.e. 
observed in β-5-like dimer 7.2 obtained by the laccase-catalyzed dimerization of (D)-4.7a. 
Anyway, these low d.e. were surprisingly accounting for a stereocomplementarity in the 
reactions outcomes depending the configuration of the sugar moiety attached to the 
phenylpropanoid structure.  
As future development, since a sugar-induced asymmetric synthesis of 2,3-
dhydrobenzufyrans via a laccase-mediated oxidative coupling of glycosylated lignols appears 
unfeasible, the will be focus on the preparative scale isolation of enantiomerically enriched 
dimers of coumaryl and coniferyl alcohols following the protocol previously exploited with 
resveratrol glucoside.141 
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7.3 Studies on intramolecular oxidative couplings 
It’s commonly accepted that intramolecular reactions can often proceed with better degrees 
of stereo-, regio- and chemo-selection, when compared to their intermolecular versions. 
Accordingly, the intramolecular laccase-mediated oxidative couplings of suitable phenolic 
substrates were undertaken.  
 
Figure 7.9: Representative phenolic substrates and linker. 
 
Figure 7.10: Target scaffolds (B). 
In this study, different phenols, even chiral glucosylated substrates, were linked, via spacers 
of diverse chain lengths, to build omoderivatives (Figure 7.9) to be used as substrates for 
the laccase-catalyzed oxidation. The aim was to investigate whatever a macrocycle structure 
containing a (±)-2,3-trans-dihydrobenzofuran moiety could have been obtained this way 
(Figure 7.10). These families of scaffolds, could be used to build interesting analogues. 
Using the activated diesters compounds (7.a – 7.c) as acyl-donors in some Novozym435-
catalyzed (Candida antarctica lipase B) transacylation reactions, a small library of linked 
omoderivatives (7.d-7.m) of coniferyl alcohol, tyrosol and piceid was built.  
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Figure 7.11: The bio-catalyzed synthesis of 7.d-7.m were conducted using Novozym435 (0.25 mg/mg) at 45 °C, 200 rpm 
in dry acetone as solvent.  
 
 
 
 
 
 
 
 
 
Figure 7.12: TLC plate of the reaction of 7.g with T. vesicolor laccase: (A) reaction outcome; (B) starting substrate 7.g.   
Laccase-mediated oxidations, reagents and conditions: 7.d-7.e =acetate buffer pH 5 20mM/acetone = 1:1, [2.5 
mg/mL], 0.05 U/mg; 7.f-7.h = acetate buffer pH 5 20mM/acetone = 1:1, [2.5 mg/mL], 0.018 U/mg; 7.i-7.m = acetate 
buffer pH 5 20mM/MeOH = 1:1, [5 mg/mL, 0.5 U/mg.  
Compounds 7.d-7.m (whose sctructres were confirmed by 1H-NMR) were than subjected 
to the action of laccases. Unfortunately, only complex mixtures of oxidized products were 
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always obtained, regardless the conditions used or the type of substrates. As an example, 
Figure 7.12, shows the reaction outcome of the laccase-mediated oxidation of compound 
7.g.  
This investigation is now focused on the finding of more suitable linkage-modalities and/or 
reactions conditions to promote the formation of the target cyclic products and avoid the 
disruption of the starting material due to undesired radical decompositions.  
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7.4 Chemo-enzymatic synthesis of potential allosteric 
modulators of the 90 kDa heatschok protein (Hsp90) 
Heat shock proteins as pharmacological target: Hsp90 and Hsc82 
Heat shock proteins (Hsp) are molecular chaperones that facilitate the maturation of a wide 
range of proteins, known as ‘clients’ which usually are enriched in signal transducers, 
including kinases and transcription factors. The human heat shock protein 90 (Hsp90), and 
its homologue found in yeast Hsc82, are the most characterized member of this class of 
polypeptides.142 In Nature, chaperones are required for essential housekeeping functions, 
such as de novo protein folding during nascent polypeptide-chain synthesis, translocation of 
proteins across membranes, quality control in the endoplasmic reticulum, and normal protein 
turnover. Chaperones also participate in many higher-order functions, such as the post-
translational regulation of signalling molecules, the assembly/disassembly of transcriptional 
complexes and the processing of immunogenic peptides by the immune system (Figure 
7.13). As such, they have been proposed as interesting target for the treatment of vascular 
disease,143 neurodegeneration144 and cancer.145 
 
Figure 7.13: Biological roles of chaperones.  
In general, the intracellular expression of Hsp increase in response to protein-denaturing 
stressors, such as temperature change, as an evolutionarily conserved response to restore the 
normal protein-folding environment and to enhance cell survival. However, most 
chaperones are ubiquitously expressed under normal conditions: Hsp90, specifically, 
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comprises as much as 1–2 % of total cellular protein content, even under non-stressed 
conditions. Hsp90 important role in cellular functionality, i.e. its ability of prevent protein-
denaturation, led researchers to develop a general approach to perturb this essential 
chaperone by impairing its pivotal functional dynamics through the modulation of its 
ATPase processes.142 
 
Figure 7.14: Crystal structures of open (ligand-free) full-length Hsp90 from E. coli and closed (ATP- and co-chaperone-
bound) yeast Hsp90. The N -domain is depicted in blue and cyan, the middle domain in dark green and light green, and 
the C -domain in red and orange. The p23 co-chaperone is in yellow, whereas ATP is depicted through a space-filling 
representation. 
Specifically, Hsp90 dynamics depend on ATP binding and hydrolysis, which 
underlies the onset of conformational transitions between substrates with different 
functional properties. Hsp90 works as a homodimer with a common modular organization 
in terms of N-terminal (NTD), middle (M) and C-terminal (CTD) domain. The CTD domain 
is the dimerization domain, while the NTD contains an ATP-binding site.146 ATPase activity 
is essential for Hsp90 to work and requires transient dimerization of the NTD in a closed 
state of the dimer (Figure 7.14). The exact mechanism of coupling between ATP 
binding/hydrolysis and client folding remains elusive. A possible model, supported by 
biochemical data, involve a nucleotide binding at the NTD which propagates a 
conformational signal to the CTD. The chaperone undergoes conformational 
rearrangements that bring the two NTDs into close association in the ATP-state and into an 
open one in the ADP-state. The formation of the closed state can be therefore induced by 
ATP. After ATP hydrolysis, the protein cycles back to the open ADP-bound state. 
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In Figure 7.15 interactions of Hsp90 with clients and co-chaperone and its consequent 
conformational changes are shown. As an example, the co-chaperone Aha1 is an Hsp90 
ATPase activity activator, while Sba1 acts as inhibitor by binding selectively to the closed 
conformation, thus blocking the chaperone dynamics.  
 
Figure 7.15: Hsp90 structure and its conformational equilibrium. AS= allosteric site; Aha1= co-chaperone; Sba1= co-
chaperone; D131D= client protein. 
Learning from Nature, the design of potential small-molecules modulators able to 
perturb Hsp90 ATPase activity, thus impairing its essential conformational dynamics, has 
emerged as a promising approach in the field of drug discovery.  
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Hsp90 synthetic allosteric modulators 
The modulation of Hsp90 conformational dynamics using small-molecules modulators can 
potentially occur by the action of both inhibitors or activators of its ATPase activity.  
Most of the known Hsp90 modulators acts as ATPase activity inhibitors by interacting with 
the chaperone at the NTD. Some of these compounds has also been tested as antitumor 
drugs. Interestingly, most of tested compounds, have shown some limitations due to their 
ability of completely inhibit the ATPase activity of Hsp90 inducing the so-called ‘heat shock 
response’ (Figure 7.16). As a prosurvival cell mechanism that cause a different aggregation 
of filament-forming proteins, the heat shock response can limit the action of a potential drug, 
especially in eukaryotes, where it leads to the disruption of the cytoskeleton, the loss of the 
correct localization of organelles and a breakdown of intracellular transport processes.147  
 
Figure 7.16: Effects of heat shock on the organization of the eukaryotic cell 
In this context, Bernardi, Colombo et al. have investigated the rational design of chemical 
compounds to select and activate Hsp90 key substrates, avoiding the mentioned heat shock 
response and targeting an allosteric pocket ‘AS’ of protomer B (Figure 7.15). Moreover, the 
authors sought a connection between protein activities, cellular outcomes and small 
molecular scaffolds.148,149,150 Thanks to their studies it was demonstrated that the three 
families of 2-(4-hydroxyphenyl)-3-methylbenzofuran-based Hsp allosteric ligands showed in 
Figure 7.17 possess a structure-dependent ability to stimulate ATPase process and to alter 
conformational dynamics, favoring synergistic effects with the activating co-chaperone Aha-
1, to modulate Hsp90 direct interactions with the co-chaperone Sba-1 (inhibitor of ATP-
hydrolysis) and to compete with the client protein D131D (Figure 7.15).  
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Figure 7.17: Novel Hsp90 allosteric ligands: first (a), second (b) and third (c) generation ligands.  
Their rational design was based on a set of computational experiments focused on targeting an allosteric site located at the 
MD/CTD interface, alternative to the ATP binding site. The best candidates were then synthetized and tested as allosteric 
modulators by measuring their effects on the ATPase activity of the Hsp90 yeast homologue (Hsc82). Following in silico 
experiments were run to optimize the structures afforded the second and third generations ligands by introducing 
substituents able to induce H-bonding.   
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2,3-Dihydrobenzofuran-based potential modulators 
As described by Bernardi, Colombo et al., allosteric ligands with 2-(4-hydroxyphenyl)-3-
methylbenzofuran structure can act as activators of Hsp90’s ATPase cycle. Moreover, their 
optimization may lead to new effective anticancer drugs with novel mechanisms of action, 
based on the perturbation of the Hsp90 machinery. Specifically, the acceleration of 
conformational dynamics could be translated into impaired chaperone functions and 
consequent cell death.  
Intrigued by their elegant results, in Submitted Manuscript I, both the synthesis and the in 
vitro evaluation of a family of substituted (±)-trans-2,3-dihydrobezofurans (i) as potential 
allosteric modulators of the Hsp90’s ATPase were investigated. At variance to the 
compounds proposed by Bernardi, Colombo et al., it was decided to introduce a remarkable 
affinity for p-aryl interactions and more conformational freedom. Accordingly, our structure 
activity relation studies (SAR) were focused on the introduction of two aryl groups at the R 
and C3-positions of the parental benzofuran moieties (p) (Figure 7.18), as the pivotal 
substitution at the R’ group had been extensively investigated in the previous works reported 
by the authors. Moreover, as a convenient and easy entry to a broad family of analogues was 
cherished, it was decided to exploit the oxidative coupling of E-stilbenes which is reported 
to produce dihydrobenzofurans as racemic mixtures of trans-2,3-diastereosimoers. Thus, the 
C2 and C3-position of the benzofuran moieties (i) were fully saturated.  
 
Figure 7.18: 2,3-dihydrobenxofurans-based potential modulators (i).  
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As previously introduced, a convenient, scalable and selective entry was needed to easily 
access a library of R, C3-modiefied compounds to be tested for their potential Hsp90’s 
dynamics modulating effects. After a careful evaluation of other commonly chemical 
oxidants available to access the target compounds staring from differently substituted (E)-4-
styrylphenols (ii), the previously described laccase-mediated synthesis of oxygenated 
heterocycles was selected as the key synthetic step. The retrosynthetic approach is proposed 
in Figure 7.19.  
 
Figure 7.19: Retrosynthetic analysis. 
 Most of the modern synthetic entries to 4’-hydroxy-E-stilbenes (ii) relay on the use 
of Pd-catalyzed Heck reactions151,152 or trans-selective reduction of alkynes,153, 154 but a metal 
and catalyst-free, cheap and versatile methodology to easily synthetize a broad family of 
styrylphenols is still cherished. As such, the microwave-based strategy proposed by Sinha 
and co-workers155 has been deeply investigated. The authors, starting from substituted 
benzaldehydes and phenylacetic acids could successfully produce various E-stilbenes under 
microwave irradiation in the presence of piperidine, imidazole and PEG.  
To further simply this convenient strategy, a study proposed by De Filippis et al. was used as 
starting point.156 The one-pot synthesis of (E)-4-styrylphenols has been achieved by heating 
to 130 °C a concentrated DCM-solution of 4-hydroxy benzaldehyde, a substituted 
phenylacetic acid and piperidine, distilling the solvent and reacting the obtained neat mixture 
for 12-24 h. Surprisingly, using these pretty harsh conditions, the authors reported that the 
target E-stilbenes could be obtained in modest to very good yield, depending on the 
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substitution pattern of the phenylacetic acid used. Specifically, electron-donating groups on 
the aromatic ring affected negatively the overall yield of the process by impairing the 
decarboxyative-formation of the C-C (E)-double bond, a key-step in mechanism of the 
transformation; the best results were instead obtained with electron-poor phenylacetic acids. 
 
Scheme  7.8: Proposed mechanism for the catalyst-free synthesis of (E)-4-styrylphenols. 
A proposed mechanism for this interesting transformation is shown in Scheme  7.8. At first, 
benzaldehyde and phenylacetic acid undergoes an aldol condensation to form an a-hydroxy 
carboxylate species that interacts with piperidine to give a quinone-like intermediate. A 
subsequent decarboxylation gives the final product hydroxy-E-stilbene. Along with a rational 
explanation of the lower yield obtained by the authors with electron-rich phenylacetic acids, 
this mechanistic proposal also underlines the key role of 4-hydroxy benzaldehyde, as its C-4 
hydroxyl group appears essential for the good functioning of the reaction. Moreover, this 
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was further confirmed conducting a control-reaction between p-hydroxy-phenylacetic acid 
and benzaldehyde: no products were formed.  
On the base of these results, the reaction conditions proposed in De Filippis’s work were 
further investigated and optimized, focusing on reaction stoichiometry. After a small set of 
experiments, the best results in terms of isolated yield of the desired E-stilbenes were 
obtained using 2.4 equivalents of phenylacetic acid and 2.5 equivalent of piperidine. In this 
way, a library of p10- and m9(11)- substituted and m9, m11 di-substituted (E)-4-styrylphenols 
was synthetized starting from commercially available phenylacetic acids, as summarized in 
Table 7.1.  
 
Table 7.1: Synthetized substituted (E)-4-styrylphenols.  
Reagents and conditions: 4-hydroxybenzaldehyde, phenylacetic acid, piperidine, DCM, 130 °C, 24 h. 
Evidence of the formation of the desired E-stilbenes came from 1H-NMR analysis. Indeed, 
the spectra showed all the expected aromatic and (if any) aliphatic signals as well as the 
presence of a (E)-olefin bond (two doublets resonating between 7.20-7.50 ppm with 
R1
R2
R3
OH
α
β
4
10
9
8
7
11
12
5
6
1
2
3
Entry Compound R1 R2 R3 Yield % 
Reaction 
Time (h) 
1 7.5 H H H 52 24 
2 7.6 H CH3 H 44 48 
3 7.7 H CN H 64 24 
4 7.8 H NO2 H 62 18 
5 7.9 H OCH3 H 38 28 
6 7.10 CH3 H H 28 24 
7 7.11 CN H H 60 24 
8 7.12 SCH3 H H 57 48 
9 7.13 OCH3 H OCH3 28 48 
10 7.14 CH3 H CH3 39 72 
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coupling constants of ca. 16.0-16.5 Hz, a typical value for a E-configured C-C double bonds). 
All the synthetized stilbenes were characterized by 1H-NMR and, when possible, compared 
with previous literature reports. As expected, the presence of electron donating groups on 
phenylacetic acid para and meta position caused a decreasing in reaction rates and yields 
(entries 2, 5, 6 of Table 7.1). Again, the presence of two electron-donating groups on the 
phenylacetic acid moiety, i.e. two methoxy groups and two methyl groups (9 and 10 of Table 
7.1), produced a substantial decrease of reactivity. 
  Once compounds 7.5-7.14 have been synthetized, their oxidative coupling to give 
the target 2,3-dihydrobenozofuran-based scaffolds (i) was studied.  
As previously stated, different chemical oxidants (MnO2, FeCl3 and CuCl2) were investigated, 
using compound 7.5 as a model. Oxidations with iron(III) trichloride and copper(II) 
chloride, conduced in a solvent made by a monophasic mixture of ethanol and water as 
solvent, gave a complex mixture of oxidized products (TLC plate shown in Figure 7.20) and 
thus these compounds were discarded.  
The oxidation with manganese(IV) oxide, run under the same experimental conditions, gave 
better results. The reaction run smoothly and, as shown Figure 7.21A, a single spot could 
be detected by TLC. Unfortunately, the 1H-NMR spectrum of the isolated product showed 
the presence of an inseparable mixture of oxidized compounds, as further confirmed by 
reverse-phase HPLC analysis, containing as major product the desired di-hydrobenzofuran 
structure, (Figure 7.21B). 
Given these selectivity issues, as more than one regioisomeric oxidized products were always 
obtained by chemical means, the mentioned laccase-mediated system for the activation of 
Csp2-H bonds. Due to the design of the stilbenic substrates carrying only one oxidizable 
phenolic moiety, the synthesis of the target heterocyclic compound could be in principle 
selectively promoted by the redox action of laccases’ tetratomic copper cluster.  
As it was previously reported by our research group for the oxidation of resveratrol,157 the 
oxidation of the model substrate 7.5 was conducted using the commercially available laccase 
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from Trametes versicolor and a 1:1 mixture of acetate buffer (pH 4.5, 50 mM) and acetone as 
solvent. The reaction proceeded smoothly, and the only detectable product (TLC analysis) 
was isolated by silica gel chromatography and analyzed by Mass spectroscopy, 1H- and 13C-
NMR. The 1H-NMR spectra underlined the formation of the dihydrodimers. Specifically, 
besides the signals of the aromatic protons, the presence of the target 2,3-trans-
dihydrobenzofuran was verified by the presence of two doublets resonating at 5.53 and 4.60 
ppm characterized by the typical value of trans-coupling constants in oxygenated 5-memberd 
rings (J ca. 8.58 Hz). Moreover, two doubles resonating at 7.06 and 6.92 and showing the 
typical value of E-configured C-C double bonds (J ca. 16.5 Hz) were detected, attesting the 
presence of E-double bond between Ca and Cb. 
 
Figure 7.20: TLC plate of the reaction outcome of the CuCl2-mediated oxidation of 7.5: 
 (a) standard of 7.5; (b) 3 h reaction; (c) overnight reaction; (d) 24 h reaction. 
A) B) 
Figure 7.21: A) TLC plate of the reaction outcome of the MnO2-mediated oxidation of 7.5: 
 (a) standard of 7.5; (b) co-chromatography of a and c; (c) 24 h reaction. 
B) HPLC chromatogram of c.  
(a) (b) (c) (d)
(a) (b) (c)
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Thanks to the action of laccases, the target oxygenated heterocycle 7.15 (with the proper 
stereochemistry) was obtained in a remarkable 76 % isolated yield from stilbene 7.5. As a 
comparison, in Figure 7.22 the HPLC chromatograms of 7.15 (A) and the mixture of 
inseparable products obtained by the oxidation mediated by MnO2 (B).  
These results pointed out how the use of the selected biocatalyst could allow a convenient 
and selective entry to 7.15, working with a cheap, non-toxic and environmental-sustainable 
(oxygen is consumed and water produced) ‘masked’ metal catalysts under mild reaction 
conditions.  
  
Figure 7.22: HPLC chromatograms of 7.15, obtained by laccase-mediated oxidation (A), and 
the mixture of oxidized products obtained via the oxidation with MnO2, enriched in 7.15 (B).   
 Once verified that the laccase catalyzed oxidation was the best method for the 
selective preparation of the target (±)-trans-dihydrobenzofuran 7.15 from stilbene 7.1, the 
same protocol was applied to the other synthetized 4-(E)-styrylphenols. The commercially 
available resveratrol (iii), whose biooxidation usually gives different oxidized products, was 
also subjected to the action of laccases from T. versicolor, aiming at isolating its natural dimer 
e-viniferin (compound 7.16, Figure 7.23). This natural compound, in fact, possesses the 
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same (±)-trans-dihydrobenzofuran structure and four different OH groups, potential 
promoters of H-bonding bridges during the binding event with Hsp90.  
 
Figure 7.23: Structures of resveratrol (iii) and e-viniferin (7.16). 
The obtained results are summarized in Table 7.2. In all cases the oxidations proceeded 
smoothly and the expected (±)-trans-dehydrodimers were isolated in 55-74 % isolated yield 
after 24 h of reaction. 
 
 
 
 
 
 
 
 
 
 
Table 7.2: Synthetized racemic-trans-2,3-dihydrobenzofurans.  
Reagents and conditions: laccases from T. versicolor (42 U mmolsubstrate -1) acetate buffer (pH 4.5, 50 mM), acetone, 27 
°C, 160 rpm, 18 h. 
O
OH
HO
OH
HO
OH
HO
OH
OH
(iii) (7.23)
R1
R2
R3
α
β
4
10
9
11
5
O
OH
R1' R2'
R3'9'
10'
11'
β'
α'
(±)
Entry Substrate Product R1 R2 R3 Yield % 
1 7.5 7.15 H H H 52 
2 7.6 7.16 H CH3 H 60 
3 7.7 7.17 H CN H 74 
4 7.8 7.18 H NO2 H 68 
5 7.9 7.19 H OCH3 H 55 
6 7.10 7.20 CH3 H H 46 
7 7.11 7.21 CN H H 49 
8 7.12 7.22 SCH3 H H 57 
9 (iii) 7.23 OH H OH 33 
10 7.13 7.24 OCH3 H OCH3 58 
11 7.14 7.25 CH3 H CH3 69 
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The lower yield obtained with resveratrol could be due to presence of more than one 
oxidizable phenolic OH: by-products and over-oxidations are very likely to occur with such 
a reactive substrate. All products were fully characterized by means of mass spectroscopy 
and 1H- and 13C-NMR.  
Moreover, in order to increase the number of compounds available for subsequent in vitro 
testing, it was decided to reduce the nitro groups of compound 7.18 to afford the di-amine 
derivative 7.26. In this way, a potential H-bonding group could be inserted in the para-
positions of scaffold (i). This task was accomplished exploiting the metal-free method 
developed by Benaglia and co-workers for the reduction of aromatic nitro compounds, 
which consisted in the use of trichlorosilane in combination with DIPEA.158 
Form the reduction of 7.18, the diamine 7.26 was obtained 21 % isolated yield, its sctructres 
being confirmed by both NMR and mass analysis. Moreover, during the purification process, 
the two mono-amines derivatives 7.27 and 7.28 were also isolated in 3 % and 8 % yield 
respectively (Figure 7.24).   
 
Figure 7.24: Reduced compounds from 7.18. 
The structural attribution of compounds 7.27 and 7.28 was far from being easy, as the two 
regioisomers shares the same molecular weight and shows very similar NMR spectra. Our 
hypothesis for the attribution was based on their TLC spots. The two compounds, in fact, 
showed different Uv-Vis-responses. One, as its parental compounds 7.8 and 7.18, appeared 
yellow in the Vis-spectrum and responds with a bright spot when irradiated with Uv-light at 
254 nm. At variance, the other was only Uv-responsive. Since the starting material showed a 
similar behavior, the structure of the mono-amine 7.27, in which a fully conjugated nitro 
group is still present, was attributed to the yellow compounds.  
H2N
O
OH
NH2
(±)-7.26
R2
O
OH
R2'R2 = NH2; R2' = NO2 (±)-7.27
R2 = NO2; R2' = NH2 (±)-7.28
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In vitro screening 
Having a battery of compounds available thanks to the described selective chemo-enzymatic 
synthesis, the potential activity of compounds 7.15-7.27 as allosteric modulators of the 
Hsp90’s ATPase cycle was tested. As previously stated, the interaction of these chemicals 
with the allosteric binding site of Hsp90 can impair the natural chaperon functions of the 
protein by perturbing its essential conformational dynamics during ATP-hydrolysis, acting 
both as inhibitors or activators. 
The homologue chaperone Hsc82 from yeast was used for the in vitro screening, thanks to 
its higher availability. The selected test, as reported by Sattin et al., consisted in a colorimetric 
assay in which the hydrolysis of ATP, promoted by the previously discussed Hsp90’s 
dynamics, was coupled with the final oxidation of NADH to NAD+ (nicotinamide adenine 
dinucleotide, Figure 7.25) in a set of cascade reactions catalyzed by the enzymes pyruvate 
kinase and lactate dehydrogenase, as shown in Scheme  7.9.148  
 
Figure 7.25: ATP, ADP and NAD+ structures.  
 
Scheme  7.9: Enzymatic cascade reactions to evaluate  
by spectrophotometer the ATPase activity of Hsc82.  
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The ADP produced by the ATPase hydrolysis cycle of Hsc82, reacts with PEP 
(phosphoenaolpyruvate) to form pyruvate in a reaction catalyzed by the enzyme pyruvate 
kinase (PK), whereby ATP is regenerated. Pyruvate then continues the cascade process and 
is reduced to lactic acid by action of lactate dehydrogenase (LDH), whereby NADH is 
oxidized to NAD+. As NADH has a maximum of absorbance in the Vis-light at 340 nm, the 
Hsc82-dynamics and ATPase cycle can be easily monitored by following the continuous 
decrease in absorbance at the listed wavelength (A340).159  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7.3: Results of the ATPase assays for compounds 7.15-7.28 and standard deviations.  
All compounds were tested three times and standard deviations were calculated accordingly. 
At first, the ‘native’ ATPase activity of Hsc82 was tested in presence of DMSO (the solvent 
used to dissolve compounds 7.15-7.27) to set a standard value to be used to normalize all 
the forthcoming experiments. After that, all the synthetized potential modulators were tested 
Entry Compound 
ATPase 
Normalize 
Activity 
STD 
1 DMSO 1.00 0.07 
2 7.15 1.10 0.07 
3 7.16 0.70 0.05 
4 7.17 0.80 0.10 
5 7.18 1.10 0.10 
6 7.19 1.00 0.14 
7 7.26 1.40 0.14 
8 7.27 0.90 0.05 
9 7.28 0.90 0.02 
10 7.20 0.90 0.10 
11 7.21 1.00 0.05 
12 7.22 1.20 0.05 
13 7.23 2.50 0.10 
14 7.24 0.90 0.05 
15 7.25 1.00 0.09 
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by preparing an HEPES (20 mM, pH 7.5) solution containing KCl (100 mM), MgCl2 (1 mM), 
PEP (1 mM), NADH (0.18 mM), LK (2.5 U ml-1), LDH (4 U ml-1), Hsc82 (2 µM) and the 
desired dihydrodimer 7.x (50 µM). The enzymatic cascade was initiated by addition of ATP 
(final concentration of 1 mM).  
The results obtained with the in vitro screening of 7.15-7.27 are summarized in table Table 
7.3. As shown, only compound 7.23 (entry 13) could promote a relevant increasing (2.5 
times) in the normalized ATPase activity, maybe due to its remarkable H-bonding capacity.  
 
Figure 7.26: Enantiomers of 7.23. 
 
 
 
 
 
Table 7.4: Normalized ATPase activity of the two enantiomers of  
compound 7.23 and its isolated enantiomers. 
Since all the tested dimers were a racemic form of trans enantiomers, it was of interest to 
verify whether their single enantiomers could give different results. The two enantiomers of 
the 7.23 were already available in our laboratory as they had been synthetized during previous 
studies.141 The isolated compounds (-)-7.23 and (+)-7.23 (Figure 7.26) were also tested and 
the results compared with the one obtained with the racemic mixture of the same compound 
(7.23). The Hsc82’s ATPase modulation efficiency of racemic 7.23 turned out to be 
comparable with the in vitro activity of the two isolated enantiomers, as shown in Table 7.4. 
O
OH
HO
OH
HO
OH
(+)-7.23
O
OH
HO
OH
HO
OH
(-)-7.23
Entry Compound 
ATPase 
Normalize 
Activity 
STD 
1 DMSO 1.00 0.07 
2 (±)-7.23 2.50 0.10 
3 (-)-7.23 2.40 0.11 
4 (+)-7.23 2.30 0.10 
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Therefore, the isolation of the enantiomers of the other dimers has been considered 
unnecessary. 
During their studies Bernardi, Colombo et al148 found that the alkylation with amine-
containing chains of the 4-hydroxyl group of the 2-(4-hydroxy-phenyl)-3-methylbenzofuran 
scaffold (second and third generation ligands) led to an increase in their ability to stimulate 
ATPase process. Accordingly, it was decided to investigate this possibilities with a small 
selection of compounds 7.15-7.28, to couple a N,N-dimethylethanamine side chain whose 
beneficial effects on the stimulation activity had already been reported.148 Specifically, the 
alkylations of the 4-phenolic group of compound 7.15, 7.24 and 7.25 were successfully 
accomplished according to published protocols, producing compounds 7.29, 7.30 and 7.31 
(Figure 7.27).  
 
Figure 7.27: Compounds 7.29, 7.30 and 7.31.  
Reagents and conditions: 2-chloro-N,N-dimethylethylamine hydrochloride, tetrabutylamonium hydrogen sulfate and 
K2CO3 , CHCl3, H2O, 50 °C, 24 h. Isolated yields: 35 % (7.29), 60 % (7.30) and 21 % (7.31).  
At first, compound 7.29 was synthetized to demonstrates the activation effects reported 
from tertiary amines on 2,3-dihydrobenzoduran moieties using the ‘nude’ skeleton of 7.15. 
Then, to investigate the possibility of activating potential Hs82’s ATPase modulators sharing 
structural similarities with compound 7.23 (i.e. compounds 7.24 and 7.25) were produced 
and tested as well. Despite its promising Hsc82’s ATPase modulation activity, compound 
7.23 was not further alkylated. The presence of five phenolic groups, in fact, could have led 
to an unselective poly-alkylation, producing a poly-amine compound. The presence of more 
than one charged residue could indeed affect the pharmacodynamics and kinetics of the 
O
O
R1
R3
R1'
R3'
N
(7.29): R1 = R3 = R1' = R3' = H;
(7.30): R1 = R3 = R1' = R3' = OCH3
(7.31): R1 = R3 = R1' = R3' = CH3
(±)
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obtained compound. Moreover, the alkylation of the 4-(E)-styrylphenols OH group would 
have irremediably affected their laccase-mediated oxidative couplings.  
 
 
 
 
 
 
 
Table 7.5: Normalized ATPase activity of the alkylated compounds  
7.29, 7.30 and 7.31. 
The in vitro testing of the alkylated compounds 7.29, 7.30 and 7.31 demonstrated the ability 
of the N,N-dimethylethanamine side chain to promote the modulation activity of the 2,3-
dihydrobenzofuran scaffolds, as the incubation of compound 7.29 with Hsc82 showed a 2.3 
increasing in the ATPase activity. Unfortunately, the same was not true for the alkylation of 
the more sterically-demanding compounds 7.24 and 7.25, as shown in the data collected in 
(Table 7.5). This might mean that steric hindrance could have affected the right orientation 
of the tertiary amine in the allosteric pocket of the protein, thus impairing its activation 
effects. Computational studies to confirm these hypotheses and evaluate the binding 
efficiencies of all the tested compounds are now in progress.  
  
Entry Compound 
ATPase 
Normalize 
Activity 
STD 
1 DMSO 1.00 0.07 
2 7.15 
7.29 
1.10 
2.30 
0.07 
0.24 
3 7.24 
7.30 
0.90 
0.90 
0.05 
0.02 
4 7.25 
7.31 
1.00 
1.00 
0.09 
0.02 
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Docking studies  
To assess at molecular level which are the binding properties that guide the efficiency in 
modulating Hsp90 ATPase activity of the active compounds, protein-ligand docking 
calculations are being performed (Colombo, D’Annessa et al, ICRM-CNR). The preliminary 
obtained results were well in agreement with experimental assays. Indeed, compound 7.23 
was the strongest binder with a predicted binding energy of -10.024 kcal mol-1 calculated for 
the best pose obtained (Figure 7.28).  
 
Figure 7.28: Docking of 2S,3S-7.23 (A) and 2S,3S-7.29 (B).  
Thanks to the presence of the hydroxyl substituents in positions R1, R3, R4 and R6 thus 
compound established a series of hydrogen bonds with residues L502, D503, R591 and L658 
all belonging to protomer B, thus strongly stabilizing the closed and activated structure of 
the target protein, which supports the high modulatory activity observed for 7.23. This 
behavior was also in line with previous results on a series of the different, yet related, 
benzofuran-based compounds.148, 150 Indeed, elimination of such substituents able to form 
hydrogen bonds strongly decreased the binding affinity, as in the case of compounds 7.5, 
7.24, 7.25, 7.30 and 7.31. Interestingly, neither the addition of a methylamine substituent in 
position R7 as for 7.30 and 7.31, potentially favoring the formation of hydrogen bonds or 
salt bridges, restored the binding efficiency. This was not the case however with compound 
7.29, the R7-dimethylamine derivative of 7.5. While 7.5 was inactive, an effect in promoting 
ATPase activity by 7.29 was observed, at similar extent when compared to 7.23 (2.30 ± 0.14 
A. B.
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vs 2.50 ± 0.10). 7.29 formed a hydrogen bond and a salt bridge, both with D503 from 
protomer B.  
It is possible to argue that the introduction of a dimethylamine substituent in position R7 is 
beneficial only when the other phenyl rings are not substituted. Indeed, the presence of larger 
groups in positions R1-R6 increases the steric hindrance of the compounds that adopt a less 
suitable conformation into the binding pocket, thus affecting the stability of the binding. 
Furthermore, the presence of a dimethylamine at the terminal of a flexible carbon chain was 
previously observed to correlate with Hsp90 ATPase activation, consistent with what 
observed here.  
 
Figure 7.29: Correlation between the DLE parameter and the measured ATPase activities. The blue spots represent the 
compounds synthetized in this study. 
It’s noteworthy that 7.23 and 7.29, compounds exerting the same degree of stimulation of 
ATPase activity, share an asymmetric binding mode, both exclusively establishing direct 
interaction with residues from only one protomer. Hsp90 is characterized by a closed 
nucleotide-bound state in which ATP hydrolysis happens in a sequential mode, with the most 
reactive protomer being significantly distorted. The active conformation of the protein, i.e. 
the one possessing kinase activity, can be described as a family of asymmetric ensembles in 
which one of the two protomers is conformationally perturbed. It was therefore hypnotized 
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that the by binding of 7.23 and 7.29 could be able to stabilize these activated ensembles, thus 
resulting in the promotion of the hydrolysis of ATP hydrolysis and the acceleration of the 
chaperone cycle.  
Finally, it is interesting to underline that a significant correlation could be found between the 
Dynamic Ligand Efficiency (DLE), a calculated parameter associating the predicted docking 
scores in a multiconformational protein to simulated ATPase stimulations, and the ATPase 
activities experimentally measured in the presence of the designed potential allosteric ligands 
(Figure 7.29). Interestingly, the correlation between the DLE of the set of newly designed 
compounds together with the ones previously described in the previously works done by 
Colombo et al. and the measured ATPase stimulations, turns out to provide an interesting 
linear correlation coefficient of -0.80 (-0.61 on the new series alone). This finding supports 
the validity of the Quantitative Structure Dynamics Activity Relationship model for the 
design of allosteric activators of Hsp90.  
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Conclusions  
A chemo-enzymatic synthesis of (±)-2,3-trans-dihydrobenzofurans was successfully proposed 
and validated by the preparation of a small library of oxygenated heterocyclic compounds. 
Moreover, the outstanding selectivity of the laccase-mediated oxidation for the regio-
selective production of compounds 7.15-7.25 with the respect to use of stoichiometric 
chemical oxidants has been also demonstrated.  
 
Figure 7.30: Normalized Hsc82-ATPase activity in the presence of un-substituted (white), p-bisubstituted (yellow), m-
bisubstituted (green), m, m’-tetrasubstituted (blue) and amine-modified (red) (±)-2,3-dihydrobenzofurans.  
A structure relation activity (SAR) study has been conducted on the R and C3-position of the 
scaffolds previously proposed by Colombo et. al, by integrating experimental data and 
computational analysis. It has been demonstrated that, in general, a bulky substitution at the 
mentioned portion of the molecules affected negatively the modulation of the Hsp90’s kinase 
activity of the parental reported scaffolds, unless H-bonding interactions could be provided 
(as in the case of compound 7.23) 
The conjugation with an alkyl chain bearing a tertiary amine promoted, as expected, an 
increased modulation activity toward the Hsp90’s ATPase cycle but only in the case of the 
less sterically demanding compound 7.29 which did not possess decorations on the aromatic 
rings. Molecular dynamics are now being run to further investigate the binding event between 
the small family of amine-containing compounds 7.29-7.31 and verify this hypothesis.   
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Compounds 7.23 and 7.29 have both demonstrated a high ability to activate the Hsp90 
ATPase cycle, thus potentially impairing its chaperone functions (as shown in Figure 7.30). 
Docking studies have shown how compounds 7.23 and 7.29 are capable to interact with 
specific aminoacidic residues of protomer B of Hsp90 via a set of hydrogen bonding and, in 
the case of 7.19, charge interactions.  
Moreover, thanks to these results, the efficiency in predicting the Hsp90’s ATPase cycle 
modulation activity of small molecules of the Quantitative Structure Dynamics Activity 
Relationship model for the design of allosteric activators of Hsp90 proposed by Colombo et 
al. (Figure 7.29) was underlined (linear correlation coefficient of -0.80). 
The aromatization of compounds 7.23 and 7.29, to restore the reported benzofuran moiety 
of the compounds proposed by Colombo, Bernardi, Sattin et al. is now being investigated.  
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7.5 Experimental  
7.5.1: Glucoside chemical synthesis 
(i)  Peracetylated glucose (1 equiv, final concentration 0.1 M) was added at room temperature 
to a solution of glacial acetic acid (3.0 equiv.) and ethylenediamine (2.5 equiv.) in 
tetrahydrofuran. The resulting mixture was stirred for 3 hours in a round bottom flask 
cupped with a calcium chloride valve. The conversion of the starting material was checked 
by TLC (mobile phase petroleum ether : AcOEt; 4 : 6). Once the peracetylated glucose was 
fully consumed, the reaction mixture was diluted with two volumes with water and extracted 
twice with DCM. The combined organic layers were washed with of a 5 % aqueous solution 
of hydrochloric acid, a saturated aqueous solution of sodium bicarbonate and water, until 
pH 7 was reached. After drying over sodium sulfate, the solvent was concentrated in vacuo 
affording the desired product used without any further purifications.  
(ii) 1,5-diazabicyclo(5.4.0)undec-5-ene (0.4 equiv.) and trichloroacetonitrile (1.1 equiv.) were 
added at room temperature and under nitrogen atmosphere to a solution of 2,3,4,6-
tetraacetylglucopyranose (1 equiv.) in dry DCM (0.2 M). The resulting mixture was stirred 
for 45 min. After checking the complete conversion of the starting material by TLC (mobile 
phase petroleum ether : AcOEt; 6 : 4), the crude product was concentrated in vacuo and 
purified by flash column chromatography (mobile phase petroleum ether : AcOEt; 7 : 3), 
affording the desired compound.  
 (iii) Under nitrogen atmosphere, glucose trichloroacetimidate (5 eq) and crushed 4 Å 
molecular sieves were added to a stirring solution of TBSM-protected phenylpropanoid 
alcohol (1 equiv.) in dry DCM (0.1 M). After cooling to -15 °C, trimethylsilyl 
trifluoromethanesulfonate (0.03 equiv.), dissolved in dry DCM, was added dropwise. The 
resulting mixture was stirred for 30 minutes at -15 °C. The reaction was subsequently 
quenched with triethylamine (0.5 equiv.), filtered through a Celite®545 pad and the solvent 
concentrated in vacuo. The desired fully-protected product was purified by flash column 
chromatography (mobile phase petroleum ether : AcOEt; 8 : 2).  
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(iv) Under nitrogen atmosphere and at 0 °C, the fully-protected phenylpropanoid glucoside 
(1 equiv.) was dissolved in dry THF (0.03 M). A 1 M solution in THF of tetra-n-
butylammonium fluoride (1 equiv.) in THF was then added and the reaction stirred for 20 
min. After checking the conversion of the starting material by TLC (mobile phase petroleum 
ether : AcOEt, 1 : 1), the mixture was diluted with diethyl ether, washed with water, brine 
and water again, dried over sodium sulfate and concentrated in vacuo, affording the desired 
product that was used without any further purifications.  
(v) Phenol-deprotected phenylpropanoid glucoside (1 equiv.) was suspended in MeOH  (0.03 
M) and, under vigorous stirring, a 0.5 M solution of MeONa in MeOH (2 eq) was added 
slowly and dropwise. The resulting mixture was stirred for 30 min. After that, the reaction 
was diluted three times with MeOH and a Dowex® 50WX8 hydrogen form resin was added. 
The mixture was than stirred until the pH 7 was reached. The resin was then filtered and the 
solvent concentrated in vacuo, affording the desired product that was used without any further 
purifications.  
 
Peracetylated (L)-glucose trichloroacetimidate. According to general procedure 7.5.1 i-
ii, L-glucose trichloroacetimidate (8.0 g, 16.39 mmol, yellow solid, 
isolated yield: 64 %) was obtained from L-glucose penta-acetate 
(10.0 g, 25.62 mmol). 1H-NMR (400 MHz; CDCl3): δ 5.61-5.55 (m, 
1H: H-1), 5.22-5.07 (m, 2H: H-6), 4.31-4.11 (m, 4H: H-2, H-3, H-4, H-5), 2.09 (s, 3H: H-7), 
2.06 (s, 3H: H-7), 2.05 (s, 3H: H-7), 2.03 (s, 3H: H-7).  
 
Compound (L)-4.7a. According to general procedure7.5.1 iii-v, fully deprotected (L)-4.7a 
(280 mg, 1.13 mmol, oil, isolated yield: 20 %) was 
obtained from phenol-protected coniferyl alcohol (1.6 g, 
5.44 mmol) and L-glucosetrichloroacetimidate (3.7 g, 7.62 mmol). The NMR data were in 
accordance to the values listed for the (D)-4.7a described in chapter 4.   
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7.5.2: Laccase-mediated dimerization of phenolic glycosides 
To a solution of phenylpropanoid glycoside (0.05 M) in acetate buffer (20 mM pH 5), the 
needed amount of a 1 mg ml-1 laccase solution prepared in the same buffer (4.6 U ml-1), was 
added to achieve the value of 0.005 U mmolsubstrate-1. The resulting mixture was incubated at 
30 °C and 300 rpm and monitored by TLC (mobile phase MeOH  : chloroform : H2O; 6:4:0.5 
or MeOH : AcOEt : H2O; 6:4:0.5). Once the starting glycoside was consumed, the pH of the 
media was changed to 7 and the mixture was lyophilized. The crude product was purified by 
flash column chromatography (mobile phase MeOH  : chloroform : H2O; 7:3:0.3 or MeOH  
: AcOEt : H2O; 7:3:0.3),  affording the desired dimers as a mixtures of trans-diastereoisomers. 
 
 Compound 7.1. According to general procedure 7.5.2, 7.2 (31 mg, 0.07 mmol, oil, isolated 
yield: 35 %) was obtained from compound 
(D)-4.5a (63 mg, 0.20 mmol) and laccase 
(0.32 U). 1H-NMR (400 MHz; MeOD, 
mixture of diastereoisomers), d: 7.54 (s, 
0.5H), 7.47 (s, 0.5H), 7.25-7.23 (m, 2H), 6.79-6.74 (m, 3H), 6.64 (d, J = 15.9 Hz, 1H: Ha), 
6.29-6.20 (m, 1H: Hb), 5.57 (d, J = 6.0 Hz, 0.5H: Ha’A), 5.53 (d, J = 6.5 Hz, 0.5H: Ha’B), 
4.54-4.48 (m, 1H), 4.40-4.37 (m, 2H: H-anomerA+B), 4.36-4.30 (m, 1H), 4.23-4.15 (m, 1H), 
3.92-3.79 (m, 3H), 3.72-3.60 (m, 4H), 3.42-3.22 (m, 14H). 13C-NMR (101 MHz; MeOD, 
mixture of diastereoisomers): δ 181.9, 179.3, 159.6, 157.07, 156.99, 132.86, 132.80, 132.59, 
132.39, 130.0, 128.3, 127.06, 126.94, 122.8, 122.4, 114.83, 114.81, 108.6, 103.0, 101.69, 
101.64, 87.38, 87.22, 76.74, 76.63, 76.59, 73.7, 70.34, 70.24, 69.6, 61.4. MS, m/z ESI = 
645.3[M+Na]+. 
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 Compound 7.2. According to general procedure 7.5.2, 7.2 (150 mg, 0.22 mmol, oil, isolated 
yield: 34 %) was obtained from compound 
(D)-4.7a (470 mg, 1.4 mmol) and laccase 
(2.35 U). 1H-NMR (400 MHz; DMSO-d6, 
mixture of diastereoisomers A and B), d: 7.12 
(s, 0.5H), 7.03 (s, 0.5H), 6.97-6.94 (m, 2H), 6.81-6.74 (m, 2H), 6.57 (d, J = 15.8 Hz, 1H: Ha), 
6.26-6.17 (m, 1H: Hb), 5.55 (d, J = 6.1 Hz, 0.5H: Ha’A), 5.50 (d, J = 7.2 Hz, 0.5H: Ha’B), 
4.40 (dd, J = 12.8, 5.7 Hz, 1H: H-7), 4.26 (d, J = 7.8, 0.5H: H-anomerA), 4.25 (d, J = 7.7, 
0.5H: H-anomerB), 4.22 (d, J = 7.8 Hz, 1H: H-anomerA+B), 4.17 (dd, J = 12.7, 5.8 Hz, 1H: 
H-7), 4.06 (dd, J = 9.5, 5.8 Hz, 1H), 3.98 (dd, J = 9.8, 7.0 Hz), 3.81 (s, 2H: OCH3A), 3.80 (s, 
1H: OCH3B), 3.75 (s, 1H: OCH3A), 3.74 (s, 2H: OCH3B), 3.72-3.56 (m, 4H), 3.50-3.42 (m, 
2H), 3.20-2.98 (m, 9H). 13C-NMR (101 MHz; DMSO-d6, mixture of diastereoisomers): δ 
147.95, 147.91, 147.80, 147.72, 144.21, 144.14, 132.7, 132.34, 132.27, 132.18, 130.79, 130.71, 
129.8, 129.2, 124.1, 119.1, 118.8, 116.10, 116.00, 115.7, 111.10, 111.08, 111.04, 110.85, 103.4, 
102.3, 87.5, 77.33, 77.24, 77.07, 77.01, 73.9, 70.9, 70.47, 70.40, 69.26, 69.20, 61.5, 56.20, 
56.17, 56.10, 51.1, 50.8. MS, m/z ESI = 705.3 Da [M+Na]+.  
 
Compound 7.3. According to general procedure 7.5.2, the desired dimers 7.3 (109 mg, 0.16 
mmol, oil, isolated yield: 37 %) was obtained 
from compound (L)-4.7a (380 mg, 0.89 
mmol) and laccase (1.90 U).  1H-NMR (400 
MHz; DMSO-d6): δ 7.14 (s, 0.5H), 7.04 (s, 
0.5H), 6.98-6.95 (m, 2H), 6.81-6.74 (m, 2H), 6.58 (d, J = 15.9 Hz, 1H: Ha), 6.27-6.18 (m, 
1H: Hb), 5.55 (d, J = 6.1 Hz, 0.5H: Ha’A), 5.50 (d, J = 7.3 Hz, 0.5H:Ha’B), 4.41 (dd, J = 
12.8, 5.5 Hz, 1H: H-7), 4.26 (dd, J = 7.8, 2.7 Hz, 0.5H: H-anomerA), 4.25 (dd, J = 7.8, 2.7 
Hz, 0.5H: H-anomerB), 4.22 (d, J = 7.8 Hz, 1H: H-anomoerA+B), 4.19-4.16 (m, 1H: 7), 4.07 
(dd, J = 9.5, 5.9 Hz, 1H), 3.99 (dd, J = 9.6, 7.0 Hz, 1H), 3.82 (s, 1.5H: OCH3A), 3.81 (s, 1.5H: 
OCH3B), 3.76 (s, 1.5H: OCH3A), 3.75 (s, 1.5H: OCH3B), 3.72-3.60 (m, 4H), 3.46 (dq, J = 12.0, 
HO
O
OH
HO
HO
HO
O O
HO
OH
OH
OH
O
O
MeO OMe
α'
β'
β
α
OMe
OH
O
HO
OH
OH
OH
OO
OH
HO
HO
HO
O
OMe
O
β
α
α'
β'
Laccases 
 126 
6.0 Hz, 3H), 3.21-2.98 (m, 8H).  1C-NMR (101 MHz; DMSO-d6): δ 148.02, 147.97, 147.84, 
147.75, 146.93, 146.80, 144.22, 144.15, 132.6, 132.33, 132.27, 132.11, 130.78, 130.70, 129.8, 
129.2, 124.08, 124.06, 119.2, 118.8, 116.14, 116.05, 115.77, 115.72, 111.16, 111.07, 110.9, 
103.45, 103.31, 102.4, 87.57, 87.56, 77.45, 77.39, 77.36, 77.32, 77.26, 74.00, 73.94, 70.61, 
70.54, 69.26, 69.20, 61.60, 61.57, 61.54, 56.22, 56.19, 56.11, 51.1, 50.8. MS, m/z ESI = 705.3 
Da [M+Na]+. 
 
Compound 7.4. According to general procedure 7.5.2, the desired dimer 7.4 (74 mg, 0.07 
mmol, oil, isolated yield: 33 %) was 
obtained from compound 4.7b (225 
mg, 0.46 mmol) and laccase (1.12 
U). 1H-NMR (400 MHz; D2O, 
mixture of diastereoisomers): δ 7.01 
(d, J = 2.6 Hz, 1H), 6.96 (dd, J = 8.5, 1.4 Hz, 1H), 6.86-6.80 (m, 2H), 6.58 (d, J = 15.8 Hz, 
1H: Ha), 6.24-6.17 (m, 1H: Hb), 5.60 (d, J = 6.2 Hz, 0.5H: Ha’A), 5.55 (d, J = 6.7 Hz, 0.5H: 
Ha’B), 4.49 (d, J = 7.9 Hz, 1H: H-anomerA), 4.45 (dd, J = 12.4, 6.2 Hz, 1H: H-7), 4.37 (d, J 
= 7.9 Hz, 1H: H-anomerA), 4.32 (dd, J = 12.7, 6.8 Hz, 1H: H-7), 4.08-4.01 (m, 1H), 3.96-
3.91 (m, 3H), 3.89-3.83 (m, 5H), 3.80-3.76 (m, 4H), 3.73-3.56 (m, 7H), 3.53-3.23 (m, 11H), 
1.25-1.15 (m, 6H). 13C-NMR (101 MHz; D2O, mixture of diastereoisomers): δ 147.6, 147.2, 
143.8, 133.7, 131.1, 128.4, 123.1, 119.0, 115.86, 115.78, 115.6, 110.9, 110.3, 102.9, 101.4, 
100.61, 100.45, 96.1, 88.0, 75.8, 74.7, 73.2, 72.1, 70.28, 70.10, 69.6, 68.7, 66.7, 56.12, 55.97, 
50.7, 48.9, 16.7. MS, m/z ESI = 997.3 Da [M+Na]+.  
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7.5.3: E-stilbenes chemical synthesis  
A solution of p-hydroxybenzaldehyde (0.5 M, 1 eq) and of the desired substituted 
phenylacetic acid (1.2-2.4 eq) was prepared in CH2Cl2 at rt. Piperidine (2.5 eq) was added and 
the resulting mixture was gradually heated to 130 °C, distilling the solvent. The resulting neat 
mixture was left reacting at 130 °C for 24-48 h. After that, the crude residue was dissolved 
in MeOH, analyzed by TLC and purified by flash chromatography (ETP : AcOEt = 7 : 3), 
obtaining the target E-stilbene.  
 
Compound 7.5 According to general procedure 7.5.3, the desired stilbene 7.5 (250 mg, 1.27 
mmol, white solid, isolated yield: 56 %) was obtained after 24 h from 
phenylacetic acid (803 mg, 5.90 mmol), p-hydroxybenzaldehyde (300 
mg, 2.46 mmol) and piperidine (608 µl, 6.15 mmol). 1H-NMR (400 
MHz; CDCl3, r.t.): 7.50-7.48 (m, 2H), 7.42-7.38 (AA'BB' system, 2H), 7.36-7.32 (m, 2H), 
7.25-7.21 (m, 1H), 7.05 (d, J = 16.3 Hz, 1H), 6.96 (d, J = 16.3 Hz, 1H), 6.87-6.84 (AA'BB' 
system, 2H), 6.44 (s, 1H). Data in agreements with those reported in literature.160 
 
Compound 7.6 According to general procedure 7.5.3, the desired stilbene 7.6 (113 mg, 0.54 
mmol, white solid, isolated yield: 44 %) was obtained after 48 h 
from 4-methyl phenylacetic acid (443 mg, 2.95 mmol), p-
hydroxybenzaldehyde (150 mg, 1.23 mmol) and piperidine (304 
µl, 3.07 mmol). 1H-NMR (400 MHz; MeOD, r.t.): δ 7.40-7.37 (m, 4H), 7.40-7.37 (m, 4H), 
7.18-7.12 (AA'BB' system, 2H), 7.03 (d, J = 16.4 Hz, 1H), 6.94 (d, J = 16.4 Hz, 1H), 6.80-
6.77 (AA'BB' system, 2H), 2.34 (s, 3H). Data in agreements with those reported in 
literature.160 
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Compound 7.7 According to general procedure 7.5.3, the desired stilbene 7.7 (58 mg, 0.26 
mmol, white solid, isolated yield: 64 %) was obtained after 44 h 
from 4-cyano phenylacetic acid (148 mg, 0.98 mmol), p-
hydroxybenzaldehyde (50 mg, 0.41 mmol) and piperidine (101 µl, 
1.02 mmol). 1H-NMR (400 MHz; MeOD, r.t.): δ 7.71-7.65 (m, 4H), 7.48-7.45 (AA'BB' 
system, 2H), 7.29 (d, J = 16.4 Hz, 1H), 7.04 (d, J = 16.3 Hz, 1H), 6.83-6.81 (AA'BB' system, 
2H). Data in agreements with those reported in literature.161 
 
Compound 7.8 According to general procedure 7.5.3, the desired stilbene 7.8 (0.63 g, 2.61 
mmol, yellow solid, isolated yield: 64 %) was obtained after 18 h 
from 4-nitro phenylacetic acid (2.27 g, 12.52 mmol), p-
hydroxybenzaldehyde (0.50 g, 4.09 mmol) and piperidine (1.01 
ml, 10.24 mmol). 1H-NMR (400 MHz; MeOD, r.t.): δ 8.22-8.19 (AA’BB’ system, 2H), 7.74-
7.71 (AA’BB’ system, 2H), 7.49-7.47 (AA’BB’ system, 2H), 7.34 (d, J = 16.4 Hz, 1H), 7.10 
(d, J = 16.4 Hz, 1H), 6.84-6.81 (AA’BB’ system, 2H). Data in agreements with the one 
reported in literature.162 
 
Compound 7.9 According to general procedure 7.5.3, the desired stilbene 7.9 (140 mg, 0.62 
mmol, oil, isolated yield: 38 %) was obtained after 48 h from 4-
hydroxy phenylacetic acid (654 mg, 3.93 mmol), p-
hydroxybenzaldehyde (200 mg, 1.64 mmol) and piperidine (406 
µl, 4.10 mmol). 1H-NMR (500 MHz; DMSO-d6, r.t.): δ 7.48 (AA'BB' system, 2H), 7.38 
(AA'BB' system, 2H), 7.01-6.92 (m, 4H), 6.76 (AA'BB' system, 2H), 3.77 (s, 3H). Data in 
agreements with those reported in literature.163 
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Compound 7.10 According to general procedure 7.5.3, the desired stilbene 7.10 (147 mg, 
0.7 mmol, white solid, isolated yield: 28 %) was obtained after 24 
h from 3-methyl phenylacetic acid (886 mg, 5.90 mmol), p-
hydroxybenzaldehyde (300 mg, 2.46 mmol) and piperidine (608 
µl, 6.15 mmol). 1H-NMR (400 MHz; MeOD, r.t.): δ 7.40-7.38 (m, 2H), 7.32-7.29 (AA'BB' 
system, 2H), 7.20 (t, J = 7.6 Hz, 1H), 7.09-7.02 (m, 2H), 6.96-6.92 (m, 1H), 6.80-6.78 (m, 
2H), 2.36 (s, 3H). Data in agreements with those reported in literature.164	
 
Compound 7.11 According to general procedure 7.5.3, the desired stilbene 7.11 (52 mg, 0.49 
mmol, white solid, isolated yield: 60 %) was obtained after 24 h 
from 3-cyano phenylacetic acid (317 mg, 1.97 mmol), p-
hydroxybenzaldehyde (100 mg, 0.82 mmol) and piperidine (204 
µl, 2.05 mmol). 1H-NMR (400 MHz; MeOD, r.t.): δ 7.87-7.81 (m, 2H), 7.56-7.44 (m, 4H), 
7.23 (d, J = 16.4 Hz, 1H), 7.01 (d, J = 16.4 Hz, 1H), 6.82-6.80 (AA'BB' system, 2H). Data in 
agreements with those reported in literature.165 	
 
Compound 7.12 According to general procedure 7.5.3, the desired stilbene 7.12 (113 mg, 
0.26 mmol, white solid, isolated yield: 57 %) was obtained after 
48 h from 3-methylthio phenylacetic acid (358 mg, 1.97 mmol), 
p-hydroxybenzaldehyde (100 mg, 0.82 mmol) and piperidine 
(204 µl, 2.05 mmol). 1H-NMR (400 MHz; CDCl3, r.t.): δ 7.43-7.39 (m, 3H), 7.31-7.24 (m, 
2H), 7.14-7.08 (m, 2H), 6.95 (d, J = 16.3 Hz, 1H), 6.81-6.78 (AA'BB' system, 2H), 2.51 (s, 
3H); 13C-NMR (101 MHz; CDCl3, r.t.): δ 156.8, 136.5, 135.1, 129.3, 128.8, 127.27, 127.19, 
125.7, 125.3, 115.1, 19.8; MS, m/z ESI = 241.3 Da [M-H]-. 
 
OH
H3C
OH
NC
OH
H3CS
Laccases 
 130 
Compound 7.13 According to general procedure 7.5.3, the desired stilbene 7.13 (55 mg, 
0.22 mmol, oil, isolated yield: 28 %) was obtained after 48 h from 
3,5-dimethoxy phenylacetic acid (386 mg, 1.97 mmol), p-
hydroxybenzaldehyde (100 mg, 0.82 mmol) and piperidine (204 
µl, 2.05 mmol). 1H-NMR (400 MHz; MeOD, r.t.): δ 7.42-7.38 (AA'BB' system, 2H), 7.07 
(d, J = 16.3 Hz, 1H), 6.92 (d, J = 16.3 Hz, 1H), 6.81-6.77 (AA'BB' system, 2H), 6.68 (d, J = 
2.2 Hz, 2H), 6.38 (t, J = 2.2 Hz, 1H), 3.82 (s, 6H). Data in agreements with those reported 
in literature.166 
 
Compound 7.14 According to general procedure 7.5.3, the desired stilbene 7.14 (72 mg, 
0.32 mmol, white solid, isolated yield: 39 %) was obtained after 
48 h from 3,5-dimethyl phenylacetic acid (323 mg, 1.97 mmol), p-
hydroxybenzaldehyde (100 mg, 0.82 mmol) and piperidine (204 
µl, 2.05 mmol). 1H-NMR (400 MHz; CDCl3, r.t.): δ 7.39-7.37 
(AA'BB' system, 2H), 7.12 (bs, 2H), 7.04 (d, J = 16.3 Hz, 1H), 6.91 (d, J = 16.4 Hz, 1H), 6.87 
(bs, 1H), 6.80-6.77 (AA'BB' system, 2H), 2.17 (s, 6H). 13C NMR (101 MHz; CD3OD), 
d 208.6, 156.9, 137.76, 137.63, 129.2, 128.2, 127.7, 127.3, 125.6, 123.6, 115.1, 29.2, 20.0. 
MS, m/z ESI 222.9 [M-H]-.   
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7.5.4: Laccase-mediated dimerization of substituted stilbenes  
A solution (1 mg/mL in acetate buffer pH 4.5) of laccase from T. versicolor (average activity: 
4 U mg-1) was added (42.2 U mmolsubstrate-1) to a solution of E-stilbene (0,078 M in acetone). 
Buffer acetate was added to the reaction mixture to reach a 1 : 1 ratio acetone/buffer. The 
reaction mixture was shaken (160 rpm) at 27 °C and monitored by TLC (CHCl3 : acetone, 9 
: 1) till the complete disappearance of the starting stilbene substrate. After 24 h, the reaction 
was quenched by extraction with AcOEt, the organic solvent evaporated in vacuo and the 
crude residue purified by flash chromatography (ETP : AcOEt, 7 : 3) to give a racemic 
mixture of trans-diastereoisomers. 
 
Compound 7.15 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.15 (62 mg, 0.16 mmol, white solid, 
isolated yield: 76 %) was obtained from compound 7.5 (83 
mg, 0.41 mmol), and laccases (17.7 U). 1H-NMR (400 
MHz; CDCl3, r.t.): δ 7.74-7.50 (d, J = 7.8 Hz, 2H), 7.42-7.32 (m, 6H), 7.26-7.21 (m, 6H), 7.06 
(d, J = 16.3 Hz, 1H), 6.97-6.90 (m, 2H), 6.86-6.83 (AA'BB' system, 2H), 5.53 (d, J = 8.5 Hz, 
1H), 4.87 (s, 1H), 4.59 (d, J = 8.4 Hz, 1H). 13C-NMR (101 MHz; CDCl3): d 159.6, 155.6, 
141.5, 137.7, 132.7, 131.0, 128.9, 128.6, 128.5, 128.4, 127.9, 127.6, 127.3, 127.1, 126.3, 126.2, 
122.9, 115.5, 109.7, 93.3, 57.6. MS-ESI, m/z 389.0 [M-H]-.  
 
Compound 7.16 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.16 (60 mg, 0.14 mmol, white solid, 
isolated yield: 60 %) was obtained from compound 
7.6 (95 mg, 0.45 mmol), and laccases (19.0 U). 1H-
NMR (400 MHz; CDCl3, r.t.): δ 7.39-7.34 (m, 2H), 
7.26-7.22 (AA'BB' system, 2H), 7.19-7.10 (m, 6H), 7.00 (d, J = 16.3 Hz, 1H), 6.94 (d, J = 8.3 
Hz, 1H), 6.89 (d, J = 16.3 Hz, 1H), 6.86-6.82 (AA'BB' system, 2H), 5.49 (d, J = 8.6 Hz, 1H), 
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4.85 (s, 1H), 4.55 (d, J = 8.5 Hz, 1H), 2.39 (s, 3H), 2.36 (s, 3H). 13C-NMR (101 MHz; CDCl3): 
d 206.9, 159.5, 155.5, 138.5, 136.9, 136.9, 134.9, 132.8, 131.2, 129.6, 129.3, 128.3, 127.6, 
127.6, 127.5, 126.2, 126.1, 122.8, 115.5, 109.6, 93.4, 57.3, 21.2, 21.1. MS-ESI, m/z 417.0 
[M-H]-.  
 
Compound 7.17 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.17 (37 mg, 0.08 mmol, white solid, 
isolated yield: 74 %) was obtained from compound 7.7 
(50 mg, 0.27 mmol), and laccases (9.5 U). 1H-NMR 
(400 MHz; CDCl3, r.t.): δ δ  7.69-7.67 (AA'BB' system, 
2H), 7.63-7.06 (AA'BB' system, 2H), 7.53-7.51 (AA'BB' system, 2H), 7.46 (dd, J = 8.4, 1.5 
Hz, 1H), 7.35-7.33 (AA'BB' system, 2H), 7.22-7.20 (AA'BB' system, 2H), 7.17-7.12 (m, 2H), 
7.00 (d, J = 8.3 Hz, 1H), 6.92-6.86 (m, 3H), 5.48 (d, J = 8.3 Hz, 1H), 5.17 (s, 1H), 4.66 (d, J 
= 8.3 Hz, 1H). 13C-NMR (101 MHz; CDCl3): d 160.4, 156.2, 156.1, 146.7, 142.0, 132.8, 
132.5, 131.8, 131.6, 130.4, 130.0, 129.1, 129.1, 127.6, 126.5, 124.7, 124.7, 123.2, 119.0, 118.5, 
115.7, 115.7, 111.5, 110.3, 110.3, 110.1, 93.1, 57.7. MS-ESI, m/z 463.2 [M+Na]+.  
 
Compound 7.18 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.18 (68 mg, 0.14 mmol, white solid, 
isolated yield: 68 %) was obtained from compound 
7.8 (100 mg, 0.45 mmol), and laccases (17.4 U). 1H-
NMR (400 MHz; CDCl3, r.t.): δ 8.24-8.22 (AA'BB' 
system, 2H), 8.17-8.15 (AA'BB' system, 2H), 7.68-7.66 (AA'BB' system, 2H), 7.54 (dd, J = 
8.3, 1.8 Hz, 1H), 7.46-7.44 (AA'BB' system, 2H), 7.32 (d, J = 16.3 Hz, 1H), 7.27 (bs, 1H), 
7.19-7.17 (AA'BB' system, 2H), 7.06 (d, J = 16.4 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.81-6.79 
(AA'BB' system, 2H), 5.52 (d, J = 8.4 Hz, 1H), 4.79 (d, J = 8.3 Hz, 1H). 13C-NMR (101 
MHz; CDCl3): d 208.6, 160.5, 157.7, 149.1, 147.3, 146.3, 144.5, 132.7, 130.6, 130.5, 130.3, 
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129.1, 128.9, 127.3, 126.4, 123.8, 123.6, 123.5, 123.2, 115.1, 109.6, 99.9, 93.3, 56.9. MS-ESI, 
m/z 479.0 [M-H]-.  
 
Compound 7.19 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.19 (33 mg, 0.07 mmol, white solid, 
isolated yield: 55 %) was obtained from compound 
7.9 (60 mg, 0.27 mmol), and laccases (9.3 U). 1H-
NMR (400 MHz; CDCl3, r.t.): δ 7.41-7.39 (AA'BB' 
system, 2H), 7.36 (dd, J = 8.3, 1.0 Hz, 1H), 7.29-7.26 (m, 3H), 7.18-7.17 (m, 3H), 6.94-6.88 
(m, 7H), 6.69-6.20 (AA'BB' system, J = 6.9 Hz, 2H), 5.46 (d, J = 8.7 Hz, 1H), 4.54 (d, J = 
8.7 Hz, 1H), 3.84 (s, 3H), 3.84 (s, 3H). 13C-NMR (101 MHz; CDCl3): d 159.3, 159.9, 158.8, 
155.6, 133.4, 132.6, 131.3, 131.6, 130.5, 129.4, 127.6, 127.5, 127.3, 126.5, 125.9, 122.6, 115.5, 
114.3, 114.1, 109.6, 93.5, 56.9, 55.3, 55.3. MS-ESI, m/z 449.0 [M-H]-.  
 
Compound 7.20 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.20 (66 mg, 0.16 mmol, white solid, 
isolated yield: 66 %) was obtained from compound 
7.10 (100 mg, 0.45 mmol), and laccases (20.0 U). 1H-
NMR (400 MHz; CDCl3, r.t.): d 7.40 (dd, J = 8.3, 1.8 
Hz, 1H), 7.26-7.19 (m, J = 4.2 Hz, 6H), 7.14 (bd, J = 7.6 Hz, 1H), 7.06-7.00 (m, 4H), 6.95 
(d, J = 8.3 Hz, 1H), 6.90 (d, J = 16.3 Hz, 1H), 6.87-6.82 (AA'BB' system, 2H), 5.53 (d, J = 
8.4 Hz, 1H), 4.82 (s, 1H), 4.54 (d, J = 8.4 Hz, 1H), 2.37 (s, 3H), 2.36 (s, 3H). 13C-NMR (400 
MHz; CDCl3): d 159.6, 155.6, 141.5, 138.6, 138.1, 137.8, 132.9, 131.2, 131.1, 128.9, 128.7, 
128.5, 128.3, 128.1, 127.9, 127.7, 127.6, 126.8, 126.4, 125.5, 123.4, 122.9, 115.6, 109.6, 97.3, 
57.6, 30.9, 214.5, 21.4. MS-ESI, m/z 417.0 [M-H]-.  
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Compound 7.21 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.21 (23 mg, 0.06 mmol, white solid, 
isolated yield: 49 %) was obtained from compound 
7.11 (50 mg, 0.23 mmol), and laccases (9.5 U). 1H-
NMR (400 MHz; CDCl3, r.t.): d 7.73-7.70 (m, 1H), 
7.69-7.63 (m, J = 1.5 Hz, 2H), 7.52-7.42 (m, 6H), 7.23-7.21 (AA'BB' system, 2H), 7.16 (s, 
1H). 7.10 (d, J = 16.3 Hz, 1H), 7.00 (d, J = 8.3 Hz, 1H), 6.90-6.86 (m, 3H), 5.47 (d, J = 8.2 
Hz, 1H), 4.64 (d, J = 8.2 Hz, 1H). 13C-NMR (101 MHz; CDCl3): d 160.2, 156.1, 143.0, 138.8, 
132.8, 131.8, 131.6, 131.2, 130.8, 130.5, 130.3, 130.2, 129.8, 129.6, 129.4, 128.8, 127.5, 124.2, 
123.1, 118.8, 118.5, 115.8, 113.2, 112.9, 110.3, 93.1, 57.2. MS-ESI, m/z 438.9 [M-H]-.  
 
 
Compound 7.22 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.22 (23 mg, 0.05 mmol, white solid, 
isolated yield: 46 %) was obtained from compound 
7.12 (50 mg, 0.21 mmol), and laccases (8.7 U). 1H-
NMR (400 MHz; CDCl3, r.t.): d 7.40 (dd, J = 8.3, 
1.7 Hz, 1H), 7.35 (b, 1H), 7.32-7.19 (m, 9H), 7.14 (dt, J = 6.7, 2.0 Hz, 1H), 7.10 (t, J = 1.7 
Hz, 1H), 7.05 (d, J = 16.3 Hz, 1H), 6.99 (dt, J = 7.6, 1.3 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 
6.90-6.83 (m, 3H), 5.52 (d, J = 8.4 Hz, 1H), 4.54 (d, J = 8.4 Hz, 1H), 2.52 (s, 3H), 2.48 (s, 
3H). 13C-NMR (101 MHz; CDCl3): d 159.7, 155.7, 142.2, 139.3, 138.7, 138.3, 132.6, 130.90, 
130.74, 129.4, 129.06, 128.99, 128.1, 127.6, 126.3, 125.8, 125.39, 125.24, 125.04, 124.4, 
123.06, 123.02, 115.5, 109.8, 93.1, 57.6, 15.9, 15.7. MS-ESI, m/z 481.1 [M-H]-.  
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Compound 7.23 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.23 (17 mg, 0.04 mmol, white solid, 
isolated yield: 33 %) was obtained from compound iii 
(50 mg, 0.22 mmol), and laccases (9.2 U). 1H-NMR 
(400 MHz; CDCl3, r.t.): d 7.43 (dd,  J= 8.3, 1.6 Hz, 
1H), 7.26 (b.s. 1H), 7.24 (m, 2H), 7.06 (d, J= 16.3 Hz, 1H), 6.90 (d, J= 16.3 Hz, 1H), 6.87 (d, 
J= 8.3 Hz, 1H), 6.85 (m, 2H), 6.54 (d, J= 2.1 Hz, 2H), 6.29 (t, J= 2.2 Hz, 1H), 6.26 (t, J= 2.1 
Hz, 1H), 6.20 (d, J= 2.2 Hz, 2H), 5.45 (d, J=8 Hz, 1H), 4.47 (d, J= 8  Hz, 1H). 13C-NMR 
(101 MHz; CDCl3): d 161.30, 160.44, 160.22, 159.10, 145.91, 141.46, 133.28, 132.81, 132.43, 
129.80, 129.29, 129.23, 127.92, 124.62, 116.85, 110.81, 108.11, 106.42, 103.43, 103.08, 94.72, 
58.52. MS-ESI, m/z 453.5 [M-H]-.  
 
Compound 7.24 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.24 (29 mg, 0.06 mmol, white 
solid, isolated yield: 58 %) was obtained from 
compound 7.13 (50 mg, 0.20 mmol), and laccases 
(8.2 U). 1H-NMR (400 MHz; CDCl3, r.t.): d 7.39 
(dd, J = 8.3, 1.7 Hz, 1H), 7.26-7.22 (m, 4H), 7.03 (d, J = 16.2 Hz, 1H), 6.94 (d, J = 8.3 Hz, 
1H), 6.88-6.81 (m, 3H), 6.64 (d, J = 2.2 Hz, 2H), 6.43 (t, J = 2.3 Hz, 1H), 6.39 (t, J = 2.2 Hz, 
1H), 6.37 (d, J = 2.3 Hz, 2H), 5.54 (d, J = 8.3 Hz, 1H), 4.50 (d, J = 8.3 Hz, 1H), 3.83 (s, 6H), 
3.78 (s, 6H). 13C-NMR (101 MHz; CDCl3): d 161.13, 160.94, 159.7, 155.8, 143.9, 139.7, 
132.7, 130.82, 130.70, 129.0, 128.0, 127.6, 126.3, 123.1, 115.5, 109.7, 106.5, 104.3, 99.7, 99.1, 
93.0, 57.8, 55.37, 55.34. MS-ESI, m/z 509.3 [M-H]-.  
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Compound 7.25 According to general procedure 7.5.4, the desired (±)-2,3-trans-
dihybenzofuran 7.25 (34 mg, 0.08 mmol, white solid, 
isolated yield: 58 %) was obtained from compound 
7.14 (50 mg, 0.22 mmol), and laccases (9.4 U). 1H-
NMR (400 MHz; CDCl3, r.t.): d 7.39 (dd, J = 8.3, 1.7 
Hz, 1H), 7.27-7.23 (AA'BB' system, 2H), 7.18 (bs, 1H), 7.09 (bs, 2H), 7.03 (d, J = 16.3 Hz, 
1H), 6.96-6.89 (m, 4H), 68.30-6.86 (m, 4H), 5.54 (d, J = 8.2 Hz, 1H), 4.50 (d, J = 8.2 Hz, 
1H), 2.33 (s, 6H), 2.32 (s, 6H). 13C-NMR (101 MHz; CDCl3): d 160.6, 157.6, 143.5, 139.6, 
137.1, 137.6, 134.9, 133.10, 129.16, 129.0, 128.7, 128.4, 128.3, 128.1, 127.9, 127.8, 127.6, 
126.8, 126.5, 125.5, 123.3, 122.9, 114.5, 108.6, 94.3, 55.6, 33.9, 21.45, 21.41, 20.45, 19.41. 
MS-ESI, m/z 445.0 [M-H]-.  
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7.5.6: Reduction of compound 7.18  
Compound 7.18 (0.14 M) and DIPEA (20 eq.) were dissolved in CH2Cl2 under magnetic 
stirring and nitrogen atmosphere.  A solution of HSiCl3 (7.14 equiv.) in dry CH2Cl2 (1.25M) 
was prepared apart, and it was added drop-wise to the first solution over 10 minutes at 0 °C, 
following the reaction with TLC analysis. As the reduction was not completed after 22 and 
28 h, 10 equivalents of DIPEA and 3.5 equivalents of HSiCl3 (1.25 M in dry CH2Cl2) were 
added to the reacting mixture, which was stirred for additional 24 h. After that, a saturated 
solution of NaHCO3 was added drop-wise and the biphasic mixture allowed to stir for 30 
min. The crude mixture was extracted with ethyl acetate, dried over Na2SO4, filtered and 
then the solvent was removed under reduced pressure to afford the crude product. The crude 
amine was then purified by flash chromatography (CHCl3 : acetone, 9.75 : 0.25) to give the 
main di-amine product 7.26 and the two reaction intermediates 7.27 and 7.28. 
 
Compound 7.26 13.7 mg, 0.033 mmol, yield: 21%; 1H-NMR (400 MHz; CD3OD, r.t.): d 
7.47-7.24 (m, 3H), 7.16-6.94 (m, 6H), 6.84-6.70 (m, 
8H), 5.36-5.34 (m, 1H), 4.43 (d, J = 8.9 Hz, 1H); 13C-
NMR (101 MHz; CD3OD): d 159.0, 157.2, 145.9, 
145.6, 131.68, 131.63, 131.44, 131.32, 128.8, 128.5, 
127.3, 126.9, 126.7, 126.0, 124.6, 122.0, 116.0, 115.5, 114.9, 108.9, 93.8, 78.2, 77.8, 77.5, 56.9, 
29.3; MS-ESI, m/z 419.0 [M-H]-.  
 
Compound 7.26 1.8 mg, 0.004 mmol, yield: 3%; 1H-NMR (400 MHz; CDCl3, r.t.): d  8.25-
8.23 (AA'BB' system, 2H), 7.41-7.38 (m, 3H), 7.30-
7.26 (AA'BB' system, J = 8.5 Hz, 2H), 7.24-7.20 
(AA'BB' system, J = 8.5 Hz, 2H), 7.10 (bs, 1H), 6.96 
(d, J = 8.4 Hz, 1H), 6.87-6.84 (m, 4H), 6.68-6.65 
(AA'BB' system, 2H), 5.46 (d, J = 8.4 Hz, 1H), 4.70 (d, J = 8.4 Hz, 1H); 13C-NMR (101 
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MHz; CDCl3): d 1159.0, 156.0, 149.0, 145.9, 132.1, 131.9, 129.5, 129.2, 127.9, 127.61, 127.44, 
126.9, 124.6, 124.2, 122.3, 115.7, 115.2, 110.1, 92.8, 57.7, 29.7; MS-ESI, m/z 449.0 [M-H]-.  
 
Compound 7.27 5.6 mg, 0.012 mmol, yield: 8 %; 1H-NMR (400 MHz; CD3OD, r.t.): d 
8.25-8.19 (AA'BB' system, 2H), 7.57-7.55 (AA'BB' 
system, 2H), 7.43-7.40 (m, 1H), 7.25-7.19 (m, 4H), 
7.01-6.93 (m, 4H), 6.85-6.83 (AA'BB' system, 2H), 
6.71-6.69 (AA'BB' system, 2H), 5.48 (d, J = 8.8 Hz, 
1H), 4.49 (d, J = 8.8 Hz, 1H); 13C-NMR (101 MHz; CD3OD), d 160.6, 155.7, 146.4, 145.7, 
144.4, 133.2, 130.9, 129.8, 129.3, 128.7, 127.6, 126.4, 124.1, 123.7, 123.4, 115.52, 115.47, 
109.9, 93.8, 56.8, 29.7; MS-ESI, m/z 449.0 [M-H]-.  
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7.5.7: Alkylation of Phenols 
Phenolic compound (0.05 M, 1 equiv.) and 2-chloro-N,N-dimethylamine hydrochloride (3 
equiv.) were suspended in chloroform. Tetrabutylammonium hydrogensulfate (0.05 equiv.), 
potassium carbonate (8 equiv.) and water (H2O : CHCl3 = 2: 100) were then added and the 
reaction stirred at 50 °C. After that, the mixture was diluted with chloroform, the organic 
phase washed with water and dried over sodium sulfate. The solvent was evaporated at 
reduced pressure and the crude residue purified by flash chromatography (CHCl3 : MeOH 
= 9 : 1) to give desired alkylated product.  
 
Compound 7.29 According to general procedure 7.5.7, the desired alkylated (±)-2,3-trans-
dihybenzofuran 7.29 (19 mg, 0.03 mmol, oil, isolated 
yield: 60 %) was obtained from compound 7.15 (21 
mg, 0.05 mmol), 2-chloro-N,N-dimethylamine 
hydrochloride (35 mg, 0.16 mmol), TBAHSO4 (9 mg, 
0.03) (9.4 U). 1H-NMR (400 MHz; CDCl3, r.t.): d 7.47-7.45 (m, 2H), 7.42-7.32 (m, 6H), 7.30-
7.26 (m, 3H), 7.25-7.20 (m, 4H), 7.05 (d, J = 16.3 Hz, 1H), 6.97-6.90 (m, 4H), 5.53 (d, J = 
8.4 Hz, 1H), 4.60 (d, J = 8.4 Hz, 1H), 4.14 (t, J = 5.7 Hz, 2H), 2.83 (t, J = 5.6 Hz, 2H), 2.42 
(s, 7H). 13C-NMR (101 MHz; CDCl3): d 160.3, 159.4, 142.1, 138.3, 133.3, 131.6, 129.5, 
129.21, 129.10, 129.00, 128.5, 127.99, 127.93, 127.7, 126.94, 126.78, 123.6, 115.3, 110.3, 94.0, 
66.3, 58.6, 58.2, 46.2, 30.30, 30.2; MS-ESI, m/z 462.3 [M+1]+.  
 
Compound 7.30 According to general procedure 7.5.7, the desired alkylated (±)-2,3-trans-
dihybenzofuran 7.30 (19 mg, 0.03 mmol, oil, 
isolated yield: 60 %) was obtained from 
compound 7.24 (27 mg, 0.05 mmol), 2-chloro-
N,N-dimethylamine hydrochloride (35 mg, 
0.24 mmol), TBAHSO4 (9 mg, 0.03). 1H-NMR (400 MHz; CDCl3, r.t.): d 7.39 (dd, J = 8.3, 
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1.7 Hz, 1H), 7.27-7.23 (AA'BB' system, 2H), 7.18 (bs, 1H), 7.09 (bs, 2H), 7.03 (d, J = 16.3 
Hz, 1H), 6.96-6.89 (m, 4H), 68.30-6.86 (m, 4H), 5.54 (d, J = 8.2 Hz, 1H), 4.50 (d, J = 8.2 Hz, 
1H), 2.33 (s, 6H), 2.32 (s, 6H). 13C-NMR (101 MHz; CD3OD): d 161.1, 160.9, 159.7, 158.5, 
158.2, 143.9, 139.7, 133.0, 130.81, 130.71, 130.3, 129.0, 128.0, 127.55, 127.36, 126.3, 123.1, 
115.7, 114.7, 114.1, 113.8, 109.7, 106.5, 104.3, 99.7, 99.0, 92.9, 65.15, 65.10, 57.8, 57.4, 55.4, 
44.96, 44.91, 44.2. MS-ESI, m/z 582.4 [M+1]+.  
 
Compound 7.31 According to general procedure 7.5.7, the desired alkylated (±)-2,3-trans-
dihybenzofuran 7.31 (19 mg, 0.03 mmol, oil, 
isolated yield: 60 %) was obtained from 
compound 7.25 (30 mg, 0.07 mmol), 2-chloro-
N,N-dimethylamine hydrochloride (44 mg, 0.30 
mmol), TBAHSO4 (12 mg, 0.04). 1H-NMR (400 MHz; CDCl3, r.t.): d 7.40-38 (m, 1H), 7.28-
7.20 (m, 3H), 7.01 (d, J = 16.5 Hz, 1H), 6.93-6.83 (m, 5H), 6.62 (s, 2H), 6.41-6.35 (m, 3H), 
5.53 (d, J = 8.3 Hz, 1H), 4.48 (d, J = 8.5 Hz, 1H), 4.14 (s, 2H), 3.81 (s, 6H), 3.76 (s, 6H), 2.97 
(s, 3H), 2.46 (s, 6H). 13C-NMR (101 MHz; CDCl3): d 159.5, 158.7, 141.6, 138.4, 138.0, 137.6, 
133.1, 131.31, 131.11, 128.98, 128.92, 128.2, 127.6, 127.3, 126.4, 126.1, 124.1, 123.0, 114.7, 
109.6, 93.2, 65.7, 58.0, 57.5, 45.6, 29.7, 21.31, 21.28. MS-ESI, m/z 518.2 [M+1]+.  
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7.5.8: HPLC methods  
a) Compounds 7.1-7.4  
- Column = Kinetex C18 HPLC 5µm EVO C18 100Å, 150x4.6 mm 
- Flow = 0.7 mL/min; - Loop = 20 µL; - Detection Lambda =: 270 nm; - Injection = 10 µL  
- Gradient of CH3CN and H2O (0.1 ppm TFA, pH 3)  
0–1 min 90% H2O, 10% CH3CN; 1–20 min 80% H2O, 20% CH3CN; 20–22 min 80% H2O, 
20% CH3CN; 22–23 90% H2O, 10% CH3CN 
 
b) Oxidations of 7.5 to 7.15 
- Column = Kinetex C18 HPLC 5µm EVO C18 100Å, 150x4.6 mm 
- Flow = 0.3 mL/min; - Loop = 20 µL; - Detection Lambda =: 270 nm; - Injection = 10 µL  
- Gradient of CH3CN and H2O (0.1 ppm TFA, pH 3)  
0 min 80% H2O, 20% CH3CN; 0–60 min 15% H2O, 85% CH3CN; 61-70 min 80% H2O, 
20% CH3CN 
 
7.5.9: ATPase assay  
Hsc82 (2 µM) was added to a solution prepared in HEPES buffer (20 mm, pH 7.5) 
containing KCl (100 mM), MgCl2 (1 mM), NADH (0.18 µM), L-lactate dehydrogenase (4 U 
ml-1), phosphoenolpyruvate (1 mM), pyruvate kinase (2.5 U ml-1) and the desired compound 
(dissolved in DMSO to a final concentration of 50 µm). The reaction was initiated by the 
addition of ATP (1 mM) and was 30 °C for 30 minutes collecting the absorbance data at 360 
nm. 
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